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2020 IPU AGM AND  
IPU SERVICES LTD AGM
7.00pm, 8 October 2020
(Confined to paid-up members of the IPU)
7.00pm 1. Welcome
2. One minute’s silence in memory of pharmacists who died since the 2019 AGM
3. Minutes of IPU 2019 AGM*
4. Minutes of IPU Services Ltd 2019 AGM*
5. Financial Report and Consolidated Accounts 2019
a. Adoption of Audited Statement of Accounts of IPU 
b. Appointment of Auditors of IPU and IPU Services Ltd
c. Adoption of Directors’ Report and Audited Statement of Accounts of IPU Services Ltd 
7.20pm 6. Address from President
7.30pm 7. Group Reports
a. Pharmacy Contractors’ Committee Report 
b. Community Pharmacy Committee Report 
c. Employee Pharmacists’ Committee Report 
d. Communications Report* 
e. International Pharmacy Matters* 
7.55pm 8. Report on Motions from 2019 AGM*
8.00pm 9. 2020 AGM Motions
8.30pm 10. Open Forum
8.45pm Closing of AGM Procedures by IPU President Daragh Connolly 
Handover of IPU Presidency to President-elect Eoghan Hanly
AGENDA
Chairperson: Mr Daragh Connolly, President
* These items are contained in a more detailed report on www.ipu.ie.
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MESSAGE FROM  
THE PRESIDENT-ELECT 
EOGHAN HANLY
It gives me great pleasure to present the IPU Annual Report, 
which details the work undertaken on your behalf by the 
Committees and staff of the IPU.
Dear Colleagues and friends,
What a difference a year makes. Who could 
have pictured a worse scenario than Brexit, 
FEMPI and an apathetic Government? These 
difficulties have now been compounded by the 
nightmare of COVID-19. The mental stresses 
faced by everyone are unrelenting and the 
demands placed on pharmacy are increasing 
day to day. Against this background, we still 
do our jobs within the framework of a contract 
that the Government has admitted is outdated 
and no longer fit for purpose. We do not get 
paid enough for our core job of dispensing 
medicines and advice safely to patients and we 
do not get paid at all for some of the essential 
services patients need like monitored dosage 
systems, medicine reviews and novel medicine 
interventions. It is difficult not to be negative 
in this context.
We have been promised continuously both 
verbally and in writing that negotiations on 
a new pharmacy contract are imminent and 
yet at this time we still have no start date for 
the talks. This is unacceptable. For Ireland 
to have a modern viable pharmacy sector 
that can practise to full scope, it needs to be 
underpinned by a contract that encompasses 
fairness and sustainability. Sláintecare has 
set out a pathway for future healthcare in 
Ireland and a new contract is needed to reflect 
pharmacy’s essential role in achieving this vision. 
At the height of the pandemic crisis, when 
the country went into a full lockdown, IPU 
members showed great leadership in their 
workplaces and communities by staying open 
to provide essential medicines, guidance and 
care. When I look proudly at the outstanding 
role pharmacy in Ireland has taken on during 
the pandemic it makes me wonder what the 
impact would have been if the Department 
of Health had forced through the cuts that 
they had wanted to impose on our already 
beleaguered sector last December. I strongly 
commend the resolve that IPU members 
showed when approaching the local politicians 
in their offices and in your pharmacies. It is 
because of these efforts and the excellent 
guidance issued from the leadership in 
Butterfield House that those cuts were 
stopped. The battle was won but the war 
continues. Thanks to your response to the 
pandemic within each of your communities, 
pharmacy is again deservedly held in the 
highest esteem by Irish people.
Also due to the crisis we have seen a hint of 
what a modern fit for purpose eprescribing 
system could look like, cutting down on 
bureaucracy, errors, environmental waste 
and phone contact, while also making life 
more convenient for both ourselves and our 
patients. The implementation of such a system 
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has been the stated goal of Government since 
2013 and yet here we are seven years later 
grateful for a sticking plaster solution forced 
on us by extraordinary circumstances.
I would like to acknowledge the dedication and 
hard work, under challenging circumstances, 
of all the members of our committees and 
the employees of the Union, all of whom have 
kept working and delivering for members, 
helping guide us through a very difficult year. 
Thank you. 
It is a new world out there and one that we will 
have to cope with for the foreseeable future. 
It is a future where pharmacy will, because of 
need, take on even more of a central role in 
local healthcare. This role must be resourced 
with proper renumeration, personnel, training 
and support. I am looking forward to working to 
achieve this in my new role as President, along 
with the Committees and staff of the IPU. 
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MINUTES OF THE  
46TH ANNUAL GENERAL 
MEETING OF THE IRISH 
PHARMACY UNION  
AND IPU SERVICES LTD
Galmont Hotel, Galway
12 May 2019
Present: The President, Daragh 
Connolly and 41 members
In attendance: Darragh O’Loughlin,  
Jim Curran, Darren Kelly, 
Pamela Logan, Roisin Molloy 
and Derek Reilly.
Apologies: Apologies were received 
from seven members.
1. The President welcomed the attendance to 
the 46th Annual General Meeting of the 
Irish Pharmacy Union.
2. On the proposal of the President all present 
stood in silence in memory of deceased 
members and family members who had died 
since the 2018 AGM. 
 On the proposal of the President, Marie 
McConn was unanimously appointed a 
Trustee of the Irish Pharmacy Union in 
accordance with article 25 of the IPU’s 
Constitution. 
3. Minutes of 2018 AGM 
The report of the 45th Annual General 
Meeting, previously made available on 
the members’ section of www.ipu.ie, was 
taken as read. The report was proposed by 
Kathy Maher, seconded by Sinead Ryan, 
unanimously approved and signed by the 
President.
4. Financial Reports and Accounts 2018 
Eoghan Hanly (Vice President) presented 
the IPU’s Financial Report and took queries 
from the floor. He reported that both 
income and expenditure had increased over 
the 2018 outturn and offered explanations 
outlining in detail relevant additional activity, 
new revenue and increased costs.
 Following the presentation, the following 
motion approving the accounts was 
proposed by Kathy Maher, seconded by 
John Carey and carried unanimously:  
“That the Executive Committee Report and 
Audited Statement of Accounts for the  
Irish Pharmacy Union for the year ended  
31 December 2018 as submitted to this 
meeting be and are hereby adopted.”
6
2020 ANNUAL REPORT OF IPU EXECUTIVE COMMITTEE
 IPU Auditors
 The following motion was proposed by 
Eoghan Hanly, seconded by Michael Tierney 
and carried unanimously: “That this meeting 
agrees to the election of JPA Brenson 
Lawlor as Auditors for the IPU and IPU 
Services Ltd”
5. IPU Services Ltd AGM
The minutes of the 2018 AGM of  
IPU Services Ltd were taken as read.
The accounts were presented by the  
Vice President and on the proposal of 
Michael Tierney seconded by John Carey  
it was resolved:
“That the Directors’ Report and Audited 
Statement of Accounts for the year ended 31 
December 2018 as submitted to this meeting, 
be and are hereby adopted.”
This motion was carried.
6. IPU Secretariat Report
The IPU Secretariat Report was taken as 
read, having been circulated to members by 
post in advance of the meeting and a more 
detailed report published on the members’ 
section of www.ipu.ie. 
7. Group Reports
a. Pharmacy Contractors Committee 
(PCC) Report
This report was presented by Eoghan 
Hanly, Chairperson of the Pharmacy 
Contractors’ Committee.
The report had been circulated to 
members in advance of the meeting and 
a more detailed report published on the 
members’ section of www.ipu.ie. 
b. Community Pharmacy Committee 
(CPC) Report
The report was presented by Jonathon 
Morrissey, Vice Chairperson of the 
Community Pharmacy Committee.
The report had been circulated to 
members in advance of the meeting and 
a more detailed report published on the 
members’ section of www.ipu.ie.  
c. Community Employee (EPC) Report
This report was delivered by Sinead 
Ryan, Chairperson of the Employee 
Pharmacists’ Committee. 
The report had been circulated to 
members in advance of the meeting and 
a more detailed report was published on 
the members’ section of www.ipu.ie. 
d. Communications Report
This report had been made available on 
the members’ section of www.ipu.ie and 
was taken as read. 
e. International Pharmacy Matters
This report had been made available on 
the members’ section of www.ipu.ie and 
was taken as read. 
9. President’s Address
The President gave a brief overview of the 
work of the IPU over the previous 12 months, 
a copy of which is attached at Appendix 1.
10.Report on Motions from 2018 AGM
The report on motions from the 45th 
Annual General Meeting was taken as read.
11. 2018 AGM Motions
The following motions were proposed 
in accordance with Article 30 of the 
Constitution. The motions were discussed 
and considered by the meeting before  
being put to a vote.
1. Proposed: Jonathon Morrissey
 Seconded: Anna Kelly
 “That this AGM commends the Sláintecare 
Programme for engaging with the IPU 
to explore the healthcare role of the 
pharmacist and looks forward to the 
expansion of pharmacy services as part  
of reforming and modernising healthcare  
in Ireland.”
 This motion was carried unanimously.
2. Proposed: John McLaughlin 
 Seconded: Conor Phelan
 “That this AGM calls on the HSE to pay  
for Blister Pack Dispensing in the  
following cases:
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a. Hospital Discharge patients prescribed 
more than three drugs on discharge;
b. Psychiatric Patients; 
c. All Patients over 80 years of age; and
d. Any Patients that clearly present an 
identifiable risk of making errors in their 
medications.”
 Following some debate and discussion, 
this motion was carried with three 
abstentions and one vote against.
3. Proposed: Daragh Connolly 
 Seconded: Sinéad Ryan
 “That this AGM calls for the Introduction 
of a new category of IPU membership for 
pharmacy students.”
 The following amendment to this motion 
was proposed and carried with two 
abstentions and three votes against:
 “That the IPU Constitution be amended by 
the insertion of a new article 3.e. to provide 
for a new category of IPU membership for 
pharmacy students.”
 Following some debate and discussion, 
this motion was carried with two 
abstentions and four votes against.
4. Proposed: Sheila O’Loughlin
 Seconded: Sinéad Ryan
 “That this AGM calls on the HSE PCRS 
and the PSI to review and reduce the 
level of unnecessary bureaucracy they 
foist on community pharmacists which 
risks exacerbating the exodus of young 
pharmacists from the profession.”
 Following some debate and discussion, 
this motion was carried with two 
abstentions.
5. Proposed: Anna Kelly
 Seconded: Denis O’ Driscoll
 “That this AGM calls on the Health Service 
Executive to discontinue the approval 
process for Direct Oral Anticoagulants 
(DOACs) as it is no longer relevant.”
 This motion was carried unanimously.
6. Proposed: Eoghan Hanly
 Seconded: Michael Tierney
 “That this AGM calls upon the Minister 
for Health, following the recent agreement 
with General Practitioners, to immediately 
commence substantive talks with the IPU to 
reverse FEMPI as it applies to community 
pharmacy contractors.”
 In light of the Minister’s announcement 
the previous day, the following 
amendment to the motion was proposed 
by Eoghan Hanly, seconded by Michael 
Tierney and agreed unanimously.
 “This AGM commends the Minister for 
Health on his commitment to commence 
substantive talks with the IPU to reverse 
FEMPI as it applies to community 
pharmacy contractors.”
 This motion was carried unanimously.
7. Proposed: Richard Collis
  Seconded: David Jordan
 “That this AGM calls on the IPU to create 
a dedicated unit, which would deal with 
all policy matters and issues emanating 
from the PSI. This unit would regularly 
update members through the IPU Review 
of any and all developments that affect the 
practice of pharmacy. It would lobby and 
articulate on issues of concern and interest 
to members such as, Inspection Policy, 
Fitness to Practice, CPD. It would act as a 
focus for members interacting with the PSI, 
enabling the IPU to be seen as safeguarding 
the interests of the general membership.”
 Following some debate and discussion, 
this motion was defeated with eight 
abstentions and 23 votes against.
MINUTES OF THE  
46TH ANNUAL 
GENERAL 
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8. Proposed: Daragh Connolly
 Seconded: Eoghan Hanly
 “That the IPU Constitution be amended 
by the insertion of a new article 4.n. and 
the amendment of the existing article 
4.m. in order to provide an alternative 
method for collection of membership fees 
in circumstances where the Health Service 
Executive ceases to make deductions 
from the professional fees payable to 
members under the Community Pharmacy 
Contractor Agreement and to remit same 
to the Pharmacy Contractors’ Committee 
of the IPU.”
 This motion was carried unanimously.
12. Open Forum
Items discussed included:
a. Nicola Cantwell raised the prospect 
of setting up a service similar to the 
Pharmacy Friends Service in the UK, for 
Irish Pharmacists. It would act as a type 
of listening/counselling services were 
pharmacists could call in to discuss any 
issues they may be having. Nicola asked 
that anyone interested in assisting in 
setting up this service to contact her.
b. Richard Collis felt the timings of the 
AGM are too tight.
c. That large hospitals be asked to provide a 
dedicated name/contact number for out 
of office hours queries on prescriptions. 
d. Michael Tierney asked if the regional 
structures could be reviewed. 
The President thanked the organisers of 
the Conference for all the work in making 
the weekend such a success. He thanked 
the IPU Secretary General and staff, 
Committee members and colleagues for 
their support during the year and then 
closed the 46th Annual General Meeting  
of the Irish Pharmacy Union. 
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Fellow pharmacists and members of the IPU, I 
would like to welcome you all here this morning 
to discharge the requirements of the Annual 
General Meeting of the Irish Pharmacy Union. 
Since we last met at our AGM 12 months ago a 
lot has happened but, as we are all aware, some 
things remain the same. 
It remains a difficult time for pharmacy 
businesses, with pressures continuing to 
intensify through reduced margins, increased 
costs, recruitment concerns and huge 
uncertainty, in both the domestic and external 
environments.
Brexit
The political landscape over the last 12 months 
has been dominated by Brexit and we all know 
the potential impact it may have on our sector; 
on the supply of medicines, medical devices and 
cosmetics and on professional qualifications. 
This time last year, I was warning of the 
uncertainty of Brexit. Little did I know what 
was coming down the tramlines and 12 months 
later we are no more the wiser to what the 
outcome will be. 
On your behalf, the IPU has worked very 
closely with the HPRA, PSI and Department 
of Health to plan and mitigate for the 
inevitable disruption Brexit will cause. We have 
participated in regular stakeholder meetings in 
the Department of Health and have produced 
a comprehensive guide to assist members with 
their planning, which has required more regular 
updates than we would have liked. We will 
obviously continue to monitor the situation and 
hopefully a solution will be found to this mess 
sooner rather than later.
Falsified Medicines Directive
Another challenge we all faced in February of 
this year was the introduction of the Falsified 
Medicines Directive. We are all aware of 
the teething problems that have occurred 
in complying with this European legislative 
requirement and all efforts are being made 
to accommodate solutions to these ongoing 
problems. While acknowledging these 
concerns, it is important to note that this 
system provides an additional layer of security 
on top of an already safe and secure medicines 
supply chain; it is not a solution to an actual 
problem. The IPU has liaised extensively with 
other stakeholders through the Irish Medicines 
Verification Organisation, with the Department 
of Health and the HPRA, to ensure that this 
legislation does not lead to patients’ access to 
perfectly good medicines being obstructed. 
We have sought the release of funds from 
the Department of Health to support full 
implementation of Medicines Authentication.
Pharmacy Interface Project
When I addressed the AGM last year, I 
announced that we had made the decision to 
withdraw from the HSE’s PCRS Pharmacy 
Interface Project. This decision was taken 
for the right reasons at that time and 
reflected our extreme frustrations at the 
HSE’s continued failure to reciprocate, in a 
meaningful way, the goodwill and cooperation 
shown to them by community pharmacists. 
It is also a consequence of the unjustifiable 
and inexplicable failure of this Government 
to engage with us on the reversal of FEMPI 
and the savage cuts imposed upon us and our 
sector.
PRESIDENT’S ADDRESS 
TO THE IPU AGM
Galmont Hotel, Galway
Sunday, 12 May 2019
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However, on foot of that decision, the PCRS 
decided to engage in heavy-handed tactics, 
which included a significant increase in 
inspection activity and intensive scrutiny of 
individual pharmacists. It also became clear that 
we were being frozen out of discussions with 
the Department of Health on key pharmacy 
concerns, including unwinding FEMPI and 
expanding the scope of pharmacists practice.
While it was not an easy decision, the Executive 
Committee and the Pharmacy Contractor’s 
Committee agreed to strategically reengage 
with the PCRS on a broad agenda that could 
potentially lead to the introduction of the 
Pharmacy Interface Project. This was on the 
condition, however, that certain IPU demands 
were met, including reengagement with the 
Minister for Health and the Department of 
Health and getting the support of the PCRS 
for the introduction of specific pharmacy-
led services, including their support for a 
HSE-reimbursed pharmacy pneumococcal 
vaccination service 
Since our decision to reengage, we have 
had several progressive meetings with the 
Minister for Health, the Executive Director of 
Sláintecare and Department of Health officials. 
The HSE is working to have the pharmacy 
pneumococcal service in place by October 
2019 and we are seeking the introduction of 
other services.
Much like Brexit, engagement, discussion and 
negotiation remain the only way forward and 
that collaboration will result in benefits, both 
for the HSE and the pharmacy profession. 
More importantly, engagement will lead to 
improvements for our patients and the public. 
FEMPI
These recent meetings have been very timely, 
as the recent reports of a deal with the GPs to 
unwind FEMPI has put a focus on Pharmacy 
and a corresponding reversal for our profession. 
I am not going to stand here and lecture you 
about the impact that FEMPI cuts have had 
on our profession over the last 10 years. You 
all know, like myself, the impact that these 
cuts have had on your pharmacy businesses. 
The IPU’s views and demands have been 
consistently highlighted in the avalanche 
of reports, submissions, press releases and 
meetings with the Minister and Department 
officials over the years in attempting to seek 
fairness of treatment. 
We have consistently made it clear that 
any reimbursement model for community 
pharmacies must include proper 
reimbursement for all medicines, a sustainable 
dispensing fee across all schemes, proper 
recognition of the value of services we provide 
and additional supports for marginal pharmacies 
in disadvantaged, rural or isolated communities. 
These views were forcibly repeated in our 
recent meetings with the Minister and his 
officials from the Department of Health and 
repeated when he addressed us yesterday.
We were delighted therefore that the Minister 
has committed to delivering a new contract and 
to moving beyond FEMPI in a way that will see 
an increased investment in pharmacy services. 
We are looking forward to beginning a process 
which should lead to reform, modernisation and 
contractual overhaul for community pharmacy 
– as the Minster himself said “similar to his 
engagement with GPs”.
Minister Harris has confirmed that he was 
looking forward to the discussions with the IPU 
in the coming months and we too are eagerly 
awaiting their commencement, as we have been 
for over two years. 
I am hopeful that progress will be made 
and that FEMPI cuts are reversed and 
the important role we play, as community 
pharmacists is recognised and supported to 
ensure equity, fairness, and the sustainability of 
pharmacies in communities across the country.
Sláintecare
While challenges remain, we must not lose 
sight of the opportunities that exist. The 
theme of this year’s conference is Community 
Pharmacy: Maximising Our Potential. 
The concept of ‘maximising our potential’ 
recognises the necessity for the community 
pharmacy profession to develop a broader 
scope of practice in the future and to be fully 
engaged in the wider health system.
It is Government policy to deliver, through 
Sláintecare, an enhanced and accessible model 
of primary care. Such a policy requires, as a key 
constituent part, a vigorous, sustainable and 
enhanced model of community pharmacy to 
deliver more for patients. The development of 
primary care is a key pillar of our public health 
policy and is correctly intended to treat more 
people, more effectively, in their community 
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where appropriate, outside of an acute hospital 
setting. This is an objective that resonates with 
community pharmacists and is one with which 
we are very well placed to play an important 
role in, delivering effectively for our patients in 
ways that are also cost-effective for the State. 
As well as being a good idea in its own right, 
it makes sense in a country with a shortage 
of GPs that community pharmacists should, 
together with doctors, play a greater role in 
delivering primary care in the community.
Working in tandem with other healthcare 
professionals, in a holistically integrated model 
of primary care, we have a much greater role 
to play. It is a role that is mutually supportive 
of the other medical professions as well as 
of obvious benefit to patients. This vision 
is not revolutionary. To the contrary, as we 
are all aware, it is tried and trusted in several 
jurisdictions across the world including the 
UK, Canada and Australia where the scope of 
pharmacy practice is far broader than here.
We, as pharmacists, are overwhelmingly in 
favour of working to full scope and would relish 
the challenge to continue to add more value to 
our communities’ healthcare, by expanding the 
range of services we provide, including where 
appropriate, chronic disease management, 
health screening, treating minor ailments, 
medicine use reviews, increased vaccinations 
and access to contraception.
We have presented a proposal for a Community 
Pharmacy-Based Triage Programme to the 
Executive Director of Sláintecare, outlining 
the triage services that could be offered in a 
community pharmacy, responding to symptoms 
through a minor ailment scheme, emergency 
medicines administration and minor injury 
management. It was heartening, therefore, 
that our proposals were well received by Laura 
Magahy, the Executive Director of Sláintecare, 
on the number of occasions we met with her 
over the last few months and at the panel 
discussion that she attended yesterday.
The IPU is continuing to work hard on your 
behalf, to get these services included as 
part of the remunerated extended services 
to patients. We will continue to advocate 
for an equitable and sustainable future for 
community pharmacy which utilises the 
accessibility and expertise and willingness 
of community pharmacists to our fullest 
potential. If the Government is serious about 
delivering primary care in the community, they 
can no longer afford to ignore these proposals, 
which have the potential to clear so many of 
the bottle necks which currently frustrate our 
healthcare system.
It was very heartening therefore that the 
Minister for Health in his address to the 
members yesterday when referring to the 
Minor Ailment Scheme said that there 
was no need for any more pilots and that 
a wider implementation was required. He 
also committed to working with the IPU to 
increase access to contraception through 
community pharmacy.  
This is progress but we need to maintain the 
momentum. For us it must always be about 
the patient, they are always at the forefront 
of what we are as healthcare providers and 
healthcare professionals. Patient safety, 
patient care and enhancing patient welfare 
is what drives us forwards, is at the centre of 
our professional ethos and will remain at the 
forefront of our deeds and actions.
Young pharmacists 
A key aspect of our strategy is to ‘mentor the 
next generation of pharmacists’ and to cater 
for the needs of new pharmacists to ensure 
our profession continues to evolve. A recent 
study we commissioned from Behaviour & 
Attitudes should act as a serious wake-up call 
to the difficult road that lies ahead to maintain 
the flow of young pharmacists into community 
pharmacy. The study highlighted the main areas 
of concern to young pharmacists, which, among 
other things, revolve around the excessive 
levels of bureaucracy and red-tape foisted on 
the sector coupled with a perception that their 
professional skills are underutilised in comparison 
to their colleagues in other countries. 
I am sure you will all agree that to make the 
sector more appealing, and professionally 
rewarding, it is essential that we are allowed to 
expand our scope of services and ensure that 
we can practise our chosen profession rather 
than act as outsourced bureaucrats.
I have already discussed our many proposals for 
expanding the scope of pharmacy practice. 
Regarding tackling excessive bureaucracy, 
the bane of many of our lives, we continue 
to act to try and alleviate our members and 
potential members’ concerns. The HSE PCRS 
PRESIDENT’S 










2020 ANNUAL REPORT OF IPU EXECUTIVE COMMITTEE
has agreed to work jointly with us to review 
the operation and administration of the States 
Community Drug schemes with a view to 
improving their efficiency, by streamlining 
and reducing the administrative burden on 
community pharmacies by moving as much 
paperwork as possible online. We continue 
to highlight our concerns in our numerous 
meetings and correspondence with the PSI and 
we will continue to push them towards reducing 
unnecessary administrative requirements, 
which invariably takes us away from helping our 
patients and providing them with appropriate 
healthcare. But, there is a lot more to do and 
this issue will be discussed in greater detail 
during the presentation of the AGM motions.
 
On a positive note, the in-depth Behaviour 
& Attitudes study highlighted that being a 
community pharmacist remains a rewarding 
professional practice, with high satisfaction 
levels expressed for using our expertise and 
knowledge to assist patients and their families 
with their healthcare needs. 
Talking of young pharmacists, we were 
delighted to support the Irish Pharmacy 
Students Association with their successful 
campaign. To build on such a positive 
collaboration I will bring forward a motion 
shortly for the introduction of a new category 
of IPU membership for pharmacy students. 
Conclusion
Our only agenda is to further the interests of 
our members and of the pharmacy profession. 
We will continue to engage constantly and 
constructively with Government and with the 
public to ensure the potential of pharmacy is 
realised. Ours is a worthy profession, one which 
is valued and appreciated by our patients. As 
we face up to the significant challenges ahead, 
the IPU, on your behalf, will continue to seek 
out and seize every opportunity to secure the 
future of community pharmacy services.
Looking forward to the rest of the year and 
further into 2020 there remains the possibility 
of a general election, which means that the IPU 
and the membership need to be on an election 
footing. It is essential therefore that members 
engage with candidates on the ground in their 
constituencies. Our accessibility within local 
communities and our local knowledge provides 
us with a considerable advantage in accessing 
these key policy makers and ensuring that our 
message is heard.
I implore you to be active and encourage 
your colleagues locally to do likewise to 
get our messages out there, not just to the 
local representatives but to all stakeholders, 
including our patients and the public, because 
it’s their votes the politicians need.
To assist in this process, we will shortly be 
sending you out a copy of our policy document 
specifically drafted with elections in mind, 
together with other materials to support the 
campaign. 
  
Before I conclude, I would like to thank all our 
committee members, who have given their time 
and energy over the past number of years.
 
I would also like to take this opportunity to 
thank Vice-President Eoghan Hanly, Honorary 
Treasurer Caitriona O’ Riordan and all our 
hard-working committee members who 
work tirelessly on your behalf. They are ably 
supported by the dedicated staff in Butterfield 
House, all of whom remain committed to 
supporting and assisting all of us. On your 
behalf, I thank all of them most sincerely for 
their commitment, dedication and enthusiasm. 
I would like to pay particular thanks to our 
Secretary General, Darragh O’Loughlin, for his 
considerable efforts in promoting our sector 
and protecting the interests of our members, 
and for his support, advice and guidance to me 
in my role as President.
 
Finally, I would like to thank you all for your 
support and kindness over the past 12 months. 
It is an honour and a pleasure to serve you my 
fellow members and community pharmacists.
I would like to wish you all the best for the rest 
of the day and a safe journey home.
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1. Proposed: Jonathon Morrissey
 Seconded: Anna Kelly
 
 “That this AGM commends the Sláintecare 
Programme for engaging with the IPU to 
explore the healthcare role of the pharmacist 
and looks forward to the expansion of 
pharmacy services as part of reforming and 
modernising healthcare in Ireland.”
We presented a Proposal for a Community 
Pharmacy-Based Triage Programme to the 
Executive Director of Sláintecare outlining 
the triage services that could be offered 
in a community pharmacy: responding 
to symptoms (minor ailment scheme); 
emergency medicines administration; and 
minor injury management. At a subsequent 
meeting with the Minister for Health, the 
Minister indicated that any new service 
would have to demonstrate a return on 
investment and would need to be backed up 
by data and research. We discussed in detail 
services such as Minor Ailment Scheme, 
New Medicine Service and Expanded 
Vaccination. The Minister clarified that there 
is a big push from Government to align all 
primary care services to the Sláintecare 
action plan.    
 
We attended a Sláintecare Workshop on the 
implementation of integrated community 
services. The workshop brought together 
key stakeholders to inform the direction 
of integrated community services, with 
particular focus on the point of contact 
for patients with community services. It 
is intended to follow up on the workshop 
with further meetings with healthcare 
professionals to identify the different roles 
for healthcare professionals in delivering 
community services.
 
A project involving the IPU, in conjunction 
with Orla Hardiman, Consultant 
Neurologist, and the Migraine Association, 
received Sláintecare funding to develop and 
pilot Pharmacy Headache Clinics which 
aim to enable migraine sufferers to access 
appropriate treatment in pharmacies. 
Implementation of the project, which was 
delayed because of coronavirus, is not set for 
September.  
 
Since April 2020, we have participated in 
a multi-stakeholder Community Pharmacy 
Contingency Planning Group. In addition to 
addressing issues related to the coronavirus 
pandemic, the Group intends to build on 
the current collaboration between various 
representative groups/bodies to change 
and improve the way community pharmacy 
operates within the health system in the 
medium to longer term.
2019 AGM MOTIONS  
AND REPORT ON 
ACTION TAKEN
The following motions were proposed in accordance 
with Article 30 of the Constitution. All motions 
were debated and considered by the meeting and 
then passed.
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2. Proposed: John McLaughlin 
 Seconded: Conor Phelan
 “That this AGM calls on the HSE to pay  
for Blister Pack Dispensing in the  
following cases:
a. Hospital Discharge patients prescribed 
more than three drugs on discharge;
b. Psychiatric Patients; 
c. All Patients over 80 years of age; and
d. Any Patients that clearly present an 
identifiable risk of making errors in their 
medications.”
The IPU lodged a formal submission, prior 
to the above motion, with the Department 
of Health in April 2018. The submission 
proposed that the state should fund a 
Monitored Dosage System (MDS) service 
for those elderly/psychiatric patients who 
are on five or more prescribed medicines to 
assist them with managing their medicines. 
In October 2019, the Department of Health 
proposed cuts to current pharmacy fees 
that were successfully resisted. Funding 
for an MDS service will be integral to 
our negotiations with the State in future 
contract talks. 
3. Proposed: Daragh Connolly 
 Seconded: Sinéad Ryan
 “That the IPU Constitution be amended by 
the insertion of a new article 3.e. to provide 
for a new category of IPU membership for 
pharmacy students.”
The IPU Constitution has been amended to 
provide for a new category of membership 
for eligible pharmacy students by inserting 
a new Article 3(e) aligned with the existing 
provision relating to Associate Membership 
(Article 3(d)). The new Article is as follows:
Article 3.e.: Membership of the IPU shall be 
open to any student enrolled in one of the 
schools of pharmacy operating within the Irish 
State and to any Irish citizen enrolled in a 
school of pharmacy outside the Irish State that 
is recognised by the IPU (“Student Member”). 
The Annual Subscription for a Student 
Member shall be one tenth of the standard 
annual subscription. A Student Member shall 
not be qualified to be elected as a member of 
the IPU Executive Committee, or be entitled 
to receive notice of or vote at any general 
meeting of the IPU. Student Members shall 
be entitled to receive the IPU Review and any 
other documentation deemed by the Executive 
Committee to be of general interest.
The application process for student members 
is managed via the IPU website, applicants 
are required to provide proof of enrolment 
in a School of Pharmacy and, in the case of 
a school of pharmacy outside the Irish State, 
proof of Irish Citizenship. All documentation 
and information deemed appropriate by 
the Executive Committee is disseminated 
to student members electronically. We 
currently have 157 student members. 
4. Proposed: Sheila O’Loughlin
 Seconded: Sinead Ryan
“That this AGM calls on the HSE PCRS 
and the PSI to review and reduce the level 
of unnecessary bureaucracy they foist 
on community pharmacists which risks 
exacerbating the exodus of young pharmacists 
from the profession.”
In all our discussions with the PCRS 
throughout the year, we have sought to 
reduce the administrative burden for 
pharmacists. At the onset of the current 
COVID-19 crisis, we demanded that 
the PCRS reduce the administrative 
requirements substantially for our members. 
Our aim was to ensure that pharmacy claims 
were paid with the minimum of fuss, without 
the stringent administrative rules that would 
ordinarily apply. 
Although the crisis is still ongoing, our focus 
has now shifted to maintaining the reduction 
in the administrative burden once the 
current crisis has passed. 
5. Proposed: Anna Kelly
 Seconded: Denis O’ Driscoll
“That this AGM calls on the Health Service 
Executive to discontinue the approval process 
for Direct Oral Anticoagulants (DOACs) as it 
is no longer relevant.”
We have through the auspices of the Joint 
Operational Group engaged with the PCRS 
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to remove this unnecessary approval process. 
In September 2019, the PCRS removed the 
requirement for Apixaban to be approved, 
which is an improvement, although they 
still require approval to prescribe other 
DOACs. We continue to point out to the 
PCRS that this is bureaucracy for the sake of 
bureaucracy.
6. Proposed: Eoghan Hanly
 Seconded: Michael Tierney
“This AGM commends the Minister for Health 
on his commitment to commence substantive 
talks with the IPU to reverse FEMPI as it 
applies to community pharmacy contractors.”
At successful negotiations last year to 
halt cuts to pharmacy payments the then 
Minister for Health and the Department of 
Health advised that it was their intention to 
commence new contract talks at some stage 
in 2020, but that they were not in a position 
to commence at that time. 
Following on from our political campaign in 
the latter months of 2019, we continued to 
engage with Government and opposition 
spokespersons, which resulted in a 
commitment in the current Programme 
for Government to commence talks with 
pharmacists on a new contract in 2020.  
While the current COVID-19 crisis has 
subsequently taken precedence over planned 
talks, we continue to press the Government 
to honour their commitment to a new 
contract in our engagement with them 
throughout the year.
7. Proposed: Daragh Connolly
 Seconded: Eoghan Hanly
“That the IPU Constitution be amended by 
the insertion of a new article 4.n. and the 
amendment of the existing article 4.m. in 
order to provide an alternative method for 
collection of membership fees in circumstances 
where the Health Service Executive ceases to 
make deductions from the professional fees 
payable to members under the Community 
Pharmacy Contractor Agreement and to 
remit same to the Pharmacy Contractors’ 
Committee of the IPU.”
 The IPU Constitution was amended 
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OVERVIEW FROM THE 
SECRETARY GENERAL  
DARRAGH O’LOUGHLIN
2019 was a year of contrast and contradiction in the relationship 
between the pharmacy sector and the Department of Health, 
which soured dramatically towards the end of the year.
2019 was a year of contrast and contradiction 
in the relationship between the pharmacy 
sector and the Department of Health,  
which soured dramatically towards the  
end of the year.
The year began with a very high profile legal 
action by the HSE against a prominent 
pharmacy chain, in which the HSE reportedly 
sought recoupment of between €5 million 
and €7 million in fees alleged to be owed for 
non-compliance with phased dispensing rules 
over a number of years. That case was settled 
at the Commercial Court, with both parties 
agreeing to a declaration that, under the 1996 
Community Contractor Pharmacy Agreement, 
phased dispensing fees were, and are, payable 
for GMS patients only where an item on a 
single prescription form is dispensed across 
multiple supply occasions. This declaration, 
which was contrary to the position taken by the 
IPU, emboldened the HSE to pursue a number 
of other pharmacy contractors for alleged 
over-claiming of phased dispensing fees and the 
IPU continues to support members in dealing 
with these issues.
Also during 2019, the twin issues of Brexit 
and the Falsified Medicines Directive were 
unwelcome new challenges which brought 
uncertainty, inconvenience and complexity 
with no apparent benefit. The IPU remained 
in regular contact with the Department of 
Health, HPRA and HSE regarding their 
contingency plans for Brexit, as well as with 
the industry and wholesalers to get 
reassurance that medicine supply chains 
were resilient and appropriately stocked. 
We also advocated continuously that 
no penalties should be introduced 
regarding medicines authentication 
until the system was fully bedded in 
and the alert rate was reduced to 
negligible proportions. We remain in 
this “use and learn” phase to this day. 
We heard repeated commitments 
from the Minister for Health to start 
discussions before the end of the year 
on a new pharmacy contract, on 
moving beyond FEMPI and on a 
programme of investment in 
pharmacy services. 
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Industry & Wholesale 2
Community Employees 1413
Hospital 0
Army, Academic & Admin 2 
Associate Members 7 2278
Student Members 145













2. DETAILS OF IPU MEMBERSHIP AND PHARMACY 
OWNERSHIP (AS AT 11 MARCH 2020)
The IPU position was clear: community 
pharmacy needed an uplift of 19.2% in our 
fees to ensure the survival of our sector and 
sustainability of pharmacy services, pending 
the promised negotiations on a new pharmacy 
contract. In discussions with the Department in 
the final months of the year, pharmacies were 
instead threatened with swingeing cuts. The 
IPU Pharmacy Contractors Committee and 
members around the country mounted a very 
successful campaign against those cuts and in 
December 2019, the Minister overturned the 
proposed cuts and left fees as they were for 
the time being. Furthermore, he committed 
the Department to commencing talks on a 
new pharmacy contract in the New Year, which 
unfortunately was superseded by a general 
election. While the decision not to impose fee 
cuts came as an enormous relief to the entire 
sector, the campaign for a new contract and a 
commensurate increase in fees still continues.
The IPU exists only to serve the interests of 
its members. There are comprehensive reports 
in this publication which illustrate the wide 
range of activities that the IPU engages in. 
The Executive Committee, which oversees the 
management of the IPU and the work of the 
three main IPU Committees – the Community 
Pharmacy Committee, Employee Pharmacists’ 
Committee and Pharmacy Contractors’ 
Committee – ensures the IPU’s continued 
importance to and focus on the needs of 
practising pharmacists. In the coming year, the 
IPU Statement of Strategy 2017-2021 will 
be reviewed, and the Executive Committee 
will develop a new IPU Statement of Strategy 
which will continue to ensure that community 
pharmacy is recognised as being at the centre 
of accessible, equitable and patient-focussed 
primary healthcare and is properly resourced to 
carry out that essential role.
The members of the IPU’s various committees 
and sub-committees have worked hard all year 
to support, advance and protect the community 
pharmacy profession. The term of office of 
the current committees will finish at the end 
of 2021. We are lucky to have a great mix of 
pharmacists of ability and integrity volunteering 
to serve on IPU committees on behalf of 
all members – keeping the perspective and 
concerns of everyday practising pharmacists to 
the fore – and we hope that they will remain 
willing to do so into the future. The pooling of 
members’ ideas, efforts and resources, matched 
with the enthusiasm of the pharmacists who give 
generously of their time, energy and experience, 
ensures that all pharmacists benefit from IPU 
support in their practices and their businesses 
and also ensures that we are here to advise and 
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One Pharmacy 659 62 721
Two pharmacies 126 6 264
Three 44 1 135
Four 12 1 52
Five 10 0 50
Six 6 1 42
Seven 4 1 35
Eight 1 0 8
Nine 2 0 18
Ten 2 20
Eleven 1 1 22
Twelve 2 24
Thirteen 2 26 34
Seventeen 2 34 27
Eighteen 1 18 36
Twenty –Seven 1 27 37
Thirty Five 1 35 63
Thirty Six 1 36 83
Sixty Four 1 64
Eighty Five 1 85
Ninety One 1 91
(1,462) (345) (1,807)
Notes on Employee Membership
817 are Supervising Pharmacists availing of the free membership for additional pharmacies
3 are Supervising Pharmacists in non-pharmacist owned pharmacies and are covered by 
the sub paid by the pharmacy. 23 are joint owners of a pharmacy.
92 are availing of the free membership. 
3. ADMINISTRATION UNIT
The Administration Unit has three staff 
members. Róisín Molloy is responsible for all 
aspects of membership and the management 
of the Secretary General’s office. Patrice 
O’Connor looks after membership support and 
assists in the day-to-day running of the office. 
Ciara Enright, who works part-time as the 
IPU’s accountant, is Secretary to the Finance 
Committee. She maintains books of account 
and advises members on a range of taxation and 
accountancy issues.
4. IPU PRODUCT  
FILE UNIT
The IPU Product File is managed 
by Fiona Hannigan and her team: 
Ger Gahan, Tara Kelly, Eilish Barrett and Alan 
Collins. As well as supplying price updates and 
product information for members, they provide 
the following services and advice:
n	Product sourcing;




IPU Product File Update
n	 In March 2019, as part of continually 
improving information on the IPU Product 
File, we flagged all items on the IPU 
Product File that must be ordered through 
the High Tech Hub. This flag is in addition 
to the reimbursement restrictions already 
on the IPU Product File;  
n	 In April 2019, the IPU Product File took a 
stand at the HPAI (Hospital Pharmacists 
Association of Ireland) Conference; this 
proved to be very successful and there 
was a lot of interest from attendees in the 
IPU Product File; and
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n	 In November 2019, we had a presentation 
on the IPU Product File at the Annual 
Health Informatics Society of Ireland 
(HISI) Conference and Scientific 
Symposium. The IPU sponsored the event 
with a stand exhibiting the IPU Product 
File to attendees. A mix of hospital and 
community-based professionals visited 
the IPU stand to learn more about how 
the IPU Product File is used in initiatives 
such electronic discharge reports, 
medication management and other 
developing use cases.
ISO Certification awarded to IPU Product File
n	Continued certification to ISO 
27001:2013 and ISO 9001:2015  
awarded February 2019; and
n	 ISO Certification maintained, through 
quarterly audits.
IPU Product File Distribution
n	Work on developing a new distribution 
method for the IPU Product File is 
complete and went live in September 
2019;
n	Piloting and rollout has begun on Web 
Service Distribution; and
n	The FTP download of the IPU Product 
File will cease once all users have been 
moved over to Web Service Distribution.
Enhancements to the IPU Product File
n	Virtual Medicinal Product (VMP) 
Classification is now complete and is 
available via Web Service Distribution;
n	SNOMED mapping is complete on the 
IPU Product File for Dose Form and 
Route of Administration and the process 
of mapping to Substance has commenced; 
n	Since early 2019, we have been working 
with SNOMED Ireland to have IPU 
Product File information in the official 
SNOMED CT file for Ireland. At the 
SNOMED CT Expo in Kuala Lumpur in 
Oct 2019, we presented on our process 
for mapping the IPU Product File to 
SNOMED; and
n	A web portal is being developed to allow 
manufacturers, suppliers and other licence 




The Contract Unit consists of 
two staff members, Derek Reilly, 
Contract Manager and Secretary to the 
Pharmacy Contractors’ Committee (PCC), and 
Linda Ahern, Contract Administrator.
As PCC Secretary, Derek plays a key role in 
developing and promoting PCC initiatives and 
the resolution of issues arising with the HSE 
PCRS and the Department of Health. 
Linda is responsible for advising and assisting 
IPU members on the administration of 
the Community Pharmacy Contractors 
Agreement, in particular processing claims 
and payments, and administering the HSE 
community drugs schemes. 
The Contract Unit engaged with the PCRS on 
behalf of members throughout the year and 
assisted a number of individual contractors in 
reaching confidential voluntary settlements 
with the HSE PCRS.
The latter part of 2019 was consumed with 
our collective response to the proposed cut to 
pharmacy fees and our strategy that opposed 
this through an administrative, political and legal 
campaign involving all members. A submission 
was made under the Public Service Pay and 
Pension Act 2017, in relation to proposed cuts 
to pharmacy fees, and in December we met 
with the Minister for Health. The Minister 
confirmed at that meeting his commitment to 
leave fees as they are.
From the onset of the COVID-19 pandemic, 
we engaged extensively with the PCRS 
to secure the elimination of the stringent 
administrative and legislative arrangements to 
ensure that pharmacy claims were paid with the 
minimum of bureaucracy and fuss throughout 
the crisis.
6. COMMUNICATIONS  
AND PUBLIC AFFAIRS
Jim Curran, as Director of 
Communications & Strategy, oversees the 
IPU’s internal and external communications 
and is responsible for developing the IPU’s 
strategy. The Communications Team, which 
includes Siobhán Kane and Ciara Browne, is 
responsible for promoting the interests of the 
IPU and the membership through effective 
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public and other parties that influence the 
sector. Jim is responsible for overseeing business 
development and policy research, as well as the 
strategy statement for the IPU, which covers 
the period 2017 – 2021. Jim is also Secretary to 
the Executive Committee and represents the 
IPU on numerous external forums.
Siobhán Kane is Press and Communications 
Manager and is responsible for coordinating the 
communication activities for the IPU across 
multiple channels. She is also responsible for 
the IPU’s public relations and dealing with the 
media, as well as IPU publications, particularly 
the IPU Review and the Annual Report. 
While Siobhán was on maternity leave, Sinéad 
Fennell joined the IPU in August 2018 to cover 
for Siobhán as Press and Communications 
Manager.
Ciara Browne as Communications and Events 
Executive is responsible for the managing 
and coordinating of the annual IPU National 
Pharmacy Conference. She coordinates 
advertising campaigns for the IPU, maintains 
the IPU’s presence on social media channels, 
manages the IPU website, www.ipu.ie, and is an 
editorial associate of the IPU Review. Ciara is 
also responsible for the production of IPU News 
(the weekly eNewsletter) and the monthly GM.
Communications update since the last AGM
n	Communications with Members: 
Communications with members continue 
to improve, with the IPU website, IPU 
News (the weekly eNewsletter) and the 
IPU’s social media channels all seeing a 
significant increase in engagement by 
members. In 2019, we launched our new 
Instagram account. The monthly GM 
is sent to members by email and post. 
Regular communications are sent to keep 
members up to date with vital current 
information to run an efficient pharmacy.
n	Advertising Campaigns: In 2019, we built 
on the success of our campaign from 
2018. Our 2019 Advertising Campaign 
consisted of three segments: a Hay Fever 
campaign, which consisted of a radio 
ad; a Think Pharmacy campaign, which 
consisted of a TV and radio ad; and a 
Flu Vaccination campaign, which also 
consisted of a TV and radio ad. The ads 
were themed with our Think Pharmacy 
tagline and were broadcast at different 
stages throughout the year. The radio ads 
received extensive airplay across national 
and regional stations and our TV ads were 
also well-received across multiple TV 
stations, including RTÉ One.
n	Publications: The IPU Review, IPU 
Yearbook & Diary and Annual Report  
are all produced in-house.
n	Annual Review: The Annual Review of the 
Sector is part of an ongoing annual series 
that authoritatively tracks changes in the 
economic and financial circumstances 
of community pharmacy. It enables us, 
as a representative body, to promote 
members’ interests based on credible 
facts that are measured consistently over 
time. The Review of the Irish Community 
Pharmacy Sector 2019 was carried out by 
Fitzgerald Power.
n	Submissions: The IPU makes submissions 
on behalf of members on a range of 
issues. A list of submissions is available in 
Appendix I.
n	Market Research: The IPU commissioned 
market research amongst the general 
public on their pharmacy usage and 
attitudes towards pharmacy.
IPU National Pharmacy Conference
The annual IPU National Pharmacy Conference 
has taken place since 2011 and is always an 
exciting and engaging weekend. Over the 
years, the conference has grown and expanded 
to facilitate the needs of members, based on 
valuable feedback from attendees and non-
attendees year-on-year. The conference 
is a great opportunity for members to 
come together in an educational and social 
environment and provides valuable networking 
opportunities for pharmacists. Over the 
weekend, pharmacists have the opportunity 
to build on their continuing professional 
development (CPD) and receive updates on the 
work of the IPU at the AGM. The President’s 




The Director of Pharmacy Services, 
Pamela Logan, coordinates all Professional 
and Training matters within the IPU. Pamela 
acts as Secretary to the CPC and details of 
issues covered by this Committee can be found 
in the CPC report. Pamela provides advice 
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and support to members on pharmacy and 
medicines legislation, assists members with 
PSI inspections and FTP, provides templates, 
guidance and policies on a range of pharmacy 
activities and services and liaises with a wide 
range of stakeholders in relation to community 
pharmacy services. Pamela also represents the 
IPU at PGEU and FIP.
Liz Hoctor is the Professional Development 
and Learning Manager and continues to drive 
and enhance IPU Academy. IPU Academy 
has gone from strength to strength in 2019, 
providing members with access to high-quality 
learning opportunities and offering them 
support and assistance in complying with their 
obligations under the regime of mandatory 
Continuing Professional Development (CPD). 
Liz also oversees IPUnet, the online web-based 
platform designed to support the delivery of 
pharmacy services and represents the IPU on 
the Irish Institute of Pharmacy Advisory Group. 
Alma Barr is the IPU Education Coordinator 
and assists Liz with running IPU Academy.
Alan Reilly is our Head of Information & 
Technology, responsible for the development 
and implementation of the IPU’s ICT strategy 
including EU regulations such as data 
protection and medicines authentication. Alan 
is also responsible for identifying current and 
forthcoming IT opportunities, investigating 
how technology will facilitate future activities, 
participating in the national eHealth agenda, 
and advocating the IPU’s technological 
standpoint by liaising on behalf of the IPU with 
bodies such as Department of Health (DoH), 
Sláintecare, HIQA, eHealth Ireland, HSE, 
Healthlink, GPIT and others. 
Since July 2019, under the Horizon 2020: 
Research and Innovation Framework 
Programme, the European Commission 
approved a proposal for a project called 
UNICOM – a consortium of organisations 
and agencies across Europe working to deliver 
improved patient safety and better healthcare 
for all through the unequivocal identification 
of medicinal products. The IPU is working with 
the HPRA, HSE and DoH on this four-year 
project.
Throughout 2019, the IPU met with Sláintecare 
to discuss ePrescribing and other eHealth 
initiatives. Separately, we are working with the 
DoH and system vendors on the standardisation 
of dispensary systems with the aim of getting 
certification to comply with pharmacy 
regulations and ePrescribing standards.
8. TRAINING AND  
HR DEPARTMENT
Susan McManus, Training and HR 
Manager, organises and coordinates a 
selection of training courses for pharmacy staff. 
Janice Burke assists Susan in this department. 
135 Pharmacy Technicians graduated on 9 
March. There are 235 students at present 
participating in Year 1 and 207 students in 
Year 2 of the Pharmacy Technician course. 
In addition, 515 attended CPD for qualified 
pharmacy technicians in 2019. 151 students 
completed the Medicines Counter Assistant 
(MCA) course in 2019 in eight venues around 
the country and eight students completed the 
Medicines Counter Assistant (MCA) Refresher 
course. 120 students completed the Interact 
course. The seventh cohort in the Diploma 
in Leadership and Management commenced 
in September 2019, with eight enrolments, 
while 24 students completed the Supervisory 
Development Course in 2019. We also continue 
to offer the Medicines in Care Homes training 
package, the Basics in Health and Nutrition 
course (30 enrolments) and the Supervisory 
Development course (24 enrolments). 
The Pharmacy Sales Traineeship course was 
administered in a number of educational 
institutes and senior colleges around the 
country.
Susan also acts as Secretary to the Employee 
Pharmacists’ Committee (EPC) and advises 
members on human resource issues.
9. BUSINESS SERVICES
The Business Development 
Manager, Darren Kelly, is 
responsible for retail business services 
and retail advice to members, along with 
Jim Curran. Darren and Jim represent IPU 
members on a number of strategic retail 
forums that have enabled us to provide a 
platform for a structured engagement between 
the retail sector and relevant Government 
departments and agencies on areas such as 
crime prevention, Brexit, upward-only rent 
issues, town centre issues, retail apprenticeship 
scheme and digital training. As part of the 
IPU Business Strategy to assist members in 
engaging with digital marketing and social 
media to enhance their business offering, 
we ran a number of training programmes for 
pharmacies in 2019. The workshops were fully 
attended, and feedback was extremely positive. 
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around the country in 2019. All sessions were 
full and feedback from attendees was very 
positive.
Members are kept up to date with 
current legislation through notices in IPU 
communications. A number of affinity schemes 
have been negotiated for members on a range 
of products and services; details are carried on 
the IPU website.
Darren also oversees the general maintenance 
and upkeep of Butterfield House.
Joyce Mulpeter, our Member Relationship 
Manager, visited over 650 pharmacies this 
year. Joyce has also been working to highlight 
the Pharmacy Watch system from HMR to 
ensure that members can get the maximum 
information from the system to assist them in 
their business.
10. EXTERNAL CONSULTANTS
MKC Communications (PR Consultants); 
Coolamber (IT Consultants); John Behan 
(Industrial Relations and Strategy Advisor) 
and Sean McHugh (Industrial Relations 
Advisor) provide advice and support to the 
IPU as requested on an ongoing basis. Leaf 
Environmental has been retained as consultants 
to the IPU on matters regarding environmental 
and waste management issues. Legal advice is 
provided by DAC Beachcroft on an ongoing 
basis and by Beauchamps solicitors in relation to 
specific matters.
11. MAIN COMMITTEE MEETINGS
The number of Committee meetings held are 
shown in the table above.
12. CONCLUSION
As Secretary General, I am lucky to work with 
a great team in Butterfield House, who are 
fully united in their determination to meet 
any challenge head-on and to represent and 
serve the community pharmacy profession to 
the best of their ability. We will continue to 
innovate and adapt in order to effectively assist 
our members in ever-changing circumstances, 
while working ceaselessly to represent, advocate 
for and defend the community pharmacy sector 
and individual pharmacists, and promote the 
valuable work that pharmacists do every day 
in every town, village and community in the 
country. We are grateful for the incredible 
support we get from our members, without 
which we could not function, and are incredibly 
proud to represent you. We are always keen 




2019 2018 2017 2016 2015 2014
Executive Committee 5 6 5 5 7 7
Community Pharmacy Committee 3 3 3 4 5 4
Pharmacy Contractors’ Committee 5 4 5 4 6 2
Employee Pharmacists’ Committee 2 2 3 3 3 5
Finance Sub Committee 7 6 6 6 5 6
All Committee Meetings 1 0 0 0 0 0
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The Pharmacy Contractors’ Committee (PCC) 
is chaired by Dermot Twomey, with Kathy 
Maher as Vice-Chairperson. The PCC’s  
mission statement is:
Advocating and negotiating on behalf of 
community pharmacy contractors with 
government and its agencies to secure fair 
remuneration and equitable contractual terms 
for the delivery of services to patients.
The role of the PCC is to:
n	Devise a strategy to ensure the 
Committee delivers on the IPU’s 
priorities and strategic position;
n	Negotiate with the Department of 
Health and the HSE on policy issues 
relating to pharmacy and on all issues 
relating to remuneration;
n	Deal with matters relating to the contract 
and the community drug schemes;
n	Provide leadership, information and 
advice to members to ensure they are 
claiming correctly for all medicines 
supplied and services provided under the 
contract; and
n	Ensure that changes to the 
administration of the community drug 
schemes do not disadvantage members 
and that they are kept informed of such 
changes.
The Committee held five meetings in 2019 
and two meetings in 2020. The following is a 
summary of the key issues dealt with over the 
past 12 months.
DEPARTMENT OF HEALTH
When pressed by the IPU, at a meeting 
in March 2019, the Minister for Health 
acknowledged the grievance the IPU has 
in relation to the failure of successive 
governments to unwind FEMPI and had 
indicated that we would have an opportunity 
to discuss this when new pharmacy contract 
negotiations commenced in the near future. 
Subsequently at the IPU conference in May 
the Minister stated “My commitment to you 
today, my commitment to the IPU and to the 
members of the IPU, is that this year let’s start 
our discussions on a new pharmacy contract, 
let’s start a discussion on how we move beyond 
FEMPI and let’s start our discussion in relation 
to a programme of investment.” 
In order to maintain pressure on the Minister 
and the Department to honour their 
commitments, the Secretary General wrote to 
the Minister to confirm pharmacy contractors’ 
legitimate expectation around moving beyond 
FEMPI and the Minister’s commitment at the 
conference to collectively start discussions on 
a new pharmacy contract. In September 2019, 
we met with the then new Chief Executive 
Officer of the HSE, Paul Reid. We put forward 
our arguments to allow community pharmacists 
to practice to their full scope and outlined the 
need for a new pharmacy contract, including 
the benefits for patients and the HSE, and 
secured his support for negotiations to 
commence.
The PCC agreed a position paper prior to 
engagement with the Department which 
sought an increase in the dispensing fees of 
19.2% from 1 January 2020. Such an increase 
would have restored funding for pharmacy 
PHARMACY 
CONTRACTORS’  
COMMITTEE (PCC)  
REPORT 2019-2020
24
2020 ANNUAL REPORT OF IPU EXECUTIVE COMMITTEE
services  to a level which would have met the 
ever-increasing costs of providing the existing 
service, ensure the sustainability of community 
pharmacy and allowed pharmacists to deliver 
on their commitment to ongoing service 
development and reform.
In October 2019, the Department of Health 
met with the IPU under the auspices of the 
Public Service Pay and Pension Act 2017 at 
which the Department outlined proposed 
‘structural changes’ to fees as follows: 
n	Replace current phased dispensing fee 
per item for each phase other than the 
first dispensing with a monthly patient 
care fee of €45;
n	Reduce number of items paid at €5.00 
from 1,667 to 1,000 per month; and 
n	Abolish the High Tech patient care fee of 
€31.02 payable in the months in which 
no dispensing takes place.
The Department also advised that it was their 
intention to commence new contract talks 
at some stage in 2020, but that they were 
not in a position to commence at that time. 
The Department did not outline any specific 
reasoning (outside of generalities) for the 
proposed changes nor why they were targeted 
in the way set out.
The IPU delegation asserted that it would 
take a 19.2% fee increase to simply get 
pharmacy back to where we were in terms 
of the percentage spend of the HSE budget 
2009-2013. Following this unjustified and 
serious threat to fees, the PCC agreed a three-
prong approach to the threat – administrative, 
political and legal. 
The first part of that strategy was to engage 
in the consultation process, notwithstanding 
our view that it was not a proper or adequate 
consultation, to object strongly to the 
cuts themselves, which were unjustifiable, 
inequitable and irrational, and to make a 
comprehensive submission to the consultation 
process arguing for a material increase in 
pharmacy fees. The PCC also obtained and 
followed legal advice from DAC Beachcroft 
throughout the campaign.
Throughout November and December, IPU 
members participated in a national campaign 
to lobby their public representatives (details 
of which are set out elsewhere). An IPU 
delegation then met with the Minister for 
Health, his advisors and Department officials in 
late December. At this meeting, the Minister 
advised that the proposed cuts would not be 
proceeding and that he had instructed his 
officials to commence contract talks with the 
IPU in 2020. 
The IPU strategy resulted – for the first time, 
in any sector – in stopping the proposed cut 
to professional fees from being implemented.  
The PCC noted at the time that, even with 
the benefit of hindsight, there were no red 
flags to forewarn of the potential cuts and, 
furthermore, that no substantive policy 
objective or other reasoning had been given by 
the Department of Health for their decision 
to propose these cuts. In fact, the Department 
accepted that what the IPU had put forward 
was ‘factually correct.’
In the first quarter of 2020, we continued to 
engage with the outgoing Minister and the 
Department on securing a starting date for the 
beginning of negotiations on a new pharmacy 
contract. We also continued to engage with 
opposition politicians to ensure that we are well 
positioned to begin talks once the COVID-19 
crisis period has passed.
HEALTH SERVICE 
EXECUTIVE PRIMARY CARE 
REIMBURSEMENT SERVICE
Engagement between the IPU and the HSE 
PCRS is guided by the Relationship Value 
Charter which was agreed in 2016. The terms 
of reference for the Joint Consultative Group 
(JCG) and the Joint Operational Group (JOG) 
are set out in the charter.
The Joint Consultative Group (JCG) met 
five times in the past year. Members of the 
PCC, the Secretary General and the Contract 
Manager met with officials from the HSE 
PCRS through this forum. The JCG was 
established with the objective of maintaining 
stable contractual relations between the 
parties. The items raised by the IPU on behalf 
of members were wide and varied throughout 
the year including the introduction of PrEP, 
the High Tech Scheme, phased dispensing, 
management of owings and members 
concerns with the administration of the 
community drug schemes.
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In 2019, following ongoing demand from the 
IPU, the LTI Scheme was finally centralised 
through the PCRS. This removed the role 
of the local HSE office. Following extensive 
lobbying of the PCRS regarding product 
shortages of GMS reimbursable items, the 
HSE agreed that a copy of the HD1 form 
signed and stamped by the pharmacy and 
a copy of the invoice will suffice under 
Discretionary Hardship Arrangements for 
products due to short supply. A doctor 
signature is no longer required thus making the 
process more efficient.
We also worked with the HSE on the further 
expansion of the Hepatitis C Treatment in the 
Community Programme in order to increase 
the number of pharmacies participating and 
patients being treated. Following consultation 
and engagement with the IPU, an updated 
handbook on administrative arrangements for 
pharmacists was produced.
At the onset of the COVID-19 crisis, we 
continued our ongoing engagement with the 
HSE PCRS and secured the elimination of 
previous stringent administrative and legislative 
arrangements to ensure that pharmacy claims 
were paid with the minimum of bureaucracy. 
We engaged continuously with the Minister for 
Health and the Department of Health about 
severe acute cost increases in pharmacy related 
to the COVID-19 Emergency. We continue to 
fight for support for pharmacies in the form of 
grants and provision for supporting or supplying 
personal protective equipment.
The Joint Operational Group met with the 
PCRS throughout 2019 on a six-weekly basis. 
Its work involves arrangements for processing 
payment of claims and resolving claim-related 
queries raised by individual community 
pharmacy contractors and other operational/
administrative arrangements. This has resulted 
in resolving some long-standing disputes and 
outstanding payments being made to individual 
members by the PCRS.
The Contract Manager also accompanied 
15 contractors to meetings with the HSE 
PCRS to assist them in reaching confidential 
voluntary settlements with the HSE PCRS. 
This resulted in the cessation of formal 
proceedings against some contractors under 
the terms of the Community Pharmacy 
Contract and the cessation of legal cases in 
other instances.
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The Community Pharmacy Committee (CPC) 
is chaired by Jonathon Morrissey (who took 
over from Elizabeth Lang in January 2020), 
with Paul Kenny as Vice-Chair. CPC’s mission 
statement is:
CPC – working to serve and support 
community pharmacists in their practices 
and to promote and expand their role as 
pharmacists by continually developing 
professional, ethical, business, and 
technological ideals and standards.
CPC is split into three sub-groups:
n	Professional Steering Group 
Louise Begley, Elaine Clarke,  
Anna Kelly, Emily Kelly,  
Brendan Quinn
n	Business Steering Group 
Matilda Allen, Pat Dalton,  
David Gormley, Paul Kenny,  
Elizabeth Lang 
n	 IT Steering Group 
Sheila O’Loughlin, Noel Stenson.  
Ann Marie Horan (Exec), Ailish Reape 
(PCC) and Tadhg Scanlon (EPC) have 
been co-opted onto ITSG along with  
Jack Shanahan and Ciaran Mulligan.
CPC met four times since the 2019 AGM 
(May and October 2019 and February and 
June 2020), dealing with a wide variety of 
issues. The following is a summary of the key 
issues dealt with over the last 12 months under 
the headings outlined in the CPC Strategy 
2018-2020, which was developed by CPC in 
May 2018. 
PROFESSIONAL
Promote the Role of the Pharmacist in 
Government and HSE Strategy 
During the coronavirus emergency February – 
June 2020, we worked closely with DoH, HSE, 
HSPC and PSI to ensure pharmacies had tools 
at their disposal to ensure continuity of supply 
of medicines to patients. Legislation was passed 
enabling transfer of prescriptions to pharmacies 
using Healthmail, prescription validity was 
extended to nine months and emergency 
supply regulations were expanded.       
Since April 2020, we have participated in 
a multi-stakeholder Community Pharmacy 
Contingency Planning Group. In addition to 
addressing issues related to the coronavirus 
pandemic, the Group intends to build on 
the current collaboration between various 
representative groups/bodies to change 
and improve the way community pharmacy 
operates within the health system in the 
medium to longer term.
In the Programme for Government published 
in June 2020, a commitment was given to 
commence talks with pharmacists on a new 
contract and enhancement of their role in 
the delivery of healthcare in the community, 
including ePrescribing and issuance of repeat 
prescriptions. The Programme also committed 
to providing community pharmacies with 
dedicated additional resources to communities, 
focused on improved health outcomes and 
driven by strong data. 
Develop Services Frameworks for  
innovative pharmacy services
We are part of the HSE Working Group to 
establish treatment of patients (on OST) 
with hepatitis C in community settings. The 
first patients were treated in June 2019 and 
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the programme is being rolled out gradually 
through selected GPs in selected areas.
To help pharmacies who provide an injection 
administration service to patients, we 
produced an SOP for the intramuscular 
injection of NeoCytamen and an SOP for the 
subcutaneous injection of Prolia. The SOPs 
were updated in June 2020 re COVID-19, as 
were SOPs for a range of pharmacy services.  
We worked with the HSE and DoH on the 
provision of medicines through community 
pharmacy for Pre-Exposure Prophylaxis 
(PrEP) for HIV. The service was rolled out in 
November 2019.  
Engage with HSE Clinical Care Programmes 
to consolidate the pharmacist’s role in chronic 
disease management 
We have a seat on Clinical Care Programmes 
for Respiratory Conditions, Sexual Health, 
Antimicrobial Resistance & Infection Control, 
and Cancer Prevention. We have facilitated 
community pharmacists on advisory groups 
for Rheumatology, Disability, Breast Cancer 
Research, Antibiotic Prescribing, Appropriate 
Prescribing of Antipsychotics, Asthma Society, 
BP Council for IHF, and some hospital Drugs 
& Therapeutics Committees.   
Develop strategies to facilitate pharmacist 
prescribing within the community practice 
setting
We met with the DoH Working Group on 
Access to Contraception in August 2019 to 
discuss our proposal that contraception should 
be made available without prescription. This 
led to a favourable review of the proposal in 
the subsequent Report from the Working 
Group and a commitment by the Minister to 
make a contraception service available in 2021, 
following the necessary legislative changes 
and negotiations with pharmacists. In the 
Programme for Government published in June 
2020, a commitment was given to provide free 
contraception over a phased period, starting 
with women aged 17-25.  
 
IT
Maintain the IPU Product File as the 
definitive file on the Irish market for 
medicines and medical devices 
The IPU Product File Web Service is up and 
running with live information; roll out began 
in October 2019. The Web Service allows for 
more frequent updates of the IPU Product 
File information. High Tech medicines available 
through the High Tech Hub and PCRS-
restricted products are flagged in the IPU 
Product File with a link to the restriction 
details, and this information is available via the 
IPU Product File Web Service. 
At the SNOMED CT Expo in Kuala Lumpur in 
October 2019, we presented on our process for 
mapping the IPU Product File to SNOMED. 
We met with the HSE and the SNOMED 
National Release Centre (NRC) for Ireland 
in December 2019 and agreed an action plan. 
Concepts not currently in SNOMED CT were 
identified by the IPU Product File Department 
and, from July 2020, a series of updates from 
the IPU Product File have been integrated into 
the SNOMED International Files. 
In November 2019, we made a presentation 
on the IPU Product File at the Annual 
Health Informatics Society of Ireland (HISI) 
Conference. The IPU had a stand exhibiting 
the IPU Product File to attendees. A mix of 
hospital and community-based healthcare 
professionals visited the IPU stand to learn 
more about how the IPU Product File is used 
in initiatives such electronic discharge reports, 
medication management and other developing 
use cases.
We developed a web portal to allow 
manufacturers, suppliers and other licence 
holders to submit online updates to the IPU 
Product File. Accord / Actavis started piloting 
the Web Portal in May 2020.
 
In July 2019, under the Horizon 2020: Research 
and Innovation Framework Programme, the 
European Commission approved a proposal 
for a project called UNICOM – a consortium 
of organisations and agencies across Europe 
– and awarded the IPU with funding for our 
contribution to the project. The IPU is working 
with the HPRA and DoH on this four-year 
project and initial meetings commenced in 
December 2019. We are working on 4 out of 13 
work packages for the project with a focus on 
mapping dose forms, identification of medicinal 
products (IDMP), SNOMED CT, FMD and 
eHealth innovations. 
Promote the adoption of the IPU Product 
File as the HSE/eHealth Ireland National 
Medicinal Product Catalogue (NMPC) 
We produce the IPU Product File based on 
the HIQA National Standard: Data model for an 
electronic medicinal product reference catalogue. 
In August 2019, a delegation from the HSE 
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Product File. In October 2019, we licensed the 
file to the HSE for use in the EU OpenNCP 
Project (cross-border prescriptions and 
summary care records). In September 2020, 
the IPU Product File will be rebranded as the 
National Health products Catalogue (NHPC) 
and there will be a campaign to market the de-
facto medicinal product catalogue for Ireland.
Continue to work with HIQA on the eHealth 
Standards Advisory Group (eSAG) and the 
development of pharmacy-related standards 
Since July 2019, the IPU has participated 
in an advisory group on the implementation 
of HIQA’s National Standard on Information 
Requirements for a National Electronic Patient 
Summary. In August 2019, HIQA invited the 
IPU to participate in an Advisory Group on 
a Model for the Collection, Use and Sharing 
of Personal Health Information. In December 
2019, we contributed to a National ‘As Is’ 
Review of the current eHealth landscape in 
Ireland by HIQA. In June 2020, we attended 
a HIQA Advisory Group meeting reviewing: 
Terminology Working Paper; Best Practice 
Review of Summary Care Records; As Is Review 
of the Irish eHealth landscape; and Draft 
Recommendations on the Implementation of a 
National, Electronic Patient Summary in Ireland.
Work with all relevant stakeholders to deliver a 
national Shared Care Record which will inform 
the Electronic Health Record 
Since July 2019, the IPU is participating in 
an advisory group on the implementation 
of HIQA’s National Standard on Information 
Requirements for a National Electronic Patient 
Summary. In November 2019, the IPU joined 
a HSE working group exploring shared care 
records with a focus on diabetes and respiratory 
conditions. 
Work with the DoH and system vendors on 
the standardisation of dispensary systems 
with the aim of getting certification to comply 
with pharmacy regulations and ePrescribing 
standards 
In September 2019, we met with the DoH to 
discuss certification/validation of pharmacy 
software. The IPU Dispensary System 
Specification will be used as a template / 
starting point for a certification process and 
we will participate in a forum to agree the 
process along with the DoH, HIQA, National 
Standards Authority of Ireland (NSAI), the 
PSI and the pharmacy system vendors. In 
October 2019, the IPU became a member of 
the National Standards Authority of Ireland 
(NSAI) Health Committee. 
Continue to work with the Irish Medicines 
Verification Organisation (IMVO) and all 
relevant stakeholders to implement  
medicines authentication in Ireland 
Throughout 2019, we continued to participate 
in the EMVO Technical Expert Advisory Group 
and the development of an alert management 
system. In September 2019, we met with the 
IT vendors and IMVO on the next stage of the 
project and preparing for the end of the ‘Use & 
Learn Period’ in 2020. In October 2019, the 
IPU produced a position paper on managing 




We have been involved in a number of briefings 
with Government departments regarding 
maintaining preparedness for Brexit. We attend 
regular meetings of the National Forum on 
Retail Crime. Garda analysis has identified that 
crimes against pharmacy are still higher than 
the retail average, with cosmetics being the 
most frequently stolen category.
In 2019, the IPU and IPHA worked together 
on a Self-Care project for the Summer season 
which was launched in May 2019 and a Winter 
campaign which was launched in September 
2019.
We commissioned B&A to get a better 
understanding of why pharmacists were 
not staying in community pharmacy. The 
Perspectives of Community Pharmacy report 
was published in January 2019. We are having 
ongoing meetings with a range of stakeholders 
to discuss the findings in detail and to discuss 
what actions we should collectively take. 
We commissioned Fitzgerald Power 
Accountants to conduct a Wages and Salaries 
Survey for pharmacy sector in Q4 2019. The 
survey is available to read on the IPU website.
Business Support & Training 
We ran workshops in Spring and Autumn 
2019 on Increasing Brand Awareness and 
Sales through Social Media. The Diploma in 
Leadership & Management continues to prove 
popular with members; eight students enrolled 
on the programme in September 2019. Basics 
in Nutrition was attended by 18 attendees in 
January 2019 and 13 attendees in October 
2019.
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We worked with Retail Ireland Skillsnet to 
develop a Retail Apprenticeship, which was 
launched in October 2019. The course had 
103 apprentices from all sectors, including 
eight from the pharmacy sector. An Executive 
Management Programme in Strategic Business 
Management was launched in October 2019 
and 12 pharmacists enrolled.
Business Department Marketing 
In June 2019, we ran a business event with 
Pharmawealth and JPA Brenson Lawlor 
entitled What the future Holds a year on. Over 
100 people attended this event. In September 
2019, we held Business Briefings in a number 
of locations around the country.
During the COVID-19 crisis, we worked with 
the Department of Business through the Retail 
Consultation Forum regarding business issues 
during the COVID-19 crisis. We provided 
advice and information to members on Business 
Supports available from Government to assist 
members’ businesses. We developed a Return 
to Work Safely Protocol to provide a range of 
easy-to-use templates to assist members in 
ensuring they were compliant with all aspects 
of Government regulations in relation to 
coronavirus. We published several coronavirus-
related articles in the IPU Review looking at 
where, how and what pharmacy may look like in 
the “new norm” going forward.
Business Intelligence 
Our Member Relationship Manager has 
encouraged members to sign up to HMR 
and is also working with HMR Ireland on the 
recruitment of pharmacies who have not 
signed up to the service. The B&A Annual 
Pharmacy Usage and Attitudes Report 2020 
was completed in May 2020 and a webinar 








2020 ANNUAL REPORT OF IPU EXECUTIVE COMMITTEE
The Employee Pharmacists’ Committee 
(EPC) represents the interests of community 
pharmacy employee members of the IPU. 
The EPC is chaired by Rebecca Barry, who 
took over from Sinead Ryan in January 2020, 
with Kerrie Finnan as Vice-Chair, succeeding 
Gillian McGrath. Currently, there are 1,423 
community employee members of the IPU, 
32 affiliate student members, which comprises 
62% of the full membership. The mission 
statement of the EPC is: 
To promote the professional and economic 
interests of employee pharmacists and 
constructively engage with other Committees 
of the IPU and other stakeholders through the 
Employee Pharmacists’ Committee.
The EPC met three times since the 2019 
AGM (June and November 2019 and January 
2020). The EPC continues to have active 
representation on other IPU Committees, 
with three employee representatives on the 
Executive Committee and four representatives 
on the Community Pharmacy Committee. 
This representation guarantees that the views 
of employee pharmacists are voiced and heard 
on the other committees of the IPU, therefore 
empowering employee input into decisions and 
in the development and implementation of 
IPU policies. 
COMMUNICATIONS
The IPU website facilitates an ‘Employee 
Pharmacists’ section. Useful resources can be 
easily accessed by employee members and the 
EPC’s objective is to continue to develop this 
online forum. 
EVENTS
In 2019, the Committee agreed to have 
an EPC representative attend the Clarity 
Careers Day Locum at the end of the year. 
The main objectives of attending were to 
engage with newly qualified and early career 
pharmacists and to outline the benefits of 
IPU membership. Sinead Ryan, made a 
presentation to pharmacists at this event on 
20 November 2019. 
Sinead Ryan and Hazel Slevin also presented 
to 86 students in UCC in October 2019 
regarding careers in community pharmacy; 80 
students signed up as Affiliate IPU Members. 
They have been invited to present at a careers 
evening in RCSI in 2020. Sinead Ryan met 
with students from RCSI in October 2019 on 
the benefits and opportunities associated with 
IPU membership and 32 students signed up as 
affiliate members that day.
STUDENT PHARMACISTS
The EPC are looking for ways to engage with 
student pharmacists moving forward. Jess 
McNamara IPSA President and Bernard 
O’Sullivan, IPSA, Vice President joined the 
EPC November and January meetings and 
updated the Committee on their annual work 
plan and events. 
REPRESENTATION  
AND SERVICES
The EPC will continue to pursue its objectives 
with intent and to actively represent the 
interests of employee members. It will also 
ensure that the IPU continues to provide 
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within the community pharmacy sector. The 
coming years will be trying for community 
pharmacy; therefore, it is vital that employee 
pharmacists have a representative body which 
supports them and advocates on their behalf. 
The EPC will continue to be this body and 
it recommends the involvement of more 
employees, on both a regional and national 
platform within the IPU, in order to strengthen 
the resolve of employee pharmacists, both in 
the IPU and throughout the profession.
CONCLUSION
The EPC urges employee members to 
use their membership to the full and keep 
themselves well-versed by reading the IPU 
weekly eNewsletter, General Memorandum, 
IPU Review and other information provided 
by the IPU. In June 2010, all IPU members 
were assigned an @ipumail.ie email account, 
which we can forward to your own personal 
email address. To forward your IPUmail account 
or update your forwarding email address, 
please contact communications@ipu.ie. The 
EPC would also recommend that employee 
members check the ‘Employee Pharmacists’ 
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The Communications Team includes Jim 
Curran, Siobhán Kane, Ciara Browne and 
external advisors, and has an important role in 
communicating key messages to the media, 
the public, stakeholders and members. A 
wide range of communication tools, including 
newsletters, emails, text alerts, social media, 
the IPU Review, the General Memorandum 
and the IPU website, are used to keep members 
up-to-date on ongoing and urgent issues. Press 
releases are issued regularly, promoting the role 
of the pharmacist and highlighting pharmacists’ 
concerns to the media. The Communications 
Team invest a great deal of time, effort and 
resources in working with the media to brief 
journalists on issues affecting community 
pharmacy. Communication with the public is 
strengthened with advertising campaigns and 
public affair campaigns throughout the year.
MEDIA RELATIONS
There has been a substantial amount of media 
coverage since the last AGM. Regular press 
releases are issued by the IPU, promoting the 
role of pharmacists, raising concerns affecting 
community pharmacists and advocating on 
behalf of patients. We receive regular coverage 
in the national media, including on RTÉ, Virgin 
Media One, Today FM and Newstalk. The 
national newspapers, including The Irish Times, 
Irish Independent, Irish Examiner and Herald, also 
carry regular articles and interviews with IPU 
representatives, in addition to opinion pieces. 
We also receive significant coverage in online 
media, medical journals and regional media, 
with IPU spokespersons appearing frequently 
on local radio and quoted in local media.
At the IPU National Pharmacy Conference 
2019, in the presence of the Minister for Health 
Simon Harris TD, we called for the immediate 
unwinding of FEMPI and expressed how FEMPI 
cuts significantly undermined the pharmacy 
sector. We highlighted that a shortage of 
community pharmacists could become a critical 
problem for Irish healthcare. According to 
research undertaken by Behaviour & Attitudes 
on behalf of the IPU, entitled Perspectives of 
Community Pharmacy, the burden of excessive 
bureaucracy and unnecessary regulation was 
identified as a major frustration, particularly 
for younger pharmacists. We issued a press 
release at our IPU Future of Pharmacy event 
in June highlighting that this research also 
identified that Irish people are increasingly 
more likely to attend their pharmacy before 
they go to their GP and want their pharmacist 
to be able to do more for them. In response to 
a public consultation on increasing access to 
contraception, we proposed a scheme by  
which women could access contraception 
directly from their community pharmacist 
without prescription and without charge.  
COMMUNICATIONS  
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Pictured are: Elma Houlihan, Orla Browne and Hazel O’Keeffe 
who graduated at the IPU Pharmacy Technicians Graduation 
Ceremony in Dublin’s Mansion House on 9 March 2020
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We called for funding to be made available 
in Budget 2020 to allow pharmacies to 
expand their service offering to patients in 
the community, and free up GP waiting lists, 
by introducing initiatives such as a Minor 
Ailment Scheme, New Medicine Service and a 
Chronic Disease Management Service, as well 
as calling for improved access to contraception 
for women. Based on our IPU Pilot to Detect 
Hypertension and Atrial Fibrillation from 2018, 
we called for a national roll out of this service, 
which would assist in the prevention, detection 
and management of suspected hypertension. 
As part of a determined political campaign in 
advance of Budget 2020, pharmacists from all 
counties called for a reversal to the FEMPI fee 
cuts and said the sustainability of the pharmacy 
profession was at risk if the Government 
did not act. When proposed fee cutes were 
announced in October 2019, pharmacists 
doubled down on efforts to ensure their voice 
was heard with their local Oireachtas Members, 
and due to the efforts of this campaign, we 
then welcomed the sensible decision by the 
Minister for Health not to proceed with 
the proposed cuts in fees to pharmacies 
but, instead, to recommit to talks on a new 
pharmacy contract.
Press releases were issued highlighting the 
role of community pharmacy and the advice 
and services pharmacists can provide to their 
patients, such as advice to people trying to 
quit smoking, hay fever, advice on the HPV 
vaccine, holiday healthcare, men’s health, 
back-to-school ailments, tips to festival 
goers, flu vaccination, children’s vaccinations, 





Pictured are IPU President Daragh Connolly; 
Vice-President Eoghan Hanly; Secretary 
General Darragh O’Loughlin; and Contracts 
Manager Derek Reilly in advance of meeting 
with Minister for Health Simon Harris TD 
regarding proposed cuts to pharmacy fees.
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We also issued press statements during the year 
in response to political decisions. We welcomed 
the reduction in the prescription charge of 
50 cent, announced in Budget 2020, but 
said that this Budget represents yet another 
missed opportunity to improve Ireland’s 
health system by expanding pharmacy-based 
services. Early in 2020 and at the start of the 
COVID-19 pandemic, we issued a statement 
to highlight that pharmacy had a critical role 
to play in this pandemic and to ensure that 
people are properly prepared and following 
the recommendations issued by public health 
authorities including the Department of Health 
and the HSE.
We thank IPU spokespersons, who do great 
work throughout the year, for taking time out 
from their pharmacies to be interviewed and 
brief journalists. 
A list of all the press releases issued since the 
last AGM is in Appendix III.
PUBLIC AFFAIRS CAMPAIGN
The IPU began a concerted lobbying campaign 
in the latter months of 2019 to ensure issues 
affecting pharmacists were highlighted to 
Ministers, TDs and Senators. In early October 
approximately 40 Oireachtas members 
attended a briefing event in Buswells Hotel 
opposite Leinster House, shortly before Budget 
2020 was announced. More than a dozen 
pharmacists from across the country also 
attended, in addition to IPU staff, to clearly 
tell politicians that the sustainability of the 
pharmacy sector is at risk if the Government 
does not act soon. Unwinding of FEMPI, the 
need for a new pharmacy contract, and the 
need to expand and resource the healthcare 
services pharmacies can offer were among the 
issues discussed.
In November and early December we 
engaged in the successful lobbying campaign, 
#SupportPharmacy, to stop cuts to pharmacy 
fees proposed by the Department of Health. 
Pictured above are: Adrian Dunne, 
Minister Helen McEntee TD, 
Kathy Maher and Damien Conaty.
Pictured left are: Darragh 
O’Loughlin, Secretary General of 
the IPU, Hildegarde Naughton 
TD and Eoghan Hanly, IPU Vice 
President; Michael Healy Rae 







2020 ANNUAL REPORT OF IPU EXECUTIVE COMMITTEE
This campaign subsequently won the Best 
Public Affairs Campaign at the National Public 
Relations Awards 2020, along with our PR 
company MKC Communications. The success 
of the campaign came from the hard work of 
members, who galvanised on working to stop 
the Minister for Health from implementing the 
proposed cuts.
We built on this campaign in advance of the 
General Election, which was held in February 
2020. Commitments were made to support 
pharmacy in the pre-election manifestos of 
all the main parties, including Fianna Fáil, 
Fine Gael, Sinn Féin and the Green Party. 
Pharmacy-specific issues were then included  
as part of the Programme for Government. 
These commitments include:  
n	Commencing talks with pharmacists on a 
new contract and enhancement of their 
role in the delivery of healthcare in the 
community, including ePrescribing and 
issuance of repeat prescriptions; 
n	Establishing a ‘Delivering Equality of 
Opportunity in Schools (DEIS)’ type 
programme for health, providing GP 
practices, community pharmacies 
and public health staff with dedicated 
additional resources to communities, 
focused on improved health outcomes 
and driven by strong data; 
n	Reducing prescription charges and the 
Drug Payment Scheme threshold; and 
n	Providing free contraception over  
a phased period, starting with women 
aged 17-25.
We will actively and constructively engage with 
the new Government to ensure they deliver on 
their commitments to community pharmacy.
Advertising Campaign – Think Pharmacy
Following on from the success of the 2018 IPU 
advertising campaign, the IPU developed a plan 
for 2019 to further establish the pharmacy as 
the public’s first port of call for their healthcare 
needs and get the nation to Think Pharmacy. 
The 2019 advertising campaign consisted of 
three segments: a Hay Fever campaign, which 
consisted of a radio ad; a Think Pharmacy 
campaign, which consisted of a TV and radio 
ad; and a Flu Vaccination campaign, which also 
consisted of a TV and radio ad. The ads were 
themed Think Pharmacy and were broadcast at 




Pictured at the launch of the 
Pfizer Health and Science Index 
2019 are Professor of Health 
Policy and Management in 
Trinity College Dublin Charles 
Normand, and Pfizer Health and 
Science Index 2019 Ambassador 
Kathríona Devereux, with IPU 
Director of Communications and 
Strategy Jim Curran.
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ads received extensive airplay across national 
and regional stations and our TV ads were 
also well-received across multiple TV stations, 
including RTÉ One.
We launched our 2019 advertising campaign 
with a Hay Fever radio campaign on 29 April. 
The week-long campaign encouraged members 
of the public to Think Pharmacy for advice 
about their symptoms and the best treatment 
options available. Our ad aired across Today 
FM and regional radio stations, and data shows 
that listeners heard the ad at least twice. 114 
ads were broadcast during the week, reaching 
approx. 900,000 listeners nationally.
During the summer, we had a multimedia 
Think Pharmacy ad campaign to encourage 
the public to visit their pharmacy if they have 
any health concerns, from coughs and colds 
to stomach upsets, and other minor ailments 
they may be suffering from. The campaign ran 
for two weeks from 19 August to 1 September, 
with a TV ad airing across all Irish national TV 
channels, Channel 4 and Sky channels. A radio 
ad also broadcast on Today FM and regional 
stations for one week from 19 August. The TV 
ads accessed 50% of the top 20 programmes 
over the course of the two weeks, including 
spots during RTÉ One’s Six One News, which 
had 334,000 viewers, and Fair City, which had 
295,000 viewers. On average, we estimate 
that members of the public saw the TV ad up to 
three times and heard the radio spot 2.6 times 
over the course of the campaign. 116 radio ads 
were placed during this campaign, reaching just 
under 1 million listeners nationwide. 
In October, we launched our final campaign, 
which was a two-week (non-consecutive) 
TV and radio Flu Vaccination campaign to 
encourage members of the public to visit their 
pharmacy for their flu vaccination. The first 
week took place from 7 – 13 October and 
the second took place from 21 – 27 October. 
Both weeks included a TV ad airing across all 
Irish national TV channels, Channel 4 and Sky 
channels, and a radio ad airing on Today FM and 
regional stations. The TV ads accessed 7 of the 
top 20 programmes over the course of the two 
weeks, including spots during RTÉ 2’s coverage 
of the Rugby World Cup, which had 547,000 
viewers and RTÉ One’s Nine O’Clock News, 
which had 477,000 viewers. On average, we 
estimate that members of the public saw the 
TV ad up to 3 times and heard our radio spot 
over 4 times throughout the campaign. 212 ads 
were placed during the week, reaching approx. 
1.1 million listeners nationally.
Be Well This Summer
- Think Pharmacy
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Another video promoting the Flu Vaccination 
message was played at the National Ploughing 
Championships in September, which had a 
strong footfall of 297,000.
For the Think Pharmacy and Flu Vaccination 
campaigns, we developed a media kit and 
emailed it to all members asking them to get 
more involved and support the campaigns in-
pharmacy and on their social media channels. 
We developed tweets and posts, as well as 
promotional images and GIFs specific to 
Twitter and Facebook. We also created posters 
that members could print out and display 
prominently in the pharmacy. There was a huge 
uptake from members using the media kit and 
tweeting throughout the campaigns.
Be Well This Summer – Think Pharmacy
In partnership with the Irish Pharmaceutical 
Healthcare Association (IPHA), we introduced 
a new self care campaign titled Be Well this 
Summer – Think Pharmacy, which ran over the 
summer months. As part of the campaign, we 
used the emoji characters to assist in getting 
our message to the public. The campaign 
consisted of two distinct elements based on a 
series of cartoon emojis, which includes a Be 
Well this Summer – Think Pharmacy in-store 
poster, and a proactive digital media campaign 
based on a series of common summer ailments 
and injuries such as hay fever, holiday care, first 
aid and care at music festivals.
Be Well This Winter – Think Pharmacy
Following on from the summer campaign, we 
launched a winter self care campaign, Be Well 
this Winter – Think Pharmacy, with IPHA. The 
campaign promoted the benefits for members 
of the public in looking after their health during 
the winter period, helping towards preventing 
common illnesses. Using animated videos, we 
brought to life four emoji characters that were 
suffering from a common ailment such as a 
cold, cough and sore throat, and we also had 
a first aid video. At the centre of this concept 




Communications to members continue to 
develop and uptake continues to increase. The 
IPU Review and monthly General Memorandum 
are vital resources of information for members. 
The open rate of IPU News, the weekly 
eNewsletter, is increasing and is now viewed 
by 59% of members with more members also 
accessing their IPUMail regularly. Social media 
is another tool for communicating with both 
members and the public, and the number 
of followers on our Facebook, Twitter and 
LinkedIn accounts are growing each week. 
There was a significant increase in the followers 
to the IPU’s social media channels during 
2019; there was a 30% increase in Facebook 
followers, a 14% increase in Twitter followers 
and a 29% increase in LinkedIn followers. We 
also launched our Instagram page, which had 
451 followers by the end of 2019. We also use 
SMS to get information to members quickly on 




Pictured right are: Daragh 
Connolly, IPU President; 
Lorraine Higgins, MKC; Grainne 
Power, HPRA; and Dan O’Brien. 
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IPU ANNUAL REPORT  
ON PGEU 2019 – 2020
PGEU 2019/20
The Pharmaceutical Group of the European 
Union (PGEU) is the European association 
representing community pharmacists in 
32 countries including EU Member States, 
EEA countries, EU applicant countries 
and the UK as an observer member. 
Overall, PGEU represents over 400,000 
community pharmacists in Europe through 
their professional bodies and pharmacists’ 
associations. PGEU’s objective is to promote 
the role of pharmacists as key players in 
healthcare systems throughout Europe and 
to ensure that the views of the pharmacy 
profession are considered in the EU decision-
making process. 
We have been very active within PGEU 
over the past year, ensuring that community 
pharmacy is considered in a wide variety of EU 
Directives and Regulations. 70% of legislation 
in Ireland comes from EU Directives and 
Regulations so it is vital that lobbying is done at 
this level rather than waiting for transposition 
into Irish legislation. 
European Commission Priorities
Health priorities for the new EU Commission 
include:
n	Encouraging the development of new 
business models fostering innovation on 
new antibiotics;
n	Promoting the development of new 
vaccines;
n	Working together with EU Member 
States and industry to mitigate medicine 
shortages;
n	 Increasing the evidence base across the 
EU regarding new medicines (cancer 
treatment is a priority); and
n	Promoting data exchange and supporting 
research on new preventative initiatives 
and treatments, medicines, medical 
devices and outcomes.
Medicines Authentication
In Ireland, the ‘use and learn period’ will end for 
all entities who supply medicines to the public 
including pharmacies and hospitals. The IPU 
is working closely with IMVO, HPRA, pre-
distribution, wholesalers and IT providers on 
several fronts to prepare for the ending of the 
‘use and learn period’, including:
n	Developing national alert management 
guidance; 
n	Developing specific advice for every 
type of exception/alert code returned to 
end-users and wholesalers so they know 
exactly what to do next;
n	Additional efforts to address scanner 
configuration/scanning practice issues, 
through guidance, lists of suitable 
scanners, etc;
n	Encouraging all parties to intensify their 
efforts to reduce alerts;
n	Pushing for increased scanning rates so 
that all end-users understand fully how 
medicines authentication will impact on 
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any problems with software and scanners 
before the ‘use and learn period’ ends. 
Similarly, the more scanning that takes 
place, the greater our understanding of 
the issues that cause alerts and how to fix 
them; and
n	Getting information on Indian packs so 
we have a better understanding of the 
size of the problem here and what fixes 
might be applicable.
eHealth
PGEU is part of the European Commission 
eHealth Stakeholder Group, which is interested 
in cross-border exchanges of ePrescriptions 
and patient summaries. Some countries have 
already developed cross-border exchanges:
n	Finland: ePrescriptions of outgoing 
travellers;
n	Estonia: ePrescriptions of incoming 
travellers;
n	Luxembourg: Patient Summaries of 
incoming travellers;
n	Czech Republic: Patient Summaries of 
outgoing travellers; and
n	Croatia: ePrescriptions and Patient 
Summaries for incoming travellers.
22 other Member States have committed 
to having both services up and running and 
exchanged by 2021, including Ireland.
In the coming three years, the Group will  
focus on:
n	Health data, including electronic health 
record exchange;
n	Digital health services;
n	Health data protection and privacy issues;
n	Cybersecurity for health and care data;
n	Digital tools for citizen empowerment 
and person-centred care;
n	Artificial intelligence and health; and 
n	Enabling technologies. 
European Medicines Agency (EMA) 
PGEU has been re-elected as a member of 
the EMA Healthcare Professionals’ Working 
Party. Topics to be covered in the next three 
years include: Sartans with N-nitrosamine 
impurities; Digital Health; Safety of Medicines; 
Medicine Shortages; Antimicrobial Resistance; 
Vaccination; Access to Clinical Data; and 
Advances in Clinical Practice. 
The EMA has agreed the principles for 
Electronic Product Information (ePI). ePI will 
not supersede or negate the requirement to 
include a paper Patient Information Leaflet 
(PIL) in the packaging of all medicines; rather 
ePI is complementary to the PIL. The EMA will 
construct a roadmap with national competent 
authorities on the implementation of ePI. 
Medicine Shortages
PGEU has had numerous meetings with EU 
stakeholders on medicine shortages.
n	European Commission (DG SANTE);
n	European Parliament (MEPs and 
Committee members);
n	European Medicines Agency (working on 
a joint paper);
n	OECD (wants to help pharmacists 
mitigate shortages, e.g. substitution);
n	WHO Europe (interested in the PGEU 
survey results); and
n	GIRP (wholesalers), EPF (patients), 
EFPIA and MfE (manufacturers), 
AESGP (OTC) and EAHP (hospital 
pharmacists).
PGEU will continue to highlight the impact 
of shortages on patients, reinforce the 
contribution of community pharmacists in 
mitigating shortages, advocate for extending 
the scope of pharmacy practice, advocate for 
better information provision to pharmacists, 
improve reporting practices of shortages, and 
call for better collaboration at a European level. 
Europe’s Beating Cancer Plan
One of the priorities of the new EU Parliament 
is a plan to fight cancer, to support member 
States and stakeholders in improving cancer 
care and control and to reduce the suffering 
caused by cancer. The plan will focus on all key 
stages of cancer:
n	Prevention
• Health promotion, improved 
vaccination coverage
• Environmental risks, smoking, 
pollution
n	Early Detection and Diagnosis
• Increase coverage for breast, cervical 
and colorectal cancer screening
• Access to high quality care
n	Treatment and Care
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n	Quality of Life for Patients,  
Survivors and Carers
• Quality of life care, including  
pain management.
Pharmaceuticals in the Environment
The European Parliament is in the process of 
producing a policy on Pharmaceuticals in the 
Environment. The policy will:
n	Call on Member States and the 
Commission to promote awareness-
raising campaigns among vets and doctors 
on the prudent use of pharmaceuticals, 
particularly antimicrobials;
n	Call on actors in the supply chain to 
provide patients with information on 
how incorrectly disposed medicines may 
negatively impact on the environment;
n	Call for package labelling to inform 
consumers how to dispose of unused 
medicines;
n	Ensure that actions taken do not 
jeopardise access to safe and effective 
pharmaceutical treatments;
n	Allow that medicines be dispensed 
in quantities better matching needs, 
including by optimising pack sizes;
n	Explore the possibility of extending expiry 
dates; and
n	Call for full enforcement of existing 
provisions regarding take-back schemes 
for unused medicines. 
IPU ANNUAL REPORT  
ON FIP 2019 – 2020
The International Pharmaceutical Federation 
(FIP) 79th Annual World Congress of 
Pharmacy and Pharmaceutical Sciences 
was held in Abu Dhabi, UAE, from 22 to 
26 September 2019. It was co-hosted by 
the Emirates Pharmacy Society. FIP is the 
global federation of national associations of 
pharmacists and pharmaceutical scientists 
and is a non-governmental organisation 
in official relations with the World Health 
Organisation. With 144 member organisations, 
FIP represents over four million experts in 
medicines, supporting the responsible use of 
medicines around the world. 
One FIP Strategy
Decreasing the gaps in pharmaceutical science, 
practice, and education between different 
regions of the world is among the aims of a 
new One FIP Strategy announced at the World 
Congress by FIP President, Dominique Jordan. 
The intended outcomes of this strategy are 
that everyone has access to medicines. All 
pharmacists, pharmaceutical scientists and 
educators have a key role in this and in the 
evolution of the profession around the world.
All pharmaceutical professionals must adapt to 
new challenges and be integrated partners in the 
health system. Pharmacists can play an active 
role in all ten current threats to global health 
identified by the World Health Organisation. 
By 2022, the profession should be able to 
prove that pharmacists are important players in 
making a difference in a region or country. 
In line with the new strategy, FIP is 
working on Global Development Goals, 
which will incorporate its existing goals for 
pharmaceutical workforce development 
alongside goals for services, patient and public 
needs, and innovations in practice and science. 
These goals will be underpinned by FIP 
standards and evidence. 
FIP is also in the process of developing a Global 
Pharmacy Observatory, which will provide 
valuable pharmacy data from around the world. 
The new strategy will be delivered at global and 
local levels, through new programmes such as 
regional conferences.
The 2020 FIP Congress was  
postponed due to COVID-19  
and will now take place on  
12-16 September 2021 in  
Seville, Spain. 
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The following motions, proposed in accordance with Article 30 of the IPU Constitution,  
are brought before the meeting for consideration:
1. Proposed: Jonathon Morrissey 
Seconded: Paul Kenny
 “That this AGM welcomes the commitment in the Programme for Government to expanding 
the scope of pharmacists, and urges the Government not to miss the opportunity presented 
by COVID-19 to the expansion of pharmacy services as part of reforming and modernising 
healthcare in Ireland.”
2. Proposed: Niall Doyle 
Seconded: Patrick O’Sullivan
 “That the individual remuneration package details (including pension, bonus, health insurance, 
expenses, etc and all other benefits, as relevant) of the Secretary General, the President and all 
other officers and trustees of the IPU are published annually, to provide proper governance and 
transparency to members.”
3. Proposed: Richard Collis  
Seconded: Pat Sweeney
 “That this AGM demands that the IPU vigorously oppose the new contract imposed on 
pharmacists who are looking for or are forced to seek a new contract, from July 1st 2020. This 
was a step by the HSE which fundamentally changed the nature of contract negotiation from 
bilateral to unilateral.”
4. Proposed: Sean Reilly 
Seconded: Paddy Hickey
 “That this meeting expresses its disapproval of the use of IPU funds (believed to currently run 
to several million Euros) in supporting Health Market Research Ireland Limited (“HMR”) and 
requires the Executive Committee to undertake an immediate investigation by an appropriately 
qualified independent third party in order to assess IPUs investment in/support of HMR and 
to issue a report to the Executive Committee and make recommendations for consideration 
by the Executive Committee in order to protect IPU funds and the interests of members, in 
respect of its exposure to HMR.”
2020 AGM MOTIONS
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5. Proposed: Edward MacManus 
Seconded: Séan Kiely
 ‘’This AGM insists, that in the interests of good governance including the exercising of proper 
control over the use of members’ resources, all information required for decision-making be 
comprehensively provided in a timely manner to all members of the Executive Committee in 
advance of all material decisions being made by the Executive Committee on behalf of the IPU’’
6. Proposed:  Edward MacManus 
Seconded:  Roy Hogan
 “This AGM insists that, having regard to the relevant provisions of the IPU Constitution, 
the Executive Committee shall immediately prepare and approve (i) a schedule of delegated 
functions and reserved functions to provide clarity on the authority of other committees 
referred to in the Constitution and (ii) terms of reference for the Standing Committee and any 
other sub-committee of the IPU in order to provide clarity on the role and function of each 
committee.’’
7. Proposed: John MacNamara 
Seconded: Michael Austin
 “That this AGM requires the Executive Committee to undertake an immediate investigation 
by an appropriately qualified  independent third party into the Dublin regional meeting held 
in Autumn 2019, into how the meeting was conducted and also into the conduct of the IPU 
Past President and Secretary General in using an unprecedented large number of proxy 
votes to thwart the will of the meeting. It also demands that all future proxy votes are to be 
independently verified.”
8. Proposed: Richard Collis 
Seconded: Donncha McDermott
 “This meeting requests the Executive to act immediately to appoint an external person who has 
a track record in negotiation and can add a sense of emotional detachment and flexibility to 
the upcoming negotiations with the HSE. This person should be added to the negotiation team 
involved directly in the face to face negotiations with the Department of Health. We further 
recommend that the negotiation team be engaged to work under a formally approved structure 
and that any proposed agreement with the DoH requires formal ratification at a full sitting 
of the IPU Executive Committee the ultimate decision making committee of the IPU. The 
urgency of the situation is crystallised by the recent unilateral actions of the HSE in terms of 
the new contract.”
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1. Irish Pharmacy Union
Financial Reports and Accounts for  
Year Ended 31 December 2019 
In accordance with the Constitution of the 
IPU, the Executive Committee submits 
the audited accounts for consideration by 
members. The full details of the accounts are 
available on the members’ area of www.ipu.ie. 
If the accounts are approved by the meeting, 
after their presentation, members will be 
asked to formally adopt the Accounts for the 
year ended 31 December 2019. In accordance 
with Article 26.b of the IPU Constitution, the 
Trustees have appointed JPA Brenson Lawlor 
as Auditors for the IPU and IPU Services Ltd. 
Members will be asked to agree the election  
of auditors. 
In this context, the following motions will be 
put to the meeting: 
a. “That the Executive Committee Report 
and Audited Statement of Accounts of the 
Irish Pharmacy Union for the year ended 31 
December 2019 as submitted to this meeting, 
be and hereby are adopted.” 
b. “That this meeting agrees to the election of 
JPA Brenson Lawlor as Auditors for the IPU 
and IPU Services Ltd.”
2. IPU Services Limited
Financial Reports and Accounts for  
Year Ended 31 December 2019
At this Annual General Meeting of IPU 
Services Ltd, members are asked to consider 
the Directors’ Report and the Auditor’s 
Report on the Accounts for the Year Ended 31 
December 2019. The full accounts and financial 
reports are available on the members’ area of 
www.ipu.ie. 
If the accounts are approved, members will be 
asked to resolve: 
 “That the Directors’ Report and Audited 
Statement of Accounts for the year ended 31 
December 2019 as submitted to this meeting, 
be and are hereby adopted.”
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Responsibilities of IPU’s Officers
The Irish Pharmacy Union’s (“IPU”) Officers 
are responsible for preparing the annual report 
and the financial statements in accordance with 
applicable Irish law and FRS 102 The Financial 
Reporting Standard applicable in the UK 
and Republic of Ireland (Generally Accepted 
Accounting Practice in Ireland) issued by the 
Financial Reporting Council.
The financial statements reflect the activities of 
the IPU, and do not include the financial affairs 
of regional committees.
The IPU’s Officers acknowledge their 
responsibility for ensuring that adequate 
financial controls are in place, and that 
competent financial management is employed. 
The IPU’s Officers also understand and concur 
with the major judgements and estimates which 
underlie the financial statements.
In accordance with current accounting 
practice and financial reporting standards it is 
recommended that the IPU’s Officers prepare 
financial statements for each financial year 
which give a true and fair view of the state of 
the affairs of the IPU as at the end of the year 
and of the profit or loss of the IPU for that year.
In preparing these financial statements, the 
IPU’s Officers are required to:
n	select suitable accounting policies for the 
financial statements and then apply them 
consistently;
n	make judgements and estimates that are 
reasonable and prudent; and
n	prepare the financial statements on the 
going concern basis.
The IPU’s Officers are responsible for keeping 
adequate accounting records which correctly 
explain and record the transactions of the 
IPU, enable at any time the assets, liabilities, 
financial position, and profit or loss of the IPU 
to be determined with reasonable accuracy 
and to enable them to ensure that the financial 
statements comply with current accounting 
practice and financial reporting standards.  They 
are also responsible for safeguarding the assets 
of the IPU and hence for taking reasonable 
steps for the prevention and detection of fraud 
and other irregularities.
 
Review of the development activities 
and achievements of IPU during  
the year
The Irish Pharmacy Union continued to 
follow its Statement of Strategy 2017-2021, 
Putting Community at the Centre of Primary 
Healthcare in Ireland, under which it has 
continued to promote the professional and 
economic interests of its members throughout 
the year. The key achievement of the IPU was 
successfully resisting and preventing cuts to 
pharmacy fees which were proposed by the 
Department of Health in the last quarter of 
2019 and would have reduced total State fees 
to pharmacies by an estimated 12-14%.
 
Other services/ supports
At 1 January 2019 the IPU had 2,326  
members. During the year, 229 members 
joined and 260 members cancelled or let their 
membership lapse. At 31 December 2019 the 
IPU had 2,295 members. Additionally, 153 
student pharmacists have joined as members 
since October 2019.
The IPU provides members with;
n	A National Voice: The IPU represents 
more than 95% of community 
pharmacies in Ireland. We negotiate on 
behalf of all Community Pharmacies with 
the HSE, Government and other bodies 
in relation to a variety of issues, including 
the Community Pharmacy Contractors 
Agreement;
n	Exclusive access to IPU Product File, 
with details of approximately 55,000 
products and regular updates on products 
which have been discontinued, are in 
short supply etc.;
n	Professional advice and support 
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President   
8 October 2020
Darragh O’Loughlin 
Secretary   
n	Pharmacy and Retail Business advice and 
training for you and your employees;
n	Up to date listing of Locum support 
available;
n	Advice and support in relation to financial 
and employment issues;
n	 IPU website with members’ only area and 
on-line information which can be tailored 
to individual pharmacies;
n	 IPU Publications including weekly 
e-newsletter, monthly General 
Memorandum, the IPU Review and  
the IPU Yearbook and Diary;
n	Detailed information and advice on 
all Community Drugs Schemes and 
individual support in resolving claim and 
payment issues with HSE PCRS, which is 
an area of increasing activity;
n	 IPUnet, a web-based application to 
support member pharmacists in delivering 
and recording services to patients; and
n	 IPU Academy, an educational service to 
support members with their Continuing 
Professional Development (CPD), which 
is now mandatory for all pharmacists.
The IPU also provides a significant number of 
training courses and other business supports to 
help IPU members develop their professional 
services, staff and business. In addition to 
providing advice on professional issues, the IPU 
issued a number of guidelines and protocols 
to assist its members in compliance with 
legislation and in the provision of new services. 
IPU also provides a whole range of other 
support and advice to members and members 
are encouraged to avail of these services. 
The IPU’s business intelligence service hmR 
Ireland, which was launched in 2014 to provide 
members with benchmarking reports for their 
businesses and to provide essential data to 
support IPU lobbying and policy proposals on 
behalf of members, continued to develop and 
evolve and by year-end had in excess of 1,300 
pharmacies sharing data. The value of the 
project was most clearly demonstrated when 
the IPU was able to calculate the precise cost 
to community pharmacy of the government’s 
ongoing reference pricing policy, as well as the 
impact on pharmacy revenues of the August 
2016 Medicines Pricing and Supply framework 
agreement between the Department of 
Health, the HSE and the pharmaceutical 
industry, for the purposes of responding to 
the Department of Health’s proposed cuts to 
Pharmacy Fees in late 2019, and to support 
our analysis of the potential cost and resource 
benefit to the HSE of implementing services 
such as the Minor Ailment Scheme and other 
proposed pharmacy services.
 
Review of the transactions and 
financial position of IPU, and an 
explanation of the salient features  
of the financial statements
IPU is conscious of the significant direct and 
indirect cuts that have been imposed on its 
members over the past decade and continues 
to lobby actively to have those cuts reversed. 
The IPU is also conscious of the need to have 
a strong Union and a united voice to deal 
with the challenges we face as a sector and a 
profession and we have worked hard to keep 
our costs under control and deliver best value 
services and support to members.
It is important that IPU has sufficient funds 
to meet its liabilities and sufficient resources 
to promote the professional and economic 
interests of members and to continue 
delivering services and supports to them. The 
Executive Committee will keep the funding and 
resources of the IPU under continuous review 
and will apply the resources to the continuing 
support, development and advancement of 
the pharmacy profession and the interests of 
community pharmacy sector as a whole.
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Opinion
We have audited the financial statements of 
Irish Pharmacy Union for the year ended 31 
December 2019 which comprise the Statement 
of Comprehensive Income, the Statement Of 
Financial Position and the related notes. The 
relevant financial reporting framework that has 
been applied in their preparation is FRS 102 
The Financial Reporting Standard applicable in 
the UK and Republic of Ireland.
In our opinion the financial statements:
n	give a true and fair view of the state of 
the entity’s affairs as at 31 December 
2019 and of its profit for the year then 
ended; and
n	have been properly prepared in 
accordance with FRS 102 The Financial 
Reporting Standard applicable in the UK 
and Republic of Ireland.
Basis for opinion
We conducted our audit in accordance with 
International Standards on Auditing (Ireland) 
(ISAs (Ireland)) and relevant legal and 
regulatory requirements. Our responsibilities 
under those standards are further described in 
the Auditor’s responsibilities for the audit of 
the financial statements section of our report. 
We are independent of the entity in accordance 
with the ethical requirements that are relevant 
to our audit of financial statements in Ireland, 
including the Ethical Standard issued by the 
Irish Auditing and Accounting Supervisory 
Authority (IAASA), and we have fulfilled our 
other ethical responsibilities in accordance with 
these requirements.
We believe that the audit evidence we have 
obtained is sufficient and appropriate to provide 
a basis for our opinion.
Conclusions relating to going concern
We have nothing to report in respect of the 
following matters in relation to which the ISAs 
(Ireland) require us to report to you where:
n	the officers’ use of the going concern 
basis of accounting in the preparation 
of the financial statements is not 
appropriate; or
n	the officers’ have not disclosed in the 
financial statements any identified 
material uncertainties that may cast 
significant doubt about the IPU’s ability 
to continue to adopt the going concern 
basis of accounting for a period of at 
least twelve months from the date when 
the financial statements are authorised 
for issue.
Other information
The IPU’s Officers are responsible for the other 
information. The other information comprises 
the information included in the annual report, 
other than the financial statements and our 
auditor’s report thereon. Our opinion on 
the financial statements does not cover the 
other information and, except to the extent 
otherwise explicitly stated in our report, we do 
not express any form of assurance conclusion 
thereon.
In connection with our audit of the financial 
statements, our responsibility is to read the 
other information and, in doing so, consider 
whether the other information is materially 
inconsistent with the financial statements 
or our knowledge obtained in the audit or 
otherwise appears to be materially misstated. 
If we identify such material inconsistencies 
or apparent material misstatements, we 
are required to determine whether there 
is a material misstatement in the financial 
statements or a material misstatement of 
the other information. If, based on the work 
INDEPENDENT AUDITOR’S 
REPORT TO IPU MEMBERS
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we have performed, we conclude that there 
is a material misstatement of this other 
information, we are required to report that fact.
We have nothing to report in this regard.
Opinions on other matters
Based solely on the work undertaken in the 
course of the audit, we report that in our 
opinion:
n	the information given in the Officer’s 
Report is consistent with the financial 
statements; and
n	the Officer’s Report has been prepared 
in accordance with applicable legal 
requirements.
We have obtained all the information and 
explanations which we consider necessary for 
the purposes of our audit.
In our opinion the accounting records of the 
IPU were sufficient to permit the financial 
statements to be readily and properly audited, 
and the financial statements are in agreement 
with the accounting records.
Based on the knowledge and understanding of 
the IPU and its environment obtained in the 
course of the audit, we have not identified any 
material misstatements in the Officers’ Report.
Matters on which we are required 
to report by the the Industrial and 
Provident Societies Act 1893 to 2018
As required by Section 13(2) of the Industrial 
and Provident Societies Act 1893 to 2018, we 
examined the Statement of Financial Position 
showing the receipts and expenditure, funds and 
effect of the IPU, and verified same with the 
books, deeds, documents, accounts and vouching 
relating threats and found them to be correct, 
duly vouched and in accordance with law.
Responsibilities of Officers for the 
financial statements
As explained more fully in the Statement of 
Responsibilities in the Officer’s Report, the 
Officers are responsible for the preparation of 
the financial statements and for being satisfied 
that they give a true and fair view, and for such 
internal control as the Officers determine 
is necessary to enable the preparation of 
financial statements that are free from material 
misstatement, whether due to fraud or error.
In preparing the financial statements, the 
Officers are responsible for assessing the 
IPU’s ability to continue as a going concern, 
disclosing, as applicable, matters related to 
going concern and using the going concern 
basis of accounting unless the Officers either 
intend to liquidate the entity or to cease 
operations, or have no realistic alternative but 
to do so.
Auditor’s responsibilities for the  
audit of the financial statements
Our objectives are to obtain reasonable 
assurance about whether the financial 
statements as a whole are free from material 
misstatement, whether due to fraud or error, 
and to issue an auditor’s report that includes 
our opinion. Reasonable assurance is a high 
level of assurance, but is not a guarantee 
that an audit conducted in accordance with 
ISAs (Ireland)  will always detect a material 
misstatement when it exists. Misstatements 
can arise from fraud or error and are considered 
material if, individually or in the aggregate, they 
could reasonably be expected to influence the 
economic decisions of users taken on the basis 
of these financial statements.
A further description of our responsibilities for 
the audit of the financial statements is located 




ISA-700-(Ireland). This description forms part 
of our auditor’s report.
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INDEPENDENT 
AUDITOR’S 
REPORT TO  
IPU MEMBERS
Continued
 The purpose of our audit work and to 
whom we owe our responsibilities
This report is made solely to the IPU’s 
members, as a body. Our audit work has been 
undertaken so that we might state to the 
IPU’s members those matters we are required 
to state to them in an auditor’s report and 
for no other purpose. To the fullest extent 
permitted by law, we do not accept or assume 
responsibility to anyone other than the IPU 
and the IPU’s members as a body, for our audit 
work, for this report, or for the opinions we 
have formed.
Ian Lawlor
for and on behalf of  
JPA Brenson Lawlor
Chartered Accountants
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  2019 2018
 Notes € €
Income 
Subscriptions    550,170 501,724
Levy income    3,149,123 3,243,156
Other income    131,298 239,107
       3,830,591 3,983,987
Expenditure 
Payroll and related expenses  2,100,031 1,939,227
Travel and meetings  167,820 151,883
Members’ expenses  211,573 180,730
Subscriptions paid   63,567 65,623
Depreciation    48,052 45,632
Staff costs     14,275 8,122
Other expenses   1,570,461 1,720,492
       4,175,779 4,111,709
Operating loss    (345,188) (127,722)
Fair value gain / (loss) on investments 6 281,370 (65,440)
Profit / (loss) on disposal of investments  115,471 (6,821)
Investment income  25,125 37,292
Bank charges and fees  (3,879) (4,696)
Profit / (loss) before taxation  72,899 (167,387)
Tax       3,937 (322)
Profit / (loss) after taxation  76,836 (167,709)
    
The Statement of Comprehensive Income has been prepared on the basis that all operations are continuing operations.
PROFIT AND LOSS 
ACCOUNT FOR THE YEAR 
ENDED 31 DECEMBER 2019
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BALANCE SHEET AS AT 
31 DECEMBER 2019
   2019  2018 
 Notes € € € € 
Fixed assets 
Tangible assets 5  869,446   891,591
Financial assets 6  5,522,709   5,840,589
   6,392,155   6,732,180
Current assets 
Debtors 7 1,721,338   1,769,701
Cash at bank and in hand  1,102,395   525,771
  2,823,733   2,295,472
Creditors: amounts falling  
due within one year 8 (340,687)   (229,287) 
   
Net current assets   2,483,046   2,066,185 
Total assets less current liabilities   8,875,201   8,798,365
Capital and reserves 
Revaluation reserve 9  389,194   398,048
Profit and loss reserves 10  8,486,007   8,400,317
   
Total equity   8,875,201   8,798,365
The financial statements were approved by the officers and authorised for issue on 8 October 2020 and are signed on its behalf by:
Eamon Daragh  Connolly Darragh O’Loughlin  
Director Secretary
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1. Accounting policies 
Entity information
Irish Pharmacy Union is an entity domiciled 
and incorporated in Republic of Ireland. 
The registered office is Butterfield House, 
Butterfield Avenue, Rathfarnham, Dublin 14.
 
1.1 Accounting convention 
 These financial statements have been 
prepared in accordance with FRS 102 
“The Financial Reporting Standard 
applicable in the UK and Republic of 
Ireland” (“FRS 102”), as adapted by 
Section 1A of FRS 102.
 The financial statements are prepared in 
euros, which is the functional currency of 
the entity. Monetary amounts in these 
financial statements are rounded to the 
nearest €.
 The financial statements have been 
prepared under the historical cost 
convention, modified to include the 
revaluation of freehold properties and to 
include investment properties and certain 
financial instruments at fair value. The 
principal accounting policies adopted are 
set out below.
 
1.2 Going concern 
 At the time of approving the financial 
statements, the Officers have a 
reasonable expectation that the entity 
has adequate resources to continue in 
operational existence for the foreseeable 
future. Thus the officers continue 
to adopt the going concern basis of 




(a) Amounts due under the levy scheme 
are recognised as income in the 
month when cash is received.
(b) All other income is accounted for on 
an accruals basis.
(c) All revenue comprises the fair 
value of consideration received and 
receivable exclusive of value added 
tax and after discounts and rebates.
 
1.4 Tangible fixed assets 
 Tangible fixed assets are initially measured 
at cost and subsequently measured at 
cost or valuation, net of depreciation and 
any impairment losses.
 Depreciation is recognised so as to write 
off the cost or valuation of assets less 
their residual values over their useful lives 
on the following bases:
 Premises 2% straight line
 Fixtures and  
fittings 10%/33% straight line
 Office equipment 33% straight line
 The gain or loss arising on the disposal of 
an asset is determined as the difference 
between the sale proceeds and the 
carrying value of the asset, and is credited 
or charged to profit or loss.
 
1.5 Fixed asset investments 
 Interests in subsidiaries, associates and 
jointly controlled entities are initially 
measured at cost and subsequently 
measured at cost less any accumulated 
impairment losses. The investments 
are assessed for impairment at each 
reporting date and any impairment losses 
or reversals of impairment losses are 
recognised immediately in profit or loss.
IRISH PHARMACY  
UNION NOTES TO THE 
FINANCIAL STATEMENTS
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IRISH PHARMACY 
UNION NOTES TO 
THE FINANCIAL  
STATEMENTS
Continued
  A subsidiary is an entity controlled by the 
company. Control is the power to govern 
the financial and operating policies of the 
entity so as to obtain benefits from its 
activities.
 An associate is an entity, being neither 
a subsidiary nor a joint venture, in which 
the entity holds a long-term interest 
and where the company has significant 
influence. The entity considers that it 
has significant influence where it has the 
power to participate in the financial and 
operating decisions of the associate.
 Entities in which the company has a long 
term interest and shares control under a 
contractual arrangement are classified as 
jointly controlled entities.
1.6 Impairment of fixed assets
 Assets not measured at fair value are 
reviewed for any indication that the asset 
may be impaired at each statement of 
financial position date.  If such indication 
exists, the recoverable amount of the 
asset, or the asset’s cash generating 
unit, is estimated and compared to the 
carrying amount.  Where the carrying 
amount exceeds its recoverable amount, 
an impairment loss is recognised in profit 
or loss unless the asset is carried at a 
revalued amount where the impairment 
loss is a revaluation decrease.
1.7 Cash at bank and in hand
 Cash and cash equivalents are basic 
financial assets and include cash in hand, 
deposits held at call with banks, other 
short-term liquid investments with original 
maturities of three months or less, and 
bank overdrafts. Bank overdrafts are shown 
within borrowings in current liabilities.
1.8 Financial instruments
The entity has elected to apply the 
provisions of Section 11 ‘Basic Financial 
Instruments’ and Section 12 ‘Other 
Financial Instruments Issues’ of FRS 102 
to all of its financial instruments.
Financial instruments are recognised in 
the entity’s statement of financial position 
when the entity becomes party to the 
contractual provisions of the instrument.
Financial assets and liabilities are offset, 
with the net amounts presented in the 
financial statements, when there is a 
legally enforceable right to set off the 
recognised amounts and there is an 
intention to settle on a net basis or to 
realise the asset and settle the liability 
simultaneously.
Basic financial assets
Basic financial assets, which include 
debtors and cash and bank balances, 
are initially measured at transaction 
price including transaction costs and are 
subsequently carried at amortised cost 
using the effective interest method unless 
the arrangement constitutes a financing 
transaction, where the transaction is 
measured at the present value of the 
future receipts discounted at a market 
rate of interest. Financial assets classified 
as receivable within one year are not 
amortised.
 Trade debtors, loans and other receivables 
that have fixed or determinable payments 
that are not quoted in an active market 
are classified as ‘loans and receivables’. 
Loans and receivables are measured 
at amortised cost using the effective 
interest method, less any impairment.
Interest is recognised by applying the 
effective interest rate, except for short-
term receivables when the recognition 
of interest would be immaterial. The 
effective interest method is a method of 
calculating the amortised cost of a debt 
instrument and of allocating the interest 
income over the relevant period. The 
effective interest rate is the rate that 
exactly discounts estimated future cash 
receipts through the expected life of 
the debt instrument to the net carrying 
amount on initial recognition.
Classification of financial liabilities
Financial liabilities and equity instruments 
are classified according to the substance 
of the contractual arrangements entered 
into. An equity instrument is any 
contract that evidences a residual interest 
in the assets of the company after 
deducting all of its liabilities.
Basic financial liabilities
Basic financial liabilities, including 
creditors, bank loans, loans from fellow 
group companies and preference shares 
that are classified as debt, are initially 
recognised at transaction price unless 
the arrangement constitutes a financing 
transaction, where the debt instrument 
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is measured at the present value of the 
future payments discounted at a market 
rate of interest. Financial liabilities 
classified as payable within one year are 
not amortised.
Debt instruments are subsequently 
carried at amortised cost, using the 
effective interest rate method.
Trade creditors are obligations to pay for 
goods or services that have been acquired 
in the ordinary course of business from 
suppliers. Amounts payable are classified 
as current liabilities if payment is due 
within one year or less. If not, they are 
presented as non-current liabilities. 
Trade creditors are recognised initially 
at transaction price and subsequently 
measured at amortised cost using the 
effective interest method.
Financial liabilities and equity instruments 
are classified according to the substance 
of the contractual arrangements entered 
into. An equity instrument is any 
contract that evidences a residual interest 
in the assets of the company after 
deducting all of its liabilities.
1.9 Equity instruments
 Equity instruments issued by the entity 
are recorded at the proceeds received, 
net of direct issue costs. Dividends 
payable on equity instruments are 
recognised as liabilities once they are no 
longer at the discretion of the entity.
1.10 Taxation
 The tax expense represents the sum of the 
tax currently payable and deferred tax.
Current tax
The tax currently payable is based on 
taxable profit for the year. Taxable profit 
differs from net profit as reported in the 
income statement because it excludes 
items of income or expense that are 
taxable or deductible in other years and 
it further excludes items that are never 
taxable or deductible. The entity’s liability 
for current tax is calculated using tax rates 
that have been enacted or substantively 
enacted by the reporting end date.
Deferred tax
Deferred tax liabilities are generally 
recognised for all timing differences and 
deferred tax assets are recognised to the 
extent that it is probable that they will be 
recovered against the reversal of deferred 
tax liabilities or other future taxable 
profits. Such assets and liabilities are 
not recognised if the timing difference 
arises from goodwill or from the initial 
recognition of other assets and liabilities 
in a transaction that affects neither the 
tax profit nor the accounting profit.
The carrying amount of deferred tax 
assets is reviewed at each reporting end 
date and reduced to the extent that it is 
no longer probable that sufficient taxable 
profits will be available to allow all or part 
of the asset to be recovered. Deferred 
tax is calculated at the tax rates that are 
expected to apply in the period when the 
liability is settled or the asset is realised. 
Deferred tax is charged or credited in the 
income statement, except when it relates 
to items charged or credited directly to 
equity, in which case the deferred tax is 
also dealt with in equity. Deferred tax 
assets and liabilities are offset when the 
company has a legally enforceable right to 
offset current tax assets and liabilities and 
the deferred tax assets and liabilities relate 
to taxes levied by the same tax authority.
 
1.11 Employee benefits 
 The costs of short-term employee 
benefits are recognised as a liability 
and an expense, unless those costs are 
required to be recognised as part of the 
cost of stock or fixed assets.
 The cost of any unused holiday entitlement 
is recognised in the period in which the 
employee’s services are received.
 Termination benefits are recognised 
immediately as an expense when the 
entity is demonstrably committed 
to terminate the employment of an 
employee or to provide termination 
benefits.
 
1.12 Foreign exchange 
 Transactions in currencies other than 
euros are recorded at the rates of 
exchange prevailing at the dates of the 
transactions. At each reporting end date, 
monetary assets and liabilities that are 
denominated in foreign currencies are 
retranslated at the rates prevailing on 
the reporting end date. Gains and losses 
arising on translation are included in the 
income statement for the period.
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2. Employees
The average monthly number of persons 
employed by the company during the year  
was 26 (2018 - 26).
3. Number of members
The number of members in 2019 was 2,295 
(2018: 2,326).
During the financial year ended 31 December 
2019 the Irish Pharmacy Union refunded 
€349,283 to contractor members in 
proportion to the amount paid by each 
individual member in levy payments in 2018 
(2018: €244,254).
   2019 2018
   € €
Interest receivable and similar income  
includes the following: 
Income from other financial assets   25,125 37,292
 Premises Fixtures Office Total
  and fittings equipment
 € € € €
Cost
At 1 January 2019 950,000 261,245 441,585 1,652,830
Additions - 5,590 23,842 29,432
Disposals - (7,118) (26,106) (33,224)
At 31 December 2019 950,000 259,717 439,321 1,649,038
Depreciation and impairment 
At 1 January 2019 95,000 243,622 422,617 761,239
Depreciation charged in the year 19,000 7,361 21,691 48,052
Eliminated in respect of disposals - (5,679) (24,020) (29,699)
At 31 December 2019 114,000 245,304 420,288 779,592
Carrying amount
At 31 December 2019 836,000 14,413 19,033 869,446
At 31 December 2018 855,000 17,623 18,968 891,591
5. Tangible fixed assets 
4. Interest receivable and similar income
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6. Financial assets 
   2019 2018
   € €
Shares in group undertakings   127 127
Other investments other than loans   5,522,582 5,840,462
Movements in fixed asset investments
  Shares Other Total 
  in group  investments
  undertakings other than
   loans
  € € €
Cost or valuation 
At 1 January 2019  127 5,840,462 5,840,589
Additions  - 794,817 794,817
Valuation changes  - 281,370 281,370
Matured  - (604,843) (604,843)
Transferred out of investments  - (533,672) (533,672)
Disposals  - (255,552) (255,552)
At 31 December 2019  127 5,522,582 5,522,709
Carrying amount 
At 31 December 2019  127 5,522,582 5,522,709
At 31 December 2018  127 5,840,462 5,840,589
7. Debtors
   2019 2018
   € €
Amounts falling due within one year:
Trade debtors   28,836 22,439
Corporation tax recoverable   7,220 66,567
Amounts owed by group undertakings   1,675,334 1,671,733
Other debtors   309 1,912
Prepayments   9,639 7,050
   1,721,338 1,769,701
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11. Retirement benefit schemes 
Defined contribution schemes 
The IPU operates a defined contribution 
pension scheme for all qualifying employees. 
The assets of the scheme are held separately 
from those of the IPU in an independently 
administered fund.
12. Capital commitments 
 There were no capital commitments contracted 
for, or authorised, at the statement of financial 
position date.
13. Events after the reporting date 
 There were no post reporting date events which 
require disclosure.
14. Related party transactions 
IPU Services Limited is a wholly owned 
subsidiary of the IPU. The IPU has availed of 
the exemption provided in FRS 102 (section 
33), “Related Party Disclosures”, for wholly 
owned subsidiary undertakings, from the 
requirement to give details of transactions with 
entities that are part of the group.
8. Creditors: amounts falling due within one year
   2019 2018
   € €
Trade creditors   113,816 90,581
Deferred income   - 4,400
Other creditors including tax and social insurance   177,909 85,994
Accruals   48,962 48,312
   340,687 229,287
9. Revaluation reserve 
 
   2019 2018
   € €
At beginning of year   398,048 406,902
Other movements   (8,854) (8,854)
At end of year   389,194 398,048
10. Profit and loss reserves 
   2019 2018
   € €
At the beginning of the year   8,400,317 8,559,171
Profit/(loss) for the year   76,836 (167,708)
Transfer from revaluation reserve   8,854 8,854
At the end of the year   8,486,007 8,400,317
IRISH PHARMACY 
UNION NOTES TO 
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Touchstore Limited is an associate as  
IPU Services Limited owns share capital  
in this company.
Health Market Research Ireland Limited is 
a jointly controlled entity, as IPU Services 
Limited owns shares in this company.  
There were no transactions during the  
year between the IPU and Health Market  
Research Ireland Limited.
15. Approval of financial statements
The executives approved the financial 
statements on the 8 October 2020.
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1. The notice convening the meeting was 
taken as read. 
2. The minutes of the 2018 AGM were  
taken as read. 
3. The Report of the Directors on the 
Accounts for the year ended 31 December 
2018, previously circulated, was taken  
as read. 
4. The Auditors’ Report on the accounts 
for the year ended 31 December 2018, 
previously circulated, was taken as read. 
5. The following motion was proposed by 
Eoghan Hanly, seconded by Michael 
Tierney and carried unanimously: 
 “That this meeting agrees to the election 
of JPA Brenson Lawlor as Auditors for the 
IPU and IPU Services Ltd”.
6. The accounts were presented by the Vice 
President and on the proposal of Michael 
Tierney seconded by John Carey it was 
resolved:
 “That the Directors’ Report and Audited 
Statement of Accounts for the year ended  
31 December 2018 as submitted to this 
meeting, be and are hereby adopted.”
 This motion was carried.
In conclusion, the Honorary Treasurer 
thanked Ciara Enright, Secretary to the 
Finance Committee, and her colleagues on 
the Committee for all their work over the past 
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The directors present their annual report  
and financial statements for the year ended  
31 December 2019.
Principal activities
The principal activity of the company is the 
production of a yearbook and a monthly 
trade journal, the supply of drugs database 
information and the provision of business 
supports, courses and other CPD services  
to Irish Pharmacy Union members and  
their employees.
Directors and secretary
The directors who held office during the year 
and up to the date of signature of the financial 






Results and dividends 
The results for the year are set out on page 68.
No ordinary dividends were paid. The directors 
do not recommend payment of a final dividend.
Accounting records
The company’s directors are aware of their 
responsibilities, under sections 281 to 285 of 
the Companies Act 2014 as to whether in their 
opinion, the accounting records of the company 
are sufficient to permit the financial statements 
to be readily and properly audited and are 
discharging their responsibility by employing 
qualified and experienced staff, ensuring that 
sufficient company resources are available for 
the task and liaising with the company’s auditor.
The accounting records are held at the 
company’s registered office, Butterfield House, 
Butterfield Avenue, Rathfarnham, Dublin 14.
Post reporting date events
There are no post reporting date events which 
require disclosure.
DIRECTORS’ REPORT   
FOR THE YEAR ENDED  
31 DECEMBER 2019
Directors’ and secretary’s interests 
The directors’ and secretary’s interests in the  
shares of the company were as stated below:
 
  Ordinary shares of €1.27 each 
 1 January 2019  31 December 2019
Eamon Daragh  Connolly –  –
Darragh O’Loughlin –  –
Eoghan Hanly –  –
Caitriona O’Riordan –  –
Irish Pharmacy Union holds 100% of the issued share capital of the company.
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Auditor
In accordance with the Companies Act 2014, 
section 383(2), JPA Brenson Lawlor offer their 
willingness to continue in office as auditor of 
the company.
Statement of disclosure to auditor
Each of the directors in office at the date of 
approval of this annual report confirms that:
n	so far as the director is aware, there is no 
relevant audit information of which the 
company’s auditor is unaware, and
n	the director has taken all the steps that 
he / she ought to have taken as a director 
in order to make himself / herself aware 
of any relevant audit information and to 
establish that the company’s auditor is 
aware of that information.
This confirmation is given and should be 
interpreted in accordance with the provisions of 
section 330 of the Companies Act 2014.
The entity has availed of the small companies 
exemption contained in the Companies 
Act 2014 with regard to the requirements 
for exclusion of certain information in the 
Directors’ report.
On behalf of the board.
Eamon Daragh Connolly 
President   
8 October 2020
Darragh O’Loughlin 
Secretary   
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The directors are responsible for preparing  
the Directors’ Report and the financial 
statements in accordance with applicable  
Irish law and regulations.
Irish company law requires the directors to 
prepare financial statements for each financial 
year. Under that law, the directors have 
elected to prepare the financial statements 
in accordance with Companies Act 2014 and 
FRS 102 The Financial Reporting Standard 
applicable in the UK and Republic of Ireland 
(Generally accepted Accounting Practice in 
Ireland) issued by the Financial Reporting 
Council. Under company law, the directors 
must not approve the financial statements 
unless they are satisfied that they give a 
true and fair view of the assets, liabilities and 
financial position of the company as at the 
financial year end date and of the profit or  
loss of the company for that financial year  
and otherwise comply with the Companies 
Act 2014.
In preparing these financial statements, the 
directors are required to:
n	select suitable accounting policies for the 
company financial statements and then 
apply them consistently;
n	make judgements and estimates that are 
reasonable and prudent;
n	state whether the financial statements 
have been prepared in accordance with 
applicable accounting standards, identify 
those standards, and note the effect and 
the reasons for any material departure 
from those standards; and
n	prepare the financial statements on 
the going concern basis unless it is 
inappropriate to presume that the 
company will continue in business.
The directors are responsible for ensuring 
that the company keeps or causes to be kept 
adequate accounting records which correctly 
explain and record the transactions of the 
company, enable at any time the assets, 
liabilities, financial position and profit or loss of 
the company to be determined with reasonable 
accuracy, enable them to ensure that the 
financial statements and Directors’ Report 
comply with the Companies Act 2014 and 
enable the financial statements to be audited. 
They are also responsible for safeguarding 
the assets of the company and hence for 
taking reasonable steps for the prevention and 
detection of fraud and other irregularities.
On behalf of the board
DIRECTORS’ 
RESPONSIBILITIES 
STATEMENT FOR THE YEAR 
ENDED 31 DECEMBER 2019
Eamon Daragh Connolly 
President   
8 October 2020
Darragh O’Loughlin 
Secretary   
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We have audited the financial statements 
of IPU Services Limited (the ‘company’) for 
the year ended 31 December 2019 which 
comprise the statement of comprehensive 
income, the statement of financial position 
and the related notes. The relevant financial 
reporting framework that has been applied in 
their preparation is the Companies Act 2014 
and FRS 102 The Financial Reporting Standard 
applicable in the UK and Republic of Ireland.
In our opinion the financial statements:
n	give a true and fair view of the assets, 
liabilities and financial position of the 
company as at 31 December 2019 and  
of its profit for the year then ended;
n	have been properly prepared in 
accordance with FRS 102 The Financial 
Reporting Standard applicable in the  
UK and Republic of Ireland; and
n	have been prepared in accordance with 
the requirements of the Companies  
Act 2014.
Basis for opinion
We conducted our audit in accordance 
with International Standards on Auditing 
(Ireland) (ISAs (Ireland)) and applicable law. 
Our responsibilities under those standards 
are further described in the Auditor’s 
responsibilities for the audit of the financial 
statements section of our report. We are 
independent of the company in accordance 
with the ethical requirements that are relevant 
to our audit of financial statements in Ireland, 
including the Ethical Standard issued by the 
Irish Auditing and Accounting Supervisory 
Authority (IAASA), and we have fulfilled our 
other ethical responsibilities in accordance with 
these requirements.
We believe that the audit evidence we have 
obtained is sufficient and appropriate to provide 
a basis for our opinion.
Conclusions relating to going concern
We have nothing to report in respect of the 
following matters in relation to which the ISAs 
(Ireland) require us to report to you where:
n	the directors’ use of the going concern 
basis of accounting in the preparation 
of the financial statements is not 
appropriate; or
n	the directors have not disclosed in the 
financial statements any identified 
material uncertainties that may cast 
significant doubt about the company’s 
ability to continue to adopt the going 
concern basis of accounting for a period 
of at least twelve months from the 
date when the financial statements are 
authorised for issue.
Other information
The directors are responsible for the other 
information. The other information comprises 
the information included in the annual report, 
other than the financial statements and our 
auditor’s report thereon. Our opinion on the 
financial statements does not cover the other 
information and, except to the extent otherwise 
explicitly stated in our report, we do not express 
any form of assurance conclusion thereon.
INDEPENDENT  
AUDITOR’S REPORT  
TO THE MEMBERS OF  
IPU SERVICES LIMITED
65
2020 ANNUAL REPORT OF IPU EXECUTIVE COMMITTEE
In connection with our audit of the financial 
statements, our responsibility is to read the 
other information and, in doing so, consider 
whether the other information is materially 
inconsistent with the financial statements 
or our knowledge obtained in the audit or 
otherwise appears to be materially misstated. 
If we identify such material inconsistencies 
or apparent material misstatements, we 
are required to determine whether there 
is a material misstatement in the financial 
statements or a material misstatement of 
the other information. If, based on the work 
we have performed, we conclude that there 
is a material misstatement of this other 
information, we are required to report that fact.
We have nothing to report in this regard.
 
Opinions on other matters prescribed 
by the Companies Act 2014
Based solely on the work undertaken in the 
course of the audit, we report that in our 
opinion:
n	the information given in the directors’ 
report is consistent with the financial 
statements; and
n	the directors’ report has been prepared 
in accordance with applicable legal 
requirements.
We have obtained all the information and 
explanations which we consider necessary for 
the purposes of our audit.
In our opinion the accounting records of the 
company were sufficient to permit the financial 
statements to be readily and properly audited, 
and the financial statements are in agreement 
with the accounting records.
Matters on which we are required to 
report by exception
Based on the knowledge and understanding  
of the company and its environment obtained 
in the course of the audit, we have not 
identified any material misstatements  
in the directors’ report.
We have nothing to report in respect of our 
obligation under the Companies Act 2014 to 
report to you if, in our opinion, the disclosures 
of directors’ remuneration and transactions 
specified by sections 305 to 312 of the Act  
are not made.
Responsibilities of directors for the 
financial statements
As explained more fully in the directors’ 
responsibilities statement, the directors 
are responsible for the preparation of the 
financial statements and for being satisfied 
that they give a true and fair view, and for such 
internal control as the directors determine 
is necessary to enable the preparation of 
financial statements that are free from material 
misstatement, whether due to fraud or error.
In preparing the financial statements, the 
directors are responsible for assessing the 
company’s ability to continue as a going 
concern, disclosing, as applicable, matters 
related to going concern and using the going 
concern basis of accounting unless the directors 
either intend to liquidate the company or to 
cease operations, or have no realistic  
alternative but to do so.
INDEPENDENT 
AUDITOR’S 
REPORT TO THE 
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Auditor’s responsibilities for the  
audit of the financial statements
Our objectives are to obtain reasonable 
assurance about whether the financial 
statements as a whole are free from material 
misstatement, whether due to fraud or error, 
and to issue an auditor’s report that includes 
our opinion. Reasonable assurance is a high 
level of assurance, but is not a guarantee 
that an audit conducted in accordance with 
ISAs (Ireland)  will always detect a material 
misstatement when it exists. Misstatements 
can arise from fraud or error and are considered 
material if, individually or in the aggregate, they 
could reasonably be expected to influence the 
economic decisions of users taken on the basis 
of these financial statements.
A further description of our responsibilities for 
the audit of the financial statements is located 




ISA-700-(Ireland). This description forms part 
of our auditor’s report.
The purpose of our audit work and to 
whom we owe our responsibilities
This report is made solely to the company’s 
members, as a body, in accordance with section 
391 of the Companies Act 2014. Our audit 
work has been undertaken so that we might 
state to the company’s members those matters 
we are required to state to them in an auditor’s 
report and for no other purpose. To the fullest 
extent permitted by law, we do not accept or 
assume responsibility to anyone other than the 
company and the company’s members, as a 
body, for our audit work, for this report, or for 
the opinions we have formed.
Ian Lawlor
for and on behalf of  
JPA Brenson Lawlor
Chartered Accountants
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  2019 2018
 Notes € €
Turnover  1,344,007 1,340,229 
Administrative expenses  (1,385,240) (1,312,807)
Operating (loss)/profit  (41,233) 27,422
Interest receivable and similar income 3 419,836 279,083
Profit before taxation  378,603 306,505
Tax on profit    (29,062) (39,010)
Profit for the financial year  349,541 267,495
PROFIT AND LOSS 
ACCOUNT FOR THE YEAR 
ENDED 31 DECEMBER 2019
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   2019  2018 
 Notes € € € € 
Fixed assets 
Financial assets 4  345,000   345,000
Current assets 
Stocks 6 47,320   49,719
Debtors 5 2,020,353   1,595,309
Cash at bank and in hand  179,982   270,454
  2,247,655   1,915,482
Creditors: amounts falling  
due within one year 7 (1,879,997)   (1,897,365) 
   
Net current assets   367,658   18,117
Total assets less current liabilities   712,658   363,117
Capital and reserves 
Called up share capital presented as equity   127   127
Profit and loss reserves 8  712,531   362,990
   
Total equity   712,658   363,117
These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small 
companies regime and in accordance with Financial Reporting Statement 102 ‘The Financial Statement Reporting Standard 
applicable in the UK and Republic of Ireland’.
The financial statements were approved by the board of directors and authorised for issue on 8 October 2020 and are signed  
on its behalf by:
Eamon Daragh  Connolly Darragh O’Loughlin  
Director Director
BALANCE SHEET AS AT 
31 DECEMBER 2019
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1. Accounting policies 
Company information
IPU Services Limited is a private company 
limited by shares, domiciled and incorporated 
in Republic of Ireland. The registered office 
is Butterfield House, Butterfield Avenue, 
Rathfarnham, Dublin 14 and it’s company 
registration number is 124242.
 
1.1 Accounting convention 
 These financial statements have been 
prepared in accordance with FRS 102  
“The Financial Reporting Standard 
applicable in the UK and Republic 
of Ireland” (“FRS 102”), as adapted 
by Section 1A of FRS 102, and the 
requirements of the Companies Act 2014.
 The financial statements are prepared in 
euros, which is the functional currency 
of the company. Monetary amounts in 
these financial statements are rounded to 
the nearest €.
 The financial statements have been 
prepared under the historical cost 
convention. The principal accounting 
policies adopted are set out below.
 
1.2 Turnover 
 Turnover is recognised at the fair value of 
the consideration received or receivable 
for goods and services provided in the 
normal course of business, and is shown 
net of VAT and other sales related taxes 
with the exception of course fees, which 
are not liable to VAT. The fair value of 
consideration takes into account trade 
discounts, settlement discounts and 
volume rebates.
 
1.3 Fixed asset investments 
 Interests in subsidiaries, associates and 
jointly controlled entities are initially 
measured at cost and subsequently 
measured at cost less any accumulated 
impairment losses. The investments 
are assessed for impairment at each 
reporting date and any impairment losses 
or reversals of impairment losses are 
recognised immediately in profit or loss.
 A subsidiary is an entity controlled by the 
company. Control is the power to govern 
the financial and operating policies of the 
entity so as to obtain benefits from its 
activities.
 An associate is an entity, being neither 
a subsidiary nor a joint venture, in which 
the company holds a long-term interest 
and where the company has significant 
influence. The company considers that it 
has significant influence where it has the 
power to participate in the financial and 
operating decisions of the associate.
 Entities in which the company has a long 
term interest and shares control under a 
contractual arrangement are classified as 
jointly controlled entities.
1.4 Stocks
 Stocks are stated at the lower of cost 
and estimated selling price less costs to 
complete and sell. Cost comprises direct 
materials and, where applicable, direct 
labour costs and those overheads that 
have been incurred in bringing the stocks 
to their present location and condition.
 Stocks held for distribution at no or 
nominal consideration are measured at 
the lower of replacement cost and cost, 
IPU SERVICES LIMITED 
NOTES TO THE FINANCIAL 
STATEMENTS
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adjusted where applicable for any loss of 
service potential.
1.5 Cash and cash equivalents
 Cash and cash equivalents are basic 
financial assets and include cash in hand, 
deposits held at call with banks, other 
short-term liquid investments with 
original maturities of three months or 
less, and bank overdrafts. Bank overdrafts 
are shown within borrowings in current 
liabilities.
1.6 Financial instruments
 The company has elected to apply the 
provisions of Section 11 ‘Basic Financial 
Instruments’ and Section 12 ‘Other 
Financial Instruments Issues’ of FRS 102 
to all of its financial instruments.
 Financial instruments are recognised in 
the company’s statement of financial 
position when the company becomes 
party to the contractual provisions of the 
instrument.
 Financial assets and liabilities are offset, 
with the net amounts presented in the 
financial statements, when there is a 
legally enforceable right to set off the 
recognised amounts and there is an 
intention to settle on a net basis or to 
realise the asset and settle the liability 
simultaneously.
 Basic financial assets
 Basic financial assets, which include 
debtors and cash and bank balances, 
are initially measured at transaction 
price including transaction costs and are 
subsequently carried at amortised cost 
using the effective interest method unless 
the arrangement constitutes a financing 
transaction, where the transaction is 
measured at the present value of the 
future receipts discounted at a market 
rate of interest.
 Classification of financial liabilities
 Financial liabilities and equity instruments 
are classified according to the substance 
of the contractual arrangements entered 
into. An equity instrument is any 
contract that evidences a residual interest 
in the assets of the company after 
deducting all of its liabilities.
 Basic financial liabilities
 Basic financial liabilities, including 
creditors, bank loans, loans from fellow 
group companies and preference shares 
that are classified as debt, are initially 
recognised at transaction price unless 
the arrangement constitutes a financing 
transaction, where the debt instrument 
is measured at the present value of the 
future payments discounted at a market 
rate of interest.
 Financial liabilities and equity instruments 
are classified according to the substance 
of the contractual arrangements entered 
into. An equity instrument is any 
contract that evidences a residual interest 
in the assets of the company after 
deducting all of its liabilities.
1.7 Equity instruments
 Equity instruments issued by the 
company are recorded at the proceeds 
received, net of transaction costs. 
Dividends payable on equity instruments 
are recognised as liabilities once they 
are no longer at the discretion of the 
company.
1.8 Taxation
 The tax expense represents the sum of 
the tax currently payable and deferred 
tax.
 Current tax
 The tax currently payable is based on 
taxable profit for the year. Taxable profit 
differs from net profit as reported in the 
income statement because it excludes 
items of income or expense that are 
taxable or deductible in other years and 
it further excludes items that are never 
taxable or deductible. The company’s 
liability for current tax is calculated using 
tax rates that have been enacted or 
substantively enacted by the reporting 
end date.
  Deferred tax
 Deferred tax liabilities are generally 
recognised for all timing differences and 
deferred tax assets are recognised to the 
extent that it is probable that they will be 
recovered against the reversal of deferred 
tax liabilities or other future taxable 
profits. Such assets and liabilities are 
not recognised if the timing difference 
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arises from goodwill or from the initial 
recognition of other assets and liabilities 
in a transaction that affects neither the 
tax profit nor the accounting profit.
 The carrying amount of deferred tax 
assets is reviewed at each reporting end 
date and reduced to the extent that it is 
no longer probable that sufficient taxable 
profits will be available to allow all or part 
of the asset to be recovered. Deferred 
tax is calculated at the tax rates that are 
expected to apply in the period when the 
liability is settled or the asset is realised. 
Deferred tax is charged or credited in the 
income statement, except when it relates 
to items charged or credited directly to 
equity, in which case the deferred tax is 
also dealt with in equity. Deferred tax 
assets and liabilities are offset when the 
company has a legally enforceable right 
to offset current tax assets and liabilities 
and the deferred tax assets and liabilities 
relate to taxes levied by the same tax 
authority.
1.9 Leases
 Rentals payable under operating leases, 
including any lease incentives received, 
are charged to profit or loss on a straight 
line basis over the term of the relevant 
lease except where another more 
systematic basis is more representative 
of the time pattern in which economic 
benefits from the leased asset are 
consumed.
2. Going concern
 The directors have prepared budgets and cash 
flows for a period of at least twelve months 
from the date of the approval of the financial 
statements which demonstrate that there is no 
material uncertainty regarding the company’s 
ability to meet its liabilities as they fall due, and 
to continue as a going concern. On this basis 
the directors consider it appropriate to prepare 
the financial statements on a going concern 
basis. Accordingly, these financial statements 
do not include any adjustments to the carrying 
amounts and classification of assets and 
liabilities that may arise if the company was 
unable to continue as a going concern.
IRISH PHARMACY 
UNION NOTES TO 
THE FINANCIAL  
STATEMENTS
Continued
   2019 2018
   € €
Interest receivable and similar income  
includes the following: 
Income receivable from joint venture   421,660 273,507
3. Interest receivable and similar income
 
4. Financial assets 
   2019 2018
   € €
Participating interests   345,000 345,000
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Movements in fixed asset investments
   Shares in group  
   undertakings and  
   participating interests
    €
Cost or valuation
At 1 January 2019 and 31 December 2019    345,000
Carrying amount 
At 31 December 2019    345,000
At 31 December 2018    345,000
5. Debtors
   2019 2018
   € €
Amounts falling due within one year:
Trade debtors   381,082 263,581
Corporation tax recoverable   8,127 1,733
Amounts owed by group undertakings   1,625,000 1,325,000
Prepayments   6,144 4,995
   2,020,353 1,595,309
6. Stocks
   2019 2018
   € €
Finished goods and goods for resale   47,320 49,719
7. Creditors: amounts falling due within one year 
   2019 2018
   € €
Trade creditors   96,516 104,178
Amounts due to group undertakings   1,675,334 1,671,732
Deferred income   97,049 115,005
Accruals   11,098 6,450
   1,879,997 1,897,365
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IRISH PHARMACY 
UNION NOTES TO 
THE FINANCIAL  
STATEMENTS
Continued
8. Profit and loss reserves 
   2019 2018
   € €
At the beginning of the year   362,990 95,495
Profit for the year   349,541 267,495
At the end of the year    712,531 362,990
9. Financial commitments
At the financial year end the company had 
financial commitments in relation to Health 
Market Research Ireland Limited (joint 
venture) of €300,000 (2018: €300,000).
10. Related party transactions
The company is a 100% subsidiary of Irish 
Pharmacy Union. The company is exempt 
under the terms of FRS 102 (Section 33) 
“Related Party Disclosures” from disclosing 
related party transactions with other members 
of the group.
The company holds 25,000 “A” ordinary 
shares in Health Market Research Ireland 
Limited. During the year the company incurred 
expenses on behalf of Health Market Research 
Ireland Limited totalling €323,245 (2018: 
€273,507). The expenses incurred are part  
of a joint venture arrangement entered into  
on 26 September 2014.
At the statement of financial position date, an 
amount of €1,625,000 (2018:€1,325,000) 
was owed by Health Market Research Ireland 
Limited to the company.
11. Parent company
Irish Pharmacy Union holds 100% of the issued 
share capital of IPU Services Limited.
12. Events after the reporting date
There are no post reporting date events which 
require disclosure.
13. Approval of financial statements
The directors approved the financial statements 
on the 8 October 2020
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APPENDIX I
A LIST OF SUBMISSIONS 
MADE SINCE THE 2019 AGM
The following submissions were made since  
the 2019 AGM, most of which are available  
on www.ipu.ie.
2019
n	MPharm Accreditation Standards  
– PSI – March and May (meetings)
n	Recognition of Prescriptions  
– Department of Health – April 2019
n	Orphan Medicinal Products  
– Joint Oireachtas Committee on  
Health – April 2019
n	HTA on PrEP Programme  
– HIQA – April 2019 (online)
n	VAT on Food Supplements  
– Department of Finance and Public 
Expenditure and Reform – May 2019  
n	Access to Contraception  
– Department of Health – July 2019
n	Expansion of Pharmacy  
Vaccination Service  
– Department of Health – August 2019 
n	Pre-Budget Submission 2020  
– Department of Finance and Public 
Expenditure and Reform – July 2019
n	PSI Registration Rules  
– PSI – October 2019 (online)
n	Fees for PPV Vaccination  
– Department of Health – October 2019 
n	Fee Increases for Pharmacy Contractors 
– Department of Health – October 2019
n	Pharmacy Fees Consultation under 
Public Pay Act  
– Department of Health – November 
2019
n	Review of the current eHealth  
landscape in Ireland  
– HIQA – December 19
n	HPRA Strategy 2021-2025  
– HPRA – December 2019 (online)
n	Guide to Biosimilars  
– HPRA – December 2019 
2020
n	Comments on EU Veterinary  
Medicines Regulation  
– DAFM – January 2020
n	Preferred Blood Glucose  
Test Strip and Meter  
– MMP – February 2020
n	Supply Route on Antiparasitics  
– HPRA – February 2020
n	HSE Corporate Strategy  
– HSE – February 2020
n	Review of Core Competency Framework 
– PSI – March 2020
n	PSI Education and Training Rules  
– PSI – March 2020
n	PSI Registration Rules  
– PSI – April 2020
n	Operational Standards for RPBs  
– PSI – May 2020
n	Guidance on Flu Vaccination  
for Children  
– May 2020
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APPENDIX II
KEY CORRESPONDENCE 
SINCE THE 2019 AGM
PSI
n	Expansion of Pharmacy  
Vaccination Service
n	Pharmacy at a Distance
n	Expansion of Pharmacy  
Vaccination Services
n	English Language Competence 
Department of Health
n	 IPU National Pharmacy Conference 
n	Brexit
n	Proposed Fee Changes
n	Commitment to Unwind FEMPI and 
Proposed Cuts to Pharmacy Fees
n	Community Pharmacy Covid-19 Urgent 
Measures 
n	Health Care Professionals returning  
to Front Line 
n	Community Pharmacy Covid-19  
Urgent Measures
n	Community Pharmacy Covid-19  
Urgent Measures
n	Community Pharmacy Covid-19 
Response – Expansion of  
Vaccination Programme 
HSE
n	Health Service and Pharmacy
n	Health Service and Community 
Pharmacy
n	Pharmacists’ Access to NMIC
n	Community Pharmacist  
Covid-19 Testing 
PCRS
n	 Inclusion of Rheumatology, Dermatology 
and Gastroenterology medicines in the 
High Tech Hub
n	Community Pharmacy Contractor 




n	Community Pharmacy Contractor 
Agreement – Changes to Claiming 
Arrangements
Oireachtas Committees
n	Report of the Working Group on  
Access to Contraception 
Other Government Departments
n	New Pharmacy Contract / Unwinding 
FEMPI (Minister for Finance and  
Public Expenditure & Reform)
n	Commitment to Unwind FEMPI  
and Proposed Cuts to Pharmacy  
Fees (Taoiseach)
n	Health Care Professionals returning  
to Front Line 
National Centre for Pharmoeconomics
n	MMP Best-value Biologicals Policy 
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Manufacturers
n	Compassionate Access Programmes – 
Impact on Pharmacists
n	PRODUCT RECALL Emerade 
150/300/500 micrograms solution for 
injection in pre-filled pens 
n	PRODUCT RECALL Emerade 
150/300/500 micrograms solution for 
injection pre-filled pens 
Revenue
n	 lrish Pharmacy Union Members’  
PSWT Tax Refunds
n	 lrish Pharmacy Union Members’  
PSWT Tax Refunds
MEPS
n	Elections to the European  
Parliament 2019
n	PGEU 60th Anniversary Event 
Other
n	Tailored Regimens for Combined 
Hormonal Contraception
n	Thank you on behalf of Irish  
community pharmacists 
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Expansion of Pharmacy  
Vaccination Service
Secretary General to PSI Registrar,  
16 April 2019 
I am writing to you in relation to the expansion 
of the existing Pharmacy Vaccination Service. In 
the attached proposal, which was previously sent 
to the Minister for Health, we reviewed all the 
vaccines within the guidelines produced by the 
National Immunisation Advisory Committee 
(NIAC) and made recommendations as to the 
suitability of certain selected vaccines for supply 
and administration within the existing Pharmacy 
Vaccination Service. We also believe that 
pharmacists should be permitted to administer 
vaccines outside the pharmacy setting, such 
as to patients in a nursing home, where a flu 
outbreak can have very serious consequences. 
At a meeting with the Minister in late March, 
his officials indicated that the PSI should 
take the lead on this proposal and subsequent 
amendment of legislation. Consequently, we are 
addressing this issue to you, in the hope that the 
PSI will secure the long-sought expansion of the 
Pharmacy Vaccination Service. 
Statistics produced by the HSE indicate that 
the existing flu vaccination service has led to 
improved accessibility of vaccination for the 
public. Pharmacy flu vaccination now accounts 
for 15% of all flu vaccinations. Moreover, since 
pharmacists first started vaccinating in 2011, 
flu vaccine deliveries through the National 
Immunisation Office (NIO) have increased 
overall by 48% and, within that, deliveries to 
GPs are up 23%, demonstrating that when 
pharmacists vaccinate, public awareness 
increases and vaccination rates increase. 
A study carried out by the Pacific Research 
Institute1 in the USA last year showed that: 
• Pharmacies are well placed to address 
barriers to uptake of vaccination as they 
tend to be more effective, lower-cost 
providers of vaccinations; 
• Pharmacies also offer greater 
convenience including expanded hours of 
operation, more flexible scheduling than 
other providers, and multiple locations 
near where people live; 
• Regulations implemented to expand 
pharmacists’ role in health care delivery 
through the administration of seasonal 
influenza immunisations have had a 
positive impact on the national efforts to 
increase immunisation rates. 
The report summarises the benefits of 
pharmacy-provided vaccination as: 
1. Pharmacies typically have lower costs 
and higher productivity in administering 
vaccines; 
2. Pharmacies offer patients greater time 
and locational convenience; 
3. Pharmacies are well positioned to 
serve under-vaccinated populations, 
particularly in rural communities; 
4. Pharmacists are well positioned to 
educate patients on the benefits from 
vaccines. 
Furthermore, the President of the European 
Commission, Jean-Claude Juncker, called for 
action to increase vaccination coverage in his 
2017 State of The Union address2. Empowering 
pharmacists to administer vaccines serves 
as an important case study for the broader 
healthcare system. Increasing access across 
the healthcare system can provide patients 
with more choices, increase overall health care 
quality, and effectively “bend the healthcare 
cost curve”. 
In light of the ongoing success of the pharmacy 
flu vaccination service in Ireland and the 
recommendations of the US report, we ask 
you to give serious consideration to expanding 
the range of vaccines that pharmacists can 
administer by way of amendment of the 
Medicinal Products (Prescription and Control 
of Supply) Regulations (Amendment) (No. 2) 
Regulations 2015 [S.I. No. 449 of 2015]. 
I would like to make it clear that our proposal 
is about allowing pharmacists to administer 
more vaccines; it is not about pharmacists 
being remunerated for vaccines, such as travel 
vaccines, which are not part of the HSE-
remunerated vaccination programme. Neither 
should the capacity of the Irish Institute of 
Pharmacy (IIOP) to produce online training 
programmes for new vaccines be a barrier to 
the expansion of the Pharmacy Vaccination 
Service. Many other jurisdictions, such as the 
UK, allow pharmacists to supply and administer 
a full range of vaccines and I am sure we could 
easily adapt their training programmes. 
I look forward to hearing from you on this 
matter and would welcome the opportunity to 
discuss it in greater detail. 
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Pharmacy at a Distance
Registrar, PSI, to Secretary General,  
26 June 2019
Thank you for your letter of 15th February 
in which you expressed concerns and the 
concerns of your members regarding the 
provision of pharmacy services at a distance 
by mail order or otherwise, together with the 
advertising or promotion of medicines on the 
basis of discounts.
The matters you refer to fall within the general 
categories of delivery and advertising and I will 
address them accordingly.
1. Delivery
The PSI considers that the optimal and safest 
way for dispensed medicines to be supplied is 
through direct supply to the patient or carer 
following a face to face interaction between 
a pharmacist and the patient or carer in 
the pharmacy. Prior to the development of 
PSI Guidance on the Delivery of Medicines 
Dispensed on Foot of a Prescription from a 
Retail Pharmacy Business (the “Guidance”) it 
was recognised that the delivery of medicines 
to patients in one form or another was always a 
part of the service provided by pharmacies.
The Guidance sets out the obligations of 
pharmacy owners and pharmacists including 
superintendent, supervising and registered 
pharmacists, in assuring the security and safety 
of delivery systems and ensuring compliance 
with legal and professional requirements. In 
addition, the Guidance reminds those arranging 
their delivery systems of the requirements 
of Regulation 19 of the Medicinal Products 
(Prescription and Control of Supply) 
Regulations 2003 (as amended) which 
expressly prohibits the supply by mail order of 
prescription-only medicinal products.
The legislation and guidance places certain 
professional requirements on the pharmacist 
supplying medicines. These obligations apply 
irrespective of whether a pharmacist is 
supplying a medicine face to face or by delivery. 
The pharmacist must review the prescription 
having regard to the pharmaceutical and 
therapeutic appropriateness of the medicine 
therapy for the patient and most importantly 
the pharmacist must be satisfied that the 
patient concerned has sufficient information 
and advice for the proper use and storage 
of the medicinal product concerned. The 
pharmacist must also offer to discuss with 
the patient or their carer all such matters as 
the pharmacist, in the exercise of his or her 
professional judgement, deems significant. 
These are essential patient safety requirements 
which must be met by any pharmacy including 
those that provide a delivery system. 
Where pharmacies are providing a delivery 
service the procedures for same are reviewed as 
part of routine inspections. Where issues arise 
these are addressed accordingly.
However, should you become aware of any 
pharmacy that is operating outside of the 
legislative and guidance provisions the PSI 
would investigate such matters should you 
bring them to our attention.
2. Advertising or promotion of medicines  
on the basis of discounts
The advertising of prescription-only medicines 
to the general public is not permitted by 
virtue of the Medicinal Products (Control of 
Advertising) Regulations 2007; however these 
regulations do not apply to factual informative 
announcements, including price lists, provided 
they include no product claims. The PSI 
published a Medicine Price Listing Clarification 
in the PSI Newsletter of May 2012. This 
clarification stated that factual information 
regarding the prices of prescription only 
medicines may be lawfully displayed.
In circumstances where additional services 
and/or information are provided from a 
pharmacy to the public it is the responsibility 
of pharmacy owners and pharmacists including 
superintendent, supervising and registered 
pharmacists to ensure that the pharmacy, and 
their practice, are at all times operating to the 
highest standards and are fully compliant with 
all relevant legislation, PSI guidance and the 
Code of Conduct for Pharmacists.
I hope the above information clarifies the 
PSI’S position. If you have a particular concern 
in relation to the mail order or inappropriate 
advertising of medicines in a particular 
pharmacy, you are invited to provide this 
information to the PSI in order for us to look 
into the matter further.
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Expansion of Pharmacy  
Vaccination Services
Registrar, PSI to Secretary General , 
24 July 2019
Thank you for your letter dated 16 April 2019 
and, as indicated at our last meeting, apologies 
for not coming back to you on this sooner. 
The PSI’S Corporate Strategy 2018-2020 
recognises that our regulatory approach 
must not stand in the way of innovation and 
developments that can facilitate improved 
healthcare outcomes for people receiving 
pharmacy care and advice. Further to 
discussions with the Department of Health, 
the National lmmunisation Office and the 
HSE, the influenza vaccination training 
programme for pharmacists is being updated. 
At its June meeting, PSI Council approved 
amendments to the Programme Specification 
for the Administration of Influenza Vaccination 
Training Course, whereby the pharmacy ‘flu 
vaccination training programme was expanded 
to include children 10 years and above for 
the 2019120 ‘flu season. PSI council further 
approved expanding the training in the 
2020/21 ‘flu season to include children 6 
months and above.
In response to your assertion that the 
Department of Health indicated the PSI should 
take the lead on “...subsequent amendment of 
legislation” in the area of expanded pharmacy 
vaccination services, I can confirm that 
introducing such legislative amendments is 
beyond the remit of the PSI. My understanding 
is that the Department of Health have 
subsequently clarified this with you.
In your letter you also address how the location 
of administration of vaccines and current 
training programmes should not be a barrier 
to the expansion of the Pharmacy Vaccination 
Service. These matters are currently being 
explored by the PSI, notwithstanding the 
parameters set out in Regulation 48 of the 
Medicinal Products (Prescription and Control 
of Supply) Regulations 2003, as amended.
The PSI is committed to ensuring that 
pharmacists in patient-facing roles are, and 
remain, competent to offer individualised 
advice and treatments to patient and the public 
into the future.
I trust the above information clarifies the PSI’s 
position.
English Language Competence 
Secretary General to PSI Registrar,  
14 October 2019 
I am writing to you about the current criteria 
that the PSI accepts as being satisfactory to 
assure language competence for pharmacists 
who have completed their training outside 
of Ireland and who are seeking registration 
with the PSI. It has been reported to us that 
significant numbers of EU pharmacists who 
wish to register and practise in Ireland are 
finding the language requirements to be an 
insurmountable barrier. 
One of the PSI criteria is that the pharmacist 
must have a certificate issued by an 
internationally recognised body or authority, 
recognised by the PSI Council, attesting 
that the holder has attained a standard of 
competence in the English language. The 
PSI requires an overall band score of 7.0 
and a minimum score of 7.0 in each module 
(speaking, writing, reading and listening). 
However, the Medical Council of Ireland 
requirements are somewhat less stringent, 
requiring an overall band score of 7.0, same as 
the PSI, but accepting a minimum score of 6.5 
in each module. 
Given that effective communication is as 
important in the practice of medicine as it is in 
pharmacy and the Medical Council is clearly 
satisfied that patient safety and public welfare 
are sufficiently well protected by its language 
requirements, we propose that the PSI adjust 
its minimum criteria to that of the Medical 
Council i.e. an overall band score of 7.0 and a 
minimum score of 6.5 in each module 
I would be happy to meet with you to discuss 
this in more detail.
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Department of Health
IPU National Pharmacy Conference 
Secretary General to Minister for Health 
Simon Harris TD, 13 June 2019
I am writing to you to thank you most sincerely 
for coming to the recent IPU National 
Pharmacy Conference in Galway and for 
delivering the keynote opening address.
We very much appreciate that you took time 
to come and speak with us and took such 
interest in our issues, particularly at such 
a busy time for you. We were gratified at 
the positive note you struck in your address 
and your commitment to the IPU and our 
members that this year we would collectively 
start discussions on a new pharmacy contract, 
on moving past FEMPI and on a programme of 
investment in pharmacy services.
Pharmacists welcomed your acknowledgement 
of the cuts that were introduced to address the 
financial crisis and the effects on the sector, 
and your recognition that there are undoubted 
opportunities for us to work together in areas 
such as vaccinations, contraception and a new 
contract, and to move beyond FEMPI to a 
higher terrain. You committed that there would 
be significant State investment in primary care, 
and we acknowledge in that context that such 
expanded remuneration will be tied to improved 
and extended services. 
I do have to apprise you that, prior to the 
National Pharmacy Conference, the IPU had 
begun preparing detailed submissions to send 
to you calling upon you to reverse the FEMPI 
cuts, as their continuation would clearly be 
unfair and disproportionate.
Between 2009 and 2016, the State, through 
both FEMPI and non-FEMPI related 
measures, extracted a total of approximately 
€2.686 billion from the community pharmacy 
sector in reduced medicine reimbursements 
and cuts to pharmacy fees. I cannot 
emphasise enough that what is reasonable and 
proportionate in a financial crisis is not so in 
the current economic circumstances.
One of the IPU’s concerns was that the 2017 
and 2018 ‘annual reviews’ by your Department 
under the FEMPI Act (obtained under the 
Freedom of Information Act) appear to suggest 
that pharmacy contractors, unlike some other 
contractors, had no legitimate expectation of 
an unwinding of the FEMPI cuts.
The conclusion of the 2017 annual review 
notes that “pharmacy contractors do not have 
a legitimate expectation for the unwinding of 
FEMPI measures, unlike some other contractors 
or public servants.” [our emphasis]
The 2017 and 2018 annual reviews for other 
contractors seem to suggest that dentists 
and opticians may have had an expectation of 
FEMPI being unwound based upon increases 
and/or the expansion of fees to dentists and 
opticians paid by the Department of Social 
Protection.
Not only was this highly dubious, it is clear from 
your commitments at the National Pharmacy 
Conference that pharmacy contractors very 
much do have a legitimate expectation around 
moving beyond FEMPI. 
We look forward to engaging with you and your 
officials, along with colleagues in Sláintecare 
and the HSE, to commence the comprehensive 
engagement that you referred to, which we are 
confident will deliver tangible benefits for Irish 
patients and the public, as well as for the health 
system itself.
Brexit
Secretary General, Department of Health; 
Chief Executive, HPRA; CEO Health Service 
Executive; Chief Executive, Food Safety 
Authority of Ireland; to Secretary General,  
12 August 2019
We wish to acknowledge and thank you for the 
substantial work already completed in respect 
of Brexit Preparedness Planning. It is important 
that your organisation and those you represent 
continue to prepare for a no deal Brexit, to 
ensure full compliance with all legislative and 
regulatory requirements, particularly in relation 
to services or products sourced in or through 
the UK.
It is the Government’s assessment that there 
is a significant risk of a no deal Brexit on 31 
October.
The Government recently published the Brexit 
Contingency Action Plan Update, reflecting the 
extensive work which has taken place at EU 
level and on a whole-of-Government basis, to 
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prepare for a no deal Brexit, and setting out the 
steps to be taken between now and 31 October.
The Department of Health, in conjunction 
with the Health Service Executive (HSE), 
the Health Products Regulatory Authority 
(HPRA) and the Food Safety Authority of 
Ireland (FSAI) has been engaged in extensive 
Brexit planning and action to ensure that the 
health sector is prepared, to the greatest extent 
possible, for any adverse impacts as a result of 
Brexit.
Some key messages to emphasise are:
• In Ireland we have, since 2016, been 
working to determine and address 
the risks to medicines supply as a 
result of Brexit. As a consequence, we 
have developed a comprehensive and 
coordinated set of preparations to ensure, 
as far as is possible, continuity of supply 
of medicines.
• Unlike in the UK, there are already 
additional stocks of medicines routinely 
built into the lrish medicine supply chain 
and these stocks will help to absorb any 
short-term delays that may occur. The 
health system is therefore well placed to 
anticipate and respond to any additional 
shortages, should they arise because of 
Brexit.
• There is no need for hospitals, 
pharmacists or patients to order extra 
quantities of medicines, or for doctors 
to issue additional prescriptions. Doing 
so could disrupt existing stock levels and 
hamper the supply of medicines for other 
patients.
• No shortages currently affecting the lrish 
market are attributable to Brexit.
• Suppliers of medicines and medical 
devices should review their supply chain 
for products that travel from or through 
the UK, determine any products or 
services that are certified for compliance 
with EU standards by a UK body and 
communicate any vulnerabilities to the 
Department of Health, the HPRA or the 
HSE.
• In order to avoid unnecessary delays of 
medicines at ports it is vital that you and 
your members are as prepared as possible. 
Businesses will need to familiarise 
themselves fully with all relevant customs 
procedures, ensure that all necessary 
documentation is completed in advance 
and that any logistic companies engaged 
are aware of their new responsibilities. 
They must also consider the implication, 
for example, of carrying mixed loads, 
where some products are likely to be 
‘green-routed’ but may be delayed if they 
are in a consignment with other products 
that may be subject to additional checks.
Brexit Preparedness – Supply of medicines 
and medical devices
Significant work has been undertaken by the 
Department of Hea tth, the HPRA and the 
HSE, together with industry, to minimise and 
address any risks to continuity of supply.
The HPRA has encouraged and supported the 
transfer of medicines authorisations and other 
industry functions from the UK to Ireland. 
While the joint labelling of medicines with the 
UK will continue to be acceptable after Brexit, 
the HPRA has also issued guidance that it 
will work with companies and other European 
regulators to help facilitate multi-lingual 
labelling solutions between Ireland and other 
EU27 Member State markets.
Nationally, the HSE and the HPRA have 
facilitated ongoing engagements with 
manufacturers of medicines and medical 
devices, to ensure that they are Brexit-ready, 
to discuss any potential issues that could 
affect the supply of medicines to Ireland and 
to identify solutions to maintain supply to the 
market.
A group of experts on medicines and medical 
devices were convened by the HSE and 
HPRA as subgroups to the Department 
of Health’s Brexit Operations Team. The 
experts were tasked with scoping out key 
risk areas and focusing contingency planning 
efforts on potentially vulnerable medicines 
and medical devices. Ongoing engagements 
with manufacturers and suppliers have been 
facilitated, to ensure that they are Brexit-
ready, to discuss any potential issues that could 
affect supply to Ireland and to identify solutions 
to maintain supply to the market.
The expert groups have completed the first 
phase of a criticality assessment exercise which 
included seeking assurances from stakeholders, 
including pharmaceutical manufacturers, 
wholesalers and healthcare professionals 
on their preparedness, understanding their 
contingency planning to date and, where 
necessary, identifying clinically appropriate 
alternatives for those products most critical to 
public health with potential to be vulnerable to 
supply issues. Between four and five thousand 
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medicines have been assessed to date. A similar 
process is underway in respect of medical 
devices. Work on this will continue up to, and in 
the months following, Brexit.
Outside of this process it is important for 
businesses and enterprises to further reflect 
on the products they use, consider where 
they originate and how those products are 
imported into lreland. Ordinarily medicines are 
not subject to additional physical checks if all 
documentation is in order. However, to prepare 
appropriately, the classification of products 
and their respective ‘CN codes’ should be 
ascertained, which will help to determine the 
nature of documentation required and whether 
additional Sanitary-Phytosanitary checks may 
be required on the import of these products.
More information can be found here.
Brexit Preparedness – Access to  
health services
On 8 May 2019, Ireland and the UK signed an 
important Memorandum of Understanding on 
the Common Travel Area (CTA), reaffirming 
their commitment to maintaining it in all 
circumstances. Under this long-standing 
reciprocal arrangement, which predates Irish 
and UK membership of the EU and is not 
dependent on it, lrish citizens can move freely 
to live, work, study and access public services 
in the UK on the same basis as British citizens, 
while British citizens can do the same in lreland. 
Through the Memorandum of Understanding, 
both Governments have committed to 
undertaking all the work necessary, including 
through legislative provision, to ensure that 
the agreed Common Travel Area rights and 
privileges are protected.
On healthcare, the lrish and British 
Governments have committed to the 
shared objective of maintaining the CTA 
arrangements, which have long facilitated lrish 
and UK residents in accessing health services 
in each other’s jurisdictions. Provision has been 
made to ensure the arrangements necessary 
to maintain health service cooperation for the 
period after a no deal Brexit. These include 
the maintenance of current arrangements for 
access to routine, planned and emergency 
health services for UK/lrish residents and 
visitors in the other jurisdiction. It also includes 
health cooperation on access to specialist 
health services in the other jurisdiction 
including, for example, continued access to 
specialist paediatric cardiology services on an all 
island basis and access to specialist cancer and 
cardiac services.
Brexit Preparedness – Recognition  
of qualifications
There is an EU Directive that currently 
allows for EU citizens to have professional 
qualifications recognised. In the event of a 
no deal Brexit all UK qualifications already 
recognised in lreland wil continue to be 
recognised.
In the event of a no deal Brexit, applications for 
UK qualifications to be recognised in Ireland 
after 31 October wilt be processed as ‘third 
country’ applications, similar to all applications 
from outside the EU, which may mean that the 
process will take longer. Further information 
can be found on the relevant health regulator’s 
website.
Brexit Preparedness – Food Safety
In the event of a no deal Brexit, the UK will 
immediately become a ‘third country’ for trade 
and customs purposes. The FSAI, together 
with the HSEJs Environmental Health Service 
and relevant Departments and Agencies is 
working with food businesses to ensure that 
they are aware of the new rules that will apply 
to food products being traded from or moving 
through the UK post Brexit. Food businesses 
should prepare now for the regulatory and 
legislative changes they will face after the UK 
leaves the EU.
Conclusions
We would appreciate if you could disseminate 
these important messages within your 
organisation, to your members and to those 
you represent and work with to provide advice 
and reassurance to patients, the general public 
and relevant businesses. 
We would also encourage your organisation to 
engage as necessary with the work of the HSE, 
HPRA and FSAI, as the process of verifying 
contingency planning continues in the coming 
weeks and months, before and after Brexit. 
More information on steps that a business may 
need to take for issues covered in this letter and 
further information on business preparedness 
for Brexit can be found at www.gov.ie/Brexit. 
We plan to continue to engage with you on 
Brexit matters during the very limited time 
available for further preparations up to 31 
October 2019 and thereafter. 
We thank you for your collaboration to ensure 
Ireland’s public health is protected, whatever 
the Brexit outcome in the coming weeks.
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Assistant Secretary, Department of Health  
to Secretary General, 25 October 2019
I refer to our meeting yesterday, 24th 
October, at which the Department and HSE 
set out proposals for certain fees which would 
apply from 1 January 2020, in accordance with 
section 42 (9) of the Public Service Pay and 
Pensions Act 2017.
I undertook to outline in writing the proposed 
structural changes which are as follows:
Phased Dispensing Fee
With effect from 1 January 2020, to replace 
the current phased dispensing fee of €3.27 
payable per drug item for each dispensing 
phase, other than the first dispensing phase, 
with a patient care fee of €45 per month, 
where the dispensing of an item is being 
phased for one of the following reasons; at 
the request of a patients physician; due to the 
inherent nature of a medicinal product i.e. 
product stability and shelf life; where a patient 
is commencing new drug therapy with a view to 
establishing patient tolerance and acceptability 
before continuing on a full treatment regimen; 
in exceptional circumstances where the patient 
is incapable of safely and effectively managing 
their medication regimen. 
High Tech Arrangement Non Dispensing Fee 
With effect from 1 January 2020, to 
discontinue payment of a patient care fee per 
month under the High Tech Medicinal Products 
Scheme, where medicinal products prescribed 
under that scheme are not dispensed to the 
patient in a particular month. A patient care fee 
will only be paid where a high tech dispensing 
occurs for the patient within the month. 
Tiered Dispensing Fees
With effect from 1 January 2020, to set the 
standard dispensing fee per item payable to 
a community pharmacy contractor under 
the General Medical Services Scheme, the 
Drug Payment Scheme, the Long Term Illness 
Scheme, the European Economic Area Scheme 
and the Health (Amendment) Act 1996 
Scheme as follows:
• Each of the first 1,000 items dispensed 
by the community pharmacy contractor 
in a month €5.00;
• Each of the next 833 items dispensed by 
the community pharmacy contractor in 
that month €4.50;
• Each other item dispensed by the 
community pharmacy contractor in that 
month €3.50.
It is proposed that all other fees which will be 
maintained at the existing rates. 
The existing statutory basis for the payment of 
all fees will expire at the end of this year, and 
to maintain a statutory basis for the payment 
of fees, new regulations need to be drafted and 
signed by the Minister with the consent of the 
Minister for Public Expenditure and Reform 
before the end of the year. In order to enable 
this timeline to be met, the consultation on the 
proposed fees to apply from 1 January 2020 
will run until November 8th.
Commitment to Unwind FEMPI and 
Proposed Cuts to Pharmacy Fees
Secretary General to Minister for Health,  
11 November 2019 
I am writing to you to express the shock and 
outrage of the Irish Pharmacy Union and 
the pharmacy profession at the recently 
communicated proposal by the Department of 
Health to make “structural changes” to the fees 
paid to pharmacists for providing services on 
behalf of the State, which changes amount to 
further cuts in pharmacy fees. These proposed 
cuts are contrary to and a clear betrayal of 
repeated commitments that you have made to 
the IPU and publicly to pharmacists generally. 
In a meeting with the IPU in March this 
year, you clearly acknowledged the cuts to 
pharmacists’ incomes that had been introduced 
to address the financial crisis and the resulting 
financial pain felt by pharmacists, and you 
expressed your intention to unwind FEMPI 
cuts to pharmacists’ fees, to “move beyond 
FEMPI to a higher terrain”, committing to 
starting negotiations on a new pharmacy 
contract this autumn. 
Subsequently, in your keynote address to the 
IPU National Pharmacy Conference in May 
this year, you again acknowledged the cuts that 
had been introduced and the effects on the 
pharmacy sector and reiterated your intention 
to move beyond FEMPI to a higher terrain. 
You repeated your clear commitment to start 
discussions on a new pharmacy contract, on 
moving beyond FEMPI and on a programme of 
investment, saying “let’s get that done this year”. 
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Pharmacists took you at your word and, based 
on your commitments to the IPU and at 
the National Pharmacy Conference, have a 
legitimate expectation around moving beyond 
FEMPI through a significant and immediate 
increase in investment in pharmacy services, 
which we are confident will deliver tangible 
benefits for Irish patients and the public, as 
well as for the health system itself. What is 
reasonable and proportionate in a financial crisis 
is not so in the current economic circumstances. 
The proposed further cuts in fees to pharmacy 
contractors are disproportionate and inequitable, 
inconsistent and irrational, not only in 
circumstances where the economic crisis is over, 
but also where pharmacists are the only major 
contractor group to have had no fee restoration 
and, despite Government commitments, 
continue to bear a burden of austerity that has 
been lifted from other sectors. 
We are now seeking an urgent meeting with 
you and insist that the proposed changes to 
pharmacy fees be set aside and that, instead, 
we commence the repeatedly-promised 
negotiations on a new pharmacy contract 
and investment in pharmacy services, with 
an agreed deadline of 30 June 2020 for the 
conclusion of talks.
Community Pharmacy Covid-19 
Urgent Measures 
Secretary General to Minister for Health,  
20 March 2020
Community pharmacists are the most 
accessible of all healthcare professionals 
and continue to provide an essential 
nationwide service to patients and the public 
in extraordinarily difficult circumstances, a 
fact that ought to be acknowledged by the 
Government and the HSE. All pharmacies are 
displaying the HSE Covid-19 posters and are 
advising significant and increasing numbers of 
patients on signs and symptoms of Covid-19, 
referring those who require testing to their 
GPs. They are also spending a great deal of 
effort resisting pressure from patients seeking 
additional supplies of medicines above their 
normal requirements, attempting to reassure 
them that contingency plans are in place 
to ensure continued supplies of medicines, 
although managing supply interruptions and 
stock-outs remains a challenge.
Retail sales in pharmacies and, consequently, 
pharmacy revenues have plummeted due to the 
elimination of discretionary spending during 
the coronavirus/Covid-19 shutdown. It has 
previously been pointed out in Department 
of Health memoranda to the Minister in the 
context of the FEMPI legislation that these 
revenues can account for up to half of all 
income for pharmacies. The absence of this 
funding is having a significant impact on cash-
flow and on pharmacies’ ability to pay their staff 
and suppliers; we are already getting reports of 
pharmacies struggling to stay afloat financially. 
In spite of the evaporation of a significant 
portion of their income, pharmacies have had 
to invest in various measures to protect their 
staff and customers/patients from onward 
transmission of Covid-19. At considerable 
cost, they are actively changing their shop 
layouts and working practices to ensure social 
distancing guidelines are met, both to protect 
vulnerable patients and to protect staff to 
ensure continuity of service. The financial 
pressures on pharmacies will continue to 
intensify as this pandemic evolves and they 
will find it increasingly difficult to sustain their 
services.
In light of the extreme circumstances, it would 
be a welcome gesture of appreciation on the 
part of the State towards the unstinting efforts 
of pharmacists and their teams, and the very 
real danger they place themselves in every 
single day, for the State to take a measure of 
responsibility for their safety and fund the 
installation of social distancing infrastructure 
by way of a one-off grant to be paid to all 
community pharmacy contractors akin to that 
paid to pharmacies who volunteer to provide 
opioid substitution treatment services.
Our members are also concerned about their 
patients who are elderly or most vulnerable 
to Covid-19 infection – a cohort of patients 
who depend most on pharmacists due to their 
increased medication and care needs. Already 
socially distancing for their own safety, these
patients will soon be directed to cocoon. As 
such, many will require a medicine delivery 
service from the pharmacy, as will patients 
who are required to self-isolate for a period. 
The UK’s NHS has already committed to 
funding pharmacies to provide a Medicines 
Delivery Service to support Covid-19 positive 
and vulnerable patients self-isolating at home. 
The Department of Health and HSE must 
do likewise here. We would be happy to work 
with the HSE to design and implement this 
scheme and agree designation of categories of 
vulnerable patients.
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One source of the increasing pressure on 
pharmacies and the key driver for the added 
responsibilities being assumed by pharmacists 
is the unbearable strain on general practice 
services and the on-going capacity issues 
that GPs are experiencing. Patients and 
pharmacists around the country are reporting 
that it is next to impossible to get repeat 
prescriptions from overwhelmed GPs and 
that pharmacies are increasingly being asked 
to renew and extend prescriptions, which 
they are perfectly positioned to do if systems 
were in place to facilitate it. Before extending 
a prescription, the pharmacist must assess 
the patient and satisfy themselves that it 
is clinically appropriate to do so, with the 
patient only being referred to a GP where the 
pharmacist’s judgment is that there is a clinical 
need. The same is true for minor ailments. 
The professional input of the pharmacist in 
such circumstances must be recognised and, 
in the same way that GPs will now receive a 
fee for telephone consultations even when 
already in receipt of capitation payments in 
respect of those patients, a fee similar to that 
which applies for an emergency contraception 
consultation should apply for every patient 
assessment made to repeat a prescription. 
The UK’s NHS has committed to funding an 
Urgent Medicines Supply Service for patients 
whose general practice is unavailable; the 
Department of Health and HSE must do 
likewise for Irish patients.
In order to ensure their survival during 
these unprecedented times, the NHS has 
also committed to payments to community 
pharmacy contractors who are required to 
close due to Covid-19 related reasons. Irish 
pharmacies, some of whom have already been 
compelled to close, urgently need similar 
arrangements put in place if they are to avoid 
insolvency and have any prospect of re-opening 
once the issue has passed.
Funding has rightly been put in place for 
GPs to support them through this crisis. 
Pharmacies, who unlike GPs have not yet had 
the benefit of any reversal of previous fee 
cuts, and the importance of whose role on the 
frontline has never been starker, urgently need 
equivalent support.
We recognise the gravity of the situation facing 
the country at present, and pharmacy teams 
are actively going above and beyond what could 
reasonably have been expected of them. The 
issues outlined in this letter are both urgent and 
critical and require immediate action if we are 
to be in a position to sustain that effort.
Health Care Professionals returning  
to Front Line 
Secretary General to Minister for Health,  
25 March 2020
You recently put out a call for health care 
professionals who are not currently working 
on the front line in Ireland to return to work 
in front line roles as part of the national effort 
to fight the Covid-19 pandemic in Ireland. 
That call has been answered by thousands of 
qualified professionals who wish to return to 
work to support the health system during this 
crisis. Pharmacists are no exception; many of 
them have contacted the Irish Pharmacy Union 
volunteering to return to front line community 
pharmacy.
One anomaly has arisen, however, that 
requires an immediate resolution. It affects all 
professionals, not just pharmacists. A health 
care worker who is currently on maternity leave 
and in receipt of State maternity benefit will, 
if she returns to work temporarily even for a 
short period before returning to maternity 
leave, immediately lose the entitlement to the 
maternity benefit for the remainder of her 
maternity leave. This permanent loss of benefit 
is inhibiting eligible qualified women from a 
temporary return to the front line in a time of 
crisis.
We urge the Government as a matter of 
urgency to amend the existing rules for the 
duration of the current emergency, so as to 
allow women who break their maternity leave to 
assist in a time of crisis to retain the remainder 
of their maternity benefit eligibility when they 
return to the maternity leave to which they are 
properly entitled.
Community Pharmacy Covid-19 
Urgent Measures
Secretary General to Minister for Health,  
6 April 2020
I write further to my letter of 20 March seeking 
urgent support for community pharmacies to 
help sustain the network of pharmacies and 
the essential access and services they provide 
during the current crisis. Pharmacies are at the 
forefront of the response to Covid-19, with 
pharmacists and their teams heroically placing 
themselves in danger all day every day in order 
to continue providing medicines, services 
and care to their patients and the public in 
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extraordinarily difficult circumstances. They 
are doing this with no official recognition and 
no additional support from the State, despite 
the severe acute financial pressures that are 
impacting on the sector. 
We previously sought a grant to fund the 
installation of social distancing infrastructure 
in pharmacies to protect staff and customers/
patients from cross infection as well as HSE 
funding for a medicines delivery service to 
support Covid-19 positive and vulnerable 
patients self-isolating at home; an Urgent 
Medicines Supply Service for patients whose 
general practice is unavailable; and payments 
to community pharmacy contractors who 
are required to close due to Covid-19 related 
reasons. Since then, Regulations have been 
amended in a manner which places significant 
additional professional responsibility on 
pharmacists. Pharmacists will now, in already 
pressurised circumstances, be exercising their 
professional judgement to assess patient needs 
in order to extend and repeat prescriptions 
where appropriate, and will be held accountable 
by the Pharmaceutical Society of Ireland 
in relation to this. The knowledge and 
expertise necessary to take on this increased 
responsibility are within the professional scope 
of pharmacy training and practice; however, 
the expansion of professional responsibility 
and, consequently, professional liability 
exposure needs to be recognised by appropriate 
professional payment structures.
In contrast to the position here, the 
Department of Health in Northern Ireland 
recognises the extreme extraordinary cost 
pressures on community pharmacies and has 
already put in place measures to alleviate those 
pressures in order to sustain pharmacy services 
at a time of great risk. A grant package worth 
£10.5 million has been put in place for the 
approximately 500 pharmacies in Northern 
Ireland, with the initial tranche of £4 million 
paid last week: £1 million to cover staffing 
pressures, £2.5 million for Covid-19 related 
security and necessary alterations to premises, 
and £0.5 million for Business Continuity 
Planning. A further £35 million in advance 
payments has been paid, which will be managed 
out of the system after the Covid-19 situation 
has ended. This amounts to approximately 
£90,000 per pharmacy in grants and advance 
payments in Northern Ireland. 
Meanwhile, pharmacies in Ireland are 
under exactly the same cost pressures 
but, additionally, have suffered an ongoing 
precipitous drop in retail income (not a feature 
of the Northern Ireland system) due to the 
necessity to limit access to the premises to 
protect staff and patients from cross-infection 
with coronavirus. However, Irish pharmacies 
have not received one cent in compensatory 
funding. Unlike GPs, pharmacies do not have 
capitation payments to rely on and have not 
yet had the benefit of any reversal of previous 
fee cuts. However, significant additional 
funding has rightly been put in place for GPs 
to support them through this crisis. Equally, 
recognising the unique challenges faced by the 
private nursing home sector, a sizeable package 
has also been agreed to protect them at this 
time. It is worrying that, despite setting out 
the urgency of the situation facing pharmacies 
in our letter of March 20, we have had no 
material engagement with the Department on 
the issues raised. 
As previously outlined, the pharmacy 
profession recognises the gravity of the 
situation facing the country at present, and 
pharmacy teams are actively going above 
and beyond what could ever reasonably have 
been expected of them. Many are close to 
breaking point as a result of the overwhelming 
additional workload and responsibilities they 
have shouldered. We are committed to working 
together in the national interests but need 
compensation for the expedited measures that 
have been put in place to ensure continuity 
of care for Irish patients. The issues outlined 
in this letter are both urgent and critical and 
require immediate action if pharmacies are to 
be in a position to sustain our efforts. 
Community Pharmacy Covid-19 
Urgent Measures
Secretary General to Minister for Health,  
10 April 2020
I write further to my letters of 20 March and 
6 April seeking urgent support for community 
pharmacies, who remain at the forefront of 
the response to Covid-19, providing medicines, 
services and care to their patients and the 
public in extraordinarily difficult circumstances 
– unsupported, isolated and forgotten 
by Government. As a direct result of the 
Covid-19 public health emergency, substantial 
protective and emergency measures have 
been required and have been put in place by 
pharmacies, and the unprecedented surge in 
demand for medicines during March also gave 
rise to significant additional staff, security and 
other costs.
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The IPU has been getting an increasing 
number of calls from distressed pharmacists 
who report that they have hit credit limits on 
their wholesale accounts and, as a result, have 
been told they will not be receiving any further 
orders until the outstanding balance is paid 
down. This is putting them in an impossible 
position, as the HSE reimbursement for 
medicines supplied in March is not scheduled 
to come through for another two weeks; 
meanwhile, there has been a precipitous 
drop in retail income which has resulted from 
government restrictions on movement and 
the need to protect pharmacy teams from 
infection, but which income is essential to fund 
the pharmacy service.
The severe acute cost increases borne by 
pharmacy businesses in the last number of 
weeks have had to be funded from their own 
resources and have depleted cash balances 
such that they are reliant on future payments 
from the HSE to fund current purchases of 
medicines for patients. However, community 
pharmacists have to meet patients’ immediate 
healthcare needs as they arise. Today’s patients 
cannot be told to wait two weeks or more for 
their medicines; to do so would put the health 
of many in jeopardy. These pressures have 
been compounded by the fact that, unlike our 
counterparts in England, Scotland, Wales and 
Northern Ireland, Irish pharmacists have had 
zero support from government to help meet 
the extraordinary Covid-19 related costs that 
have arisen.
Fears for the wellbeing of their patients, the 
safety of their staff and the survival of their 
businesses, combined with the overwhelming 
additional workload and responsibilities they 
have shouldered, have led to a worrying 
increase in the number of pharmacists requiring 
the support of organisations such as the 
Samaritans. The apparent callous indifference 
of the Department of Health to the serious 
situation facing pharmacies and their staff, 
evidenced by an inexplicable failure to respond 
to repeated correspondence seeking support, 
stands in stark contrast to the immediate extra 
funding for our colleagues in General Practice 
and the significant emergency supports from 
governments in neighbouring jurisdictions for 
their pharmacy sectors.
The IPU and its members are committed to 
patient welfare and the national interest but 
cannot, on our own, ensure the sustainability 
of our services or continuity of care for Irish 
patients. Government must step up to the 
mark, stop ignoring the issues outlined in 
this and previous letters, and immediately 
put in place urgent and critical supports for 
pharmacies to sustain our efforts through this 
emergency situation.
Community Pharmacy Covid-19 
Response – Expansion of Vaccination 
Programme 
Secretary General to Minister for Health,  
20 April 2020
The Chief Medical Officer, Dr Tony Holohan 
(the CMO), has outlined the need to vaccinate 
early and in more significant numbers for the 
upcoming 2020/21 influenza season, as we 
will be dealing with more than one significant 
respiratory viral infection at this time, posing a 
significant challenge for our health system. In 
his Covid-19 briefing on 15 April, Dr Holohan 
said “one of the things we want to try to do is to 
greatly extend the flu vaccination programme 
and bring more people into the programme to 
receive flu vaccine than would normally receive 
it”. He also stated that he hopes to see a 
greater uptake amongst healthcare workers.
Community pharmacy is ideally placed to 
support a universal vaccination programme, 
with pharmacists currently permitted to 
administer influenza vaccines to any patient 
aged six months and older, albeit only within 
community pharmacy settings. For a universal 
vaccination programme to be successful, 
barriers to uptake must be identified and 
eliminated. For example, access to the vaccine 
must be made as simple as possible and it 
should be universally State funded.
We wrote to you in August last year with a 
proposal to extend the current vaccination 
programme by allowing pharmacists to 
administer vaccines to patients outside 
the pharmacy setting, such as in a nursing 
home, where a flu outbreak can have grave 
consequences. In light of the ongoing Covid-19 
pandemic and the need to extend the flu 
vaccination service in Ireland that was identified 
by the CMO, the locations where pharmacists 
can administer a vaccine should be expanded 
to include not just nursing homes but all 
workplaces.
Provision should also be made for pharmacists 
to participate in any pandemic vaccination 
programme. With over 1,850 community 
pharmacies serving all areas of the country, 
many with extended opening hours, this 
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valuable network could greatly enhance a 
national vaccination programme for Covid-19. 
In addition, reimbursement arrangements for 
pneumococcal vaccination in pharmacies, which 
were supposed to have been put in place last 
winter, must now be expedited.
The IPU and its members are committed to 
patient welfare and the national interest and 
see these proposed changes as necessary 
and aligned to the Sláintecare principles and 
public health priorities. Statistics produced by 
the HSE indicate that the accessibility of the 
existing
pharmacy flu vaccination service has led to 
improved uptake of vaccination by the public. 
Pharmacy flu vaccination deliveries now 
account for one in six flu vaccines nationwide. 
Moreover, since pharmacists first started 
vaccinating in 2011, flu vaccine deliveries 
through the National Immunisation Office 
(NIO) have increased overall by 59.5% and, 
within that, deliveries to GPs are up 27%, 
suggesting that pharmacists’ promotion 
of vaccination has helped increase public 
awareness and vaccination rates overall.
We look forward to working with your 
Department and the HSE to increase 
pharmacists’ capacity to improve the 
vaccination rates for the 2020/2021 influenza 
season and help reduce the incidence of serious 
respiratory illness this winter and are available 
to discuss any aspect of this letter.
HSE
Health Service and Pharmacy
Secretary General to Director General,  
HSE, 12 July 2019
On behalf of the President and Executive 
Committee of the Irish Pharmacy Union, I 
write to congratulate you (belatedly) on your 
appointment as Director General of the HSE 
and to wish you well in achieving reform of 
the health service. You take on the role at a 
challenging time, as the health service in Ireland 
is undergoing a period of profound challenge, 
faced with the twin pressures of increasing 
demand and limited resources. 
The community pharmacy profession plays 
a valuable role in primary care and has a 
significant part to play in the delivery of 
healthcare in a reformed health service. 
Pharmacists are the most accessible 
healthcare profession, due to their presence 
in every town, village and community, and 
are therefore in a perfect position to deliver 
a broader range of structured, high quality, 
cost-effective healthcare services. In other 
jurisdictions, pharmacists have been enabled 
to practise to full scope and the network of 
community pharmacies has been used to 
deliver a broad range of high quality, accessible 
and trusted healthcare services that meet 
the needs of patients and the public. These 
services include treatment of minor ailments, 
medicines optimisation and adherence services, 
contraception, vaccination, smoking cessation 
and chronic disease management, and have 
been shown to improve access to healthcare, 
enhance health outcomes and, ultimately, 
result in long term efficiencies. 
We look forward to working constructively 
with you in the development of a reformed 
system of primary healthcare which meets the 
objectives of the Government’s healthcare 
strategy and delivers for patients and the 
public. We would welcome an opportunity to 
meet with you to discuss in more detail how 
pharmacists can support the development and 
delivery of a sustainable, accessible and best-
in-class primary healthcare system in Ireland.
I look forward to your reply. 
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Health Service and  
Community Pharmacy
Secretary General to Chief Executive Officer, 
HSE, 7 October 2019
I am writing to thank you for meeting with us 
in September and for your willingness to listen 
to and discuss our proposals for the additional 
contribution that a properly resourced and 
empowered community pharmacy profession 
could make to healthcare in Ireland. We 
believe that our respective organisations have 
a shared interest in working together to meet 
the challenges that currently face the health 
service and to deliver a sustainable, accessible 
and best-in-class primary healthcare system in 
Ireland.
As we discussed, it is our belief that a new 
community pharmacy contract is now 
needed. The current contract has become 
outdated and no longer meets the needs of 
the pharmacy profession or the HSE, as has 
become increasingly evident in recent years. 
Additionally, the persistence of cuts imposed 
at a time of financial emergency continues to 
undermine the development and sustainability 
of pharmacy services, particularly in areas 
of greatest need such as rural, isolated and 
disadvantaged communities. 
It has been recognised for more than a decade 
that a new community pharmacy contract is 
required. In May this year, the Minister for 
Health Simon Harris made a clear commitment 
to start discussions on a new pharmacy 
contract, on moving beyond FEMPI and on 
a programme of investment. The IPU has 
consistently stated our desire to enter into 
contract talks at the earliest opportunity. As 
we outlined at the meeting, we are prepared to 
enter such talks without precondition and to 
engage on a broad agenda of modernisation and 
development of pharmacy services along with 
contractual reform and sustainable investment. 
We very much welcomed your agreement that 
a new contract is required and your willingness 
to engage with the IPU and the Department 
of Health on developing and agreeing such 
a contract. We look forward to an early 
engagement.
Pharmacists’ Access to NMIC
Secretary General to National Director, 
Quality Improvement, HSE, 3 January 2020
Recently, the National Medicines Information 
Centre (NMIC) announced a decision to 
restrict their clinical enquiry answering service 
to prescribers as of 1 January 2020. 
When this decision was announced in the 
Therapeutics Today bulletin published on 16 
December, we emailed NMIC to find out why 
the decision had been taken. They advised 
us that the decision to restrict the service 
to prescribers only had been made following 
a recent review of NMIC services and in 
consultation with the HSE.
This move has caused some disquiet among 
pharmacists. Many of our members have 
contacted us to express their concern that 
this service will no longer be available to 
pharmacists. They report that they regularly 
use this valuable service, for example to 
confirm paediatric doses, clarify off-label use 
of medicines and/or to identify alternatives 
to medicines in short supply – all of which 
supports the safe prescribing and use of 
medicines and protects patient safety.  
In July this year, we liaised with your 
department to promote the Know, Check, 
Ask Campaign to help improve the safe use 
of medicines. The campaign formed part of 
the World Health Organisation Medication 
without Harm initiative, which aims to reduce 
severe avoidable medication related harm by 
50% over the next five years. Indeed, you were 
quoted in the campaign press release saying 
that “everyone has a role to play in medication 
safety and so before you prescribe, dispense or 
take medicine you need to make sure you know 
about it”. It seems to us that for the HSE to 
remove pharmacists’ access to a valuable source 
of medicines information a few short months 
later is inconsistent with that position. 
I therefore ask that, in the interests of patient 
safety, you request the NMIC to reverse this 
decision as a matter of urgency. I look forward 
to hearing from you. 
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Community Pharmacist  
Covid-19 Testing 
Secretary General to Chief Executive Officer, 
HSE, 23 March 2020
Community pharmacists continue to provide an 
essential nationwide service to patients and the 
public in extraordinarily difficult circumstances. 
Pharmacies are displaying the HSE Covid-19 
posters and are advising significant and 
increasing numbers of patients on signs and 
symptoms of Covid-19, referring those who 
require testing to their GPs. They are also 
spending a great deal of effort resisting pressure 
from patients seeking additional supplies of 
medicines above their normal requirements, 
attempting to reassure them that contingency 
plans are in place to ensure continued supplies 
of medicines, although managing supply 
interruptions and stock-outs remains a 
challenge. Pharmacists are also managing repeat 
prescriptions, normally done by GPs, under a 
protocol circulated by HSE PCRS.
Fast-track testing for Covid-19 has been 
introduced for a range of healthcare workers, 
such as hospital healthcare professionals and 
GPs. Unfortunately, community pharmacists 
and their teams appear to have been 
overlooked, as they do not have access to 
Public Health or Occupational Health referrals. 
Community pharmacists who have developed 
symptoms of Covid-19 are reporting a wait 
of 4-5 days for a Covid-19 test and a further 
3-4 days for the results. This means that the 
pharmacist is unable to work for 8-9 days or 
more. Given that, currently, most test results 
are negative for Covid-19, and that community 
pharmacy services are already operating 
above capacity, community pharmacists’ 
testing needs to be fast-tracked to ensure the 
pharmacies can sustain their services. Some 
pharmacies have already had to close as a result 
of delays in testing and in getting their test 
results. If these delays are not reduced to the 
minimum and more pharmacies have to close 
pending testing, there is a risk of significant 
disruption to the service, potentially a complete 
breakdown in places.
Only this morning, on Morning Ireland, the 
Minister for Health said that said every effort 
will be made to protect healthcare workers and 
that priority testing for healthcare workers 
would be implemented. As a matter of urgency, 
can you please ensure that community 
pharmacy teams can access priority testing via 
GP referral.
PCRS
Inclusion of Rheumatology, 
Dermatology and Gastroenterology 
medicines in the High Tech Hub
Contract Manager to Head of Operations, 
PCRS, 27 May 2019
We note from your recent circular to 
pharmacists that the next phase of the 
deployment of the High Tech Hub is due to 
commence on 1st June and will encompass 
High Tech medicines used in rheumatology, 
dermatology and gastroenterology, thus 
affecting approximately 15,000 (± 1,000) 
patients.
We have raised concerns and issues with you 
previously regarding the operation of the Hub 
and we acknowledge the work that has been 
done to address many of the concerns and 
resolve specific issues. However, given the 
high patient numbers and medicine volumes 
associated with this phase of the roll out, IPU 
members remain very concerned that it will 
impact on their ability to procure and supply 
medicines for their patients in a timely fashion 
and that unavoidable treatment interruptions 
and delays will result. Many medicine suppliers 
have expressed similar concerns regarding 
the impact of the Hub on their ability to 
supply medicines expeditiously to pharmacies, 
particularly in urgent or out-of-hours situations.
Pharmacists’ experience to date suggests that 
clinicians are not universally familiar with or 
committed to the Hub and that, as a result, 
prescriptions have not been generated within 
the Hub, instead having to be entered by 
pharmacists or PCRS staff. This additional 
workload for pharmacists and their teams has 
so far been manageable, albeit unwelcome, 
but the significantly larger number of patients 
and clinicians implicated by the next phase of 
the Hub roll-out will make it unsustainable to 
continue in this fashion.
The HSE PCRS will need to put significant 
planning and resources in place to ensure 
that the Hub operates effectively without 
negatively impacting on patients. High 
Tech Hub staff will need to be facilitated 
to support pharmacies, consultants and 
suppliers while also ensuring that orders are 
being processed smoothly and efficiently. 
Workarounds will have to be put in place to 
provide for circumstances where patients 
have an immediate need for a medicine 
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but the requirements of the Hub have, for 
whatever reason, not been met by the clinical 
team. It is these exceptional cases that have 
been seen to cause the most hardship for 
pharmacists and worry for patients. As the 
prescriptions are now restricted to consultant 
signed prescriptions, rather than GP, (with 
the exception of Urology) and as prescriptions 
are only legally valid for a maximum of six 
months, this will necessitate patients having 
six-monthly reviews, regardless of clinical 
need or clinician availability. Our members 
are concerned that this will prove to be 
unsustainable and that as a result patient 
access to medicines may be negatively 
impacted.
Other questions have also been asked. Has 
there been engagement with patient and 
clinical advocacy groups such as Arthritis 
Ireland, Ankylosing Spondylitis Association 
of Ireland, lrish Skin Foundation and the lrish 
Society for Colitis & Crohns Disease, advising 
them that there is a new system in place for 
managing the High Tech scheme and ordering 
medicines, and explaining the impact on their 
clinician and patient members? Given that the 
Hub has, at best, no impact on delivery times 
but more frequently has contributed to longer 
waiting times, have the patient groups been 
advised that they may have to wait before their 
medicine is received by a pharmacy? Have 
absolute assurances been received from all 
clinics and specialists that the capacity exists 
to review all patients every six months and to 
generate new prescriptions within the Hub; 
have they acknowledged that, if this is not 
done, medicines cannot be procured for or 
supplied to their patients?
We can discuss these issues further when we 
meet at the JCG next Wednesday 29th May. 
In the meantime, can you please provide us 
with the updated High Tech Hub User Guide 
and FAQ documents for our review and input, 
and for subsequent circulation to our members.
Community Pharmacy Contractor 
Agreement – Changes to Claiming 
Arrangements
Secretary General to Assistant National 
Director, HSE, 19 July 2019
I am writing in response to your recent circular 
to community pharmacy contractors, Circular 
025/19. 
In a letter to pharmacy contractors on 25 
May 2016, the PCRS acknowledged that ‘the 
majority of pharmacy claims are reasonable, 
valid and in compliance with contractual 
agreements in place’. It was also acknowledged 
in the same letter that ‘circumstances may 
arise in practice where the full quantity of a 
prescription item is not filled and supplied and, 
as a result, the pharmacy will owe their patient 
a balancing quantity.’ 
In the latest circular, you assert that ‘despite 
direct correspondence with contractors and 
discussions since 2016 with the IPU, the 
HSE PCRS does not have visibility of claims 
submitted where products have not actually 
been supplied’. This is disingenuous given that, 
as you are fully aware, the IPU has engaged 
with the HSE PCRS and jointly developed a 
specification known as the PCRS-Pharmacy 
Interface Project (PPIP) which, among other 
benefits, would provide the transparency that 
the HSE PCRS requires on this issue. 
The IPU has delivered on a number of 
initiatives which have brought benefit to the 
State while the effort and costs have been 
borne by pharmacists. Community pharmacists 
have cooperated fully with the introduction 
of new validation arrangements for the 
dispensing of phased medicines, which ensure 
greater probity and financial transparency 
to account for State spending. Pharmacists 
also agreed to take on the task of ensuring all 
GMS prescriptions are signed for at the point 
of collection, a massive and time-consuming 
addition to their administrative workload. The 
IPU’s collaboration on projects such as the 
introduction of the High Tech Hub and the 
implementation in community pharmacies of 
medicines authentication under the Falsified 
Medicines Directive (FMD), both of which 
have been delivered, also clearly demonstrates 
our continued bona fides. 
Furthermore, the IPU has committed to both 
the HSE and the Department of Health that 
we would implement the Interface Project as 
soon as the Department honoured its earlier 
commitment, first made in January 2016, to 
release an additional €2.5m in remuneration 
to pharmacy contractors. The IPU has 
repeatedly sought immediate release of the 
payment (to which we are entitled) to support 
the roll-out of medicines authentication and 
the implementation of the PPIP. It is worth 
noting that an economic assessment by Ernest 
& Young (EY), a copy of which has already 
been submitted to the Department of Health 
and copied to the HSE PCRS, illustrates that 
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the true cost impact on the pharmacy sector 
associated with medicines authentication is a 
multiple of the €2.5m currently sought. 
The IPU made this commitment to deliver 
the PPIP at the beginning of the year and we 
have reiterated it on a number of occasions 
since, to both the HSE and the Department of 
Health. It was possible to have implemented it 
several months ago, were it not for the delay in 
releasing the already committed funds. Indeed, 
we believed it would be in place long before 
now. Furthermore, in response to apparent 
concerns regarding potential complications 
surrounding making such payments, the 
IPU provided a memo of advice from Eileen 
Barrington SC confirming that there is no legal 
or legislative impediment to such a payment 
being made under the contract. The reality is 
that the ongoing delay in the implementation 
of the PPIP is solely down to foot-dragging on 
the part of the Department of Health, not any 
action or inaction on the part of the IPU. 
It has always been the IPU’s consistent position 
that we do not and have never supported or 
condoned wrongful or dishonest behaviour. 
Where proven, such instances must be dealt 
with appropriately. As is acknowledged in 
previous circulars, there is no issue with the 
overwhelming majority of pharmacy claims. If 
there have been invalid claims, the HSE can 
and should utilise the procedures provided for 
in the Contract. 
For the avoidance of doubt: 
i. Claims for medicines/products supplied 
must be reimbursed in accordance with 
the Contract. 
ii. Clause 1(4)(i) of the Contract, which 
states that ‘a medicine dispensed and 
awaiting collection in the pharmacy shall 
be deemed to have been supplied’, stands. 
iii. There are no changes to the 
arrangements for the non-dispensing fee, 
which will continue to be claimable and 
payable as set out in the contract. 
The circular which you have issued should be 
withdrawn. It clearly contravenes the terms of 
the Contract, which has been in place for 23 
years. The HSE is not entitled to change the 
contractual arrangements in place in respect 
of the schemes except with the agreement of 
the Minister / Department and the IPU. In this 
case, there has been no such agreement with 
the IPU. As such, the HSE is acting ultra vires 
in seeking to implement this new circular. Non-
payment of pharmacy contractors in respect 
of legitimate owings is not a matter which 
can be determined by the HSE unilaterally 
and imposed by circular. Owings have formed 
part of payments to pharmacists under the 
Contract since its inception. Pharmacists 
who continue to comply with their contract 
as written are entitled to be reimbursed on 
that basis unless and until such time as revised 
arrangements have been agreed and put in 
place. In the meantime, Department of Health 
should release the funding required to advance 
the PPIP and thereby resolve this issue once 
and for all. 
I await your response.
Owings
Assistant National Director, Primary Care 
Eligibility & Reimbursement, HSE to  
Secretary General, 24 July 2019
I refer to your letter of the 19th July 2019 
in relation to HSE PCRS Circular number 
025/19. I refer also to previous correspondence 
in relation to the matter of ‘owings’.
I note and acknowledge the various areas where 
the IPU has worked with the HSE.
In your letter you quote from the Circular 
025119 ‘despite direct correspondence with 
contractors and discussions since 2016 with 
the IPU, the HSE PCRS does not have 
visibility of claims submitted where products 
have not actually been supplied’. You suggest 
this is disingenuous on the basis that the IPU 
did engage in the pharmacy interface project. 
However, it was the IPU who unilaterally 
withdrew from the project after the first 
pharmacy had successfully submitted an 
‘owings’ file via the project.
The pharmacy interface project was agreed 
in 2016 following consultation between the 
HSE and the IPU, and the principles and 
provisions were set out in a Memorandum of 
Understanding agreed between both parties. 
The parties worked together in a project group 
governance structure. The interface was 
deployed to the first site just before the IPU 
withdrew its support. The pharmacy interface 
project could deliver benefits for pharmacy 
contractors and the HSE which have been well 
described. The interface would also deliver full 
visibility for the HSE and pharmacists in relation 
to owing’s which the HSE do not currently have.
93
2020 ANNUAL REPORT OF IPU EXECUTIVE COMMITTEE
APPENDIX II
Continued
Our routine inspections have not given 
reassurance to the HSE that repeated owings 
have ceased and therefore the issue remains 
a probity concern. In fact, it is our experience 
that ‘owings’ visibility has become even more 
difficult to achieve on site in pharmacies 
due to changes in software implemented by 
contractors. However, available evidence 
gathered through inspections and investigations 
will be considered in the context of the 
provisions of the Contract.
Owings had been included in the Pharmacy 
Contract since 1996 when the clear 
understanding and spirit of the arrangements 
were ‘that circumstances may arise in practice 
where the full quantity of a prescription item 
is not filled and supplied and, as a result, the 
pharmacy will owe their patient a balancing 
quantity. At that time claims were presented 
manually for reimbursement and issues did not 
arise such that are now presented electronically 
to PCRS where full month’s requirements 
are placed in owings files and submitted 
automatically via the current software for 
reimbursement. While it might be understood 
that prescription charges have created 
momentum on the rise of ‘owings’ as patients 
choose whether they wish to access further 
supplies (exactly as the legislation intended), 
it is not acceptable to opaquely raise a cost to 
the State in a manner that was never envisaged 
nor intended in 1996, A number of inspections 
and investigations have demonstrated repeated 
owings claims for the same patient which were 
submitted for reimbursement of a product(s) 
which has been entered in the pharmacy 
system and it was neither supplied nor intended 
for supply to the patient. It is our firm opinion 
that inserting quantities owed on a repeated 
basis for the same patient extinguishes any 
rationale for ‘genuine expectation’ of supply.
It is important to state that the interface 
project would not only give assurance to the 
HSE in relation to owings, but it would also 
give a protection to the pharmacy profession in 
relation to the submission of valid claims.
I have discussed and communicated with 
you on many occasions in relation to the 
responsibilities of the HSE in terms of the 
public funding it receives which include:
1. The HSE is accountable to the Minister 
for Health for the expenditure of all 
public monies it receives.
2. The HSE is accountable to the 
Oireachtas through the Public Accounts 
Committee, which body consider the 
reports of the Comptroller and Auditor 
General on the expenditure and activity 
of the HSE.
3. The HSE is also accountable to the Joint 
Oireachtas Committee on Health in 
respect of matters relating to the health 
service.
4. The financial management of the monies 
(and other resources) available the HSE 
is fundamental to the exercise of its 
functions.
5. Pursuant to Section 7(1) of the 2004 
Act, the objective of the HSE is to ‘use 
the resources available to it in the most 
beneficial, effective and efficient manner 
to improve, promote and protect the 
health and welfare of the public’.
It is incumbent therefore, on the HSE to meet 
its responsibilities and to engage Pharmacy 
Contractors to support us in this regard.
The actions of the IPU since February 2018 
and your recent correspondence and direction 
to pharmacists not to engage are obstructing 
and preventing the HSE need to resolve the 
matter of owings.
Owings
Interim Assistant National Director, Primary 
Care Eligibility & Reimbursement, HSE to 
Secretary General, 25 November 2019
I refer to our previous correspondence in 
relation to the matter of ‘owings’.
You will be aware that in 2016, the HSE PCRS 
and the IPU entered into a Pharmacy Interface 
Project underpinned by a Memorandum 
of Understanding which, when delivered, 
would provide benefits to all stakeholders. 
While the Project is designed to deliver a 
number of benefits for pharmacy contractors 
including electronic claiming for all schemes 
and enhanced reporting on payments, one 
key priority for the HSE PCRS was to bring 
transparency of items filed under owings 
through an enhancement of the pharmacy 
software interface.
I reiterate that the interface project would 
not only give assurance to the HSE in relation 
to owings but it would also give a protection 
to the pharmacy profession in relation to the 
submission of valid claims. 
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In circumstances where the interface has not 
progressed, I am notifying you that from a 
date to be specified and no later than 1 July 
2020, the HSE will not grant a new contractor 
agreement to a pharmacy that does not have 
the enhanced assurance for the HSE provided 
by the transparency of ‘owings’ functionality 
developed during the interface engagement.
The HSE will be informing pharmacy system 
vendors accordingly to give them sufficient 
time to develop their software systems and 
have them available for contractors next year. 
The HSE will be clear that the vendors will 
require to have the functionality in place if they 
wish to supply software to new contract holders 
after the specified date.
Community Pharmacy Contractor 
Agreement – Changes to Claiming 
Arrangements 
Secretary General to Assistant National 
Director, HSE, PCRS, 19 June 2020
Further to our recent JCG meeting, it has 
come to our attention that a system vendor has 
recently issued a communication to community 
pharmacy contractors declaring that they 
are now “HSE-certified for Transparency of 
Claims”. We understand that it is now the 
position of the HSE that it will not enter into 
a new Community Pharmacy Contractors 
Agreement unless the applicant pharmacy 
confirms to the PCRS that their computer 
software complies with “HSE standards of 
transparency of claims”. This, we understand, 
relates to “owings”, the correct management of 
which is set out in the Contract. Furthermore, 
it now appears that the changed arrangements 
sought by the HSE differ from those previously 
agreed in the yet to be implemented PCRS-
Pharmacy Interface Project.
As outlined in our previous correspondence to 
the HSE PCRS in July 2019 (copy attached),  
the HSE is not entitled to change the 
contractual arrangements in place in respect of 
the schemes except with the agreement of the 
Minister/Department of Health and the IPU. 
In this case there has been no such agreement 
with the IPU. 
The Secretary General of the Department of 
Health, Mr Jim Breslin, recently confirmed 
to the IPU the Department’s intention to 
progress work in a substantive way over the 
coming months on a new community pharmacy 
contract to promote greater use of the 
capacity and scope of practice of pharmacists. 
Furthermore, the draft Programme for 
Government also contains a commitment to 
commence talks on a new pharmacy contract 
and enhancement of pharmacists’ role. 
Proposed changes in contractual arrangements 
are appropriately dealt with in the context of 
the forthcoming negotiations. The constructive 
and collaborative approach of the IPU has been 
acknowledged by Department of Health, which 
has expressed hope that this approach can be 
maintained into the future. For the HSE to 
adopt a unilateral approach is not conducive 
to maintaining constructive and collaborative 
relationships. 
We look forward to engaging with the 
Department and the HSE on the terms of a 
new contract; any proposals for change which 
the HSE wishes to make can be addressed in 
that context. 
Oireachtas Committees
Report of the Working Group on 
Access to Contraception 
Clerk to the Committee, Joint Committee  
on Health, 11 November 2019
  
I am writing to you in relation to the recent 
publication of the Report of the Working 
Group on Access to Contraception. The 
Working Group held a public consultation 
in July, to which the Irish Pharmacy Union 
(IPU) made a submission. We also met with 
the Group in August to further discuss the 
details of our proposal that the Department 
of Health and HSE put in place a scheme to 
enable women to access contraception directly 
from their community pharmacist without 
prescription and, subject to policy decisions on 
funding, without charge.
The IPU proposal is that:  
• Pharmacists will only be able to supply 
contraceptives after undertaking 
additional training and according to 
strict criteria. Clear criteria and formal 
assessment that are used internationally 
when certain contraceptives are 
supplied will be applied in the controlled 
pharmacist-only model of supply;
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• Supply of contraceptives will include 
oral contraceptives, patches, rings and 
injections;
• It would not be a requirement for 
the woman to have previously been 
prescribed a contraceptive; 
• Supply of contraceptives by the 
pharmacist would initially be restricted to 
women aged 17 years and older;
• A woman will need to have a formal 
consultation and BP/BMI check with the 
pharmacist every 6 months. Following the 
consultation, the pharmacist can supply 
up to 3 months’ contraceptive, followed 
by a further 3 months’ contraceptive in 
the same pharmacy before a follow-up 
consultation is required;    
• A record of the supply of the 
contraceptive will be kept on the patient’s 
medication record (PMR).
We welcome that the Report from the Working 
Group details our proposal and highlights that 
there is precedent internationally for such an 
approach, with a 2015 review of contraceptive 
services across 147 countries finding that oral 
contraceptives were legally available in 35 
countries over the counter; informally available 
in 56 countries; and available on a “behind the 
counter” basis following eligibility screening by 
trained pharmacy staff in a further 11 countries. 
The Report also acknowledges that The Lancet 
has twice recommended non-prescription 
availability for oral contraception, while 
pharmacist prescribing and supply of oral 
contraceptives is permitted in California and 
other US states. Furthermore, the Report 
confirms that the World Health Organisation 
(WHO) has recently recommended that over 
the counter oral contraceptives should be made 
available without a prescription. 
It is therefore incongruous that the Report 
would conclude, in relation to the IPU proposal, 
that the provision of contraception through 
pharmacy raises questions about patient 
safety with a supposed risk that pharmacists 
will prescribe without sufficient knowledge 
of the woman’s medical and family history. 
No evidence is provided for this assertion 
and it has certainly not been an issue in the 
aforementioned countries where pharmacists 
have been supplying oral contraceptives for 
years without any patient safety concerns 
arising; indeed, evidence to the contrary has 
been found, as outlined below. The Report 
acknowledges that contraindications and side-
effects of oral contraceptives may be rare, but 
they do occur. It is the role of the pharmacist 
to identify and address such contraindications 
and side-effects; therefore, it makes no sense 
for this to be used as a reason not to permit 
pharmacist supply. 
The Report states that, by reducing the level of 
interaction with a health professional, women 
may lose the wider health benefits that can 
be associated with more regular visits to their 
GP. Again, no evidence is provided for this 
statement. Pharmacists are health professionals 
and have the knowledge, skills and competence 
to provide a wide range of health advice to 
patients and know when to refer to the GP 
where appropriate. 
The Report acknowledges that medical 
supervision of access to contraception can 
be associated with increased costs, reduced 
accessibility and restricted development of 
informed self-care. The IPU agrees with this 
statement. The Report goes on to say that 
medical management of patients allows for 
education, counselling and helps to ensure that 
the patient correctly avails of the contraceptive 
method most suitable to them. Pharmacists are 
more than capable of carrying out this role, as 
they already do with emergency contraception. 
The Report states that the Working Group is 
not opposed, in principle, to the concept of 
pharmacist prescribing of contraception but 
suggests that a more detailed examination of 
the issue is required. How much more detail 
does the Group require? We have evidence 
from over 100 countries and recommendations 
from The Lancet and the WHO.  Two studies 
carried out by Oregon Health & Science 
University and published in the journal 
Obstetrics and Gynecology in May 2019 show 
that the safety profile seen with pharmacists is 
equal to that seen among clinicians prescribing 
contraception. The studies also found that, 
in the first two years after the policy change, 
pharmacist prescribing of contraception 
averted more than 50 unintended pregnancies 
and saved the state of Oregon, with a 
population of 4.2 million people, an estimated 
$1.6 million (€1.42m) in public costs. There is 
no reason the same benefits could not be seen 
in Ireland. 
It is worth noting that not all barriers 
to contraception are financial, and free 
contraception alone may not necessarily lead 
to increased use. Financial and non-financial 
barriers to access are often connected; a 
woman who can’t afford to take time off work 
96
2020 ANNUAL REPORT OF IPU EXECUTIVE COMMITTEE
can’t access a free consultation with a GP, but 
she can often see a pharmacist in her free time. 
The WHO reports that, in Scotland and Spain, 
making emergency contraception available 
without prescription was more effective 
at meeting unmet demand than making it 
available free of charge with a prescription. 
That is why, if the Government is sincere about 
improving access for all, the prescription-free 
element of the proposal is at least as important 
as the free-of-charge component.
In summary, the IPU is surprised that the 
Working Group inexplicably chose to ignore 
the weight of evidence in favour of pharmacist 
prescribing of oral contraceptives and instead 
suggested alternative approaches to expanding 
access to contraception that will, in our opinion, 
have limited success.
We ask that you circulate this letter to the 
members of the Joint Committee on Health 
and request that they challenge the Group on 
their conclusions and recommendations in the 
Report when they next meet.        
We would welcome the opportunity to meet 
with the Joint Committee to discuss or clarify 
any of the issues raised in this letter and our 




New Pharmacy Contract /  
Unwinding FEMPI 
Secretary General to Minister for Finance  
and Public Expenditure & Reform,  
12 November 2019 
In a meeting with the IPU in March this year, 
the Minister for Health, Simon Harris, clearly 
acknowledged the cuts to pharmacists’ incomes 
that had been introduced to address the financial 
crisis and the resulting financial pain felt by 
pharmacists, and expressed the Government’s 
intention to unwind FEMPI cuts to pharmacists’ 
fees, to “move beyond FEMPI to a higher 
terrain”, committing to starting negotiations on 
a new pharmacy contract this autumn. 
Subsequently, in his keynote address to the IPU 
National Pharmacy Conference in May, the 
Minister again acknowledged the cuts and the 
effects on the pharmacy sector and reiterated 
the intention to move beyond FEMPI to a 
higher terrain. He repeated the previous clear 
commitment to start discussions on a new 
pharmacy contract, on moving beyond FEMPI 
and on a programme of investment, saying “let’s 
get that done this year”. 
Pharmacists took the Government at its word 
and, based on clear commitments, have a 
legitimate expectation around moving beyond 
FEMPI through a significant and immediate 
increase in investment in pharmacy services, 
which we are confident will deliver tangible 
benefits for Irish patients and the public, as 
well as for the health system itself. Following 
the announcement of increases in payments to 
general practitioners, community pharmacists 
are now the only major contractor group 
to have had no fee restoration and, despite 
Government commitments, continue to bear 
a burden of austerity that has been lifted from 
other sectors. 
We are now urgently seeking that the 
Government commence the repeatedly-
promised negotiations on a new pharmacy 
contract and investment in pharmacy services, 
with an agreed deadline of 30 June 2020 for 
the conclusion of talks, and that no changes to 
pharmacy payments be implemented until the 
conclusion of those talks.
Commitment to Unwind FEMPI and 
Proposed Cuts to Pharmacy Fees
Secretary General to Taoiseach,  
21 November 2019 
I am writing to you on a matter of grave 
concern to the IPU and to all community 
pharmacists. Compared with public servants 
and other contracted professions, our members 
have been treated unfairly, inequitably and in 
bad faith regarding the unwinding of FEMPI 
cuts and reform of our contract and the 
situation is now unsustainable. 
In 2016, when you were Minister for Health, 
you committed to commencing the unwinding 
of FEMPI for pharmacists but no unwinding 
ever occurred. In that year, the Government 
committed to the IPU to increase pharmacy 
remuneration by €2.5 million per annum, 
describing it as a statement of intent. Despite 
being a tiny sum, it was never paid. 
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In a meeting with the IPU in March this year, 
the Minister for Health Simon Harris TD, 
clearly acknowledged the financial pain felt by 
pharmacists as a result of cuts to pharmacists’ 
incomes which had been introduced to address 
the financial crisis. Minister Harris expressed 
the Government’s intention to unwind FEMPI 
cuts to pharmacists’ fees, and to “move 
beyond FEMPI to a higher terrain”. He clearly 
committed to starting negotiations on a new 
pharmacy contract this autumn. 
Subsequently, in his keynote address to the 
IPU National Pharmacy Conference in May, 
the Minister reiterated this commitment 
to the IPU’s 2,300 members. He again 
acknowledged the cuts and the effects on the 
pharmacy sector and repeated his intention 
to move beyond FEMPI to a higher terrain. 
He restated the previous clear commitment 
to start discussions on a new pharmacy 
contract and on moving beyond FEMPI to a 
programme of investment, saying “let’s get 
that done this year”. 
We were therefore surprised and alarmed to 
be informed recently by the Department of 
Health that, instead of the long-promised 
increased investment in pharmacy services, 
the opposite is planned with significant cuts 
proposed to be introduced from 1 January. 
The proposed cuts, which in many cases equate 
to a crippling 9% cut in fees, would have a 
negative long-term impact on community 
pharmacies throughout the country. 
However, they would disproportionately 
damage pharmacies serving rural, isolated 
and disadvantaged areas and will have dire 
consequences for pharmacy services in these 
local communities. These pharmacies operate 
on the thinnest margins and cannot survive any 
further reduction in their incomes. 
These proposed cuts are nothing less than a 
betrayal of clear public commitments your 
Government has made to the pharmacy 
profession. Pharmacists took the Government 
at its word and, based on those commitments, 
have a legitimate expectation around moving 
beyond FEMPI through a significant and 
immediate increase in 
investment in pharmacy services, which we are 
confident will deliver tangible benefits for Irish 
patients and the public, as well as for the health 
system itself. 
I am now requesting an urgent meeting 
to discuss the issue and insist that the 
Government row back on these unfair and 
unjustifiable cuts and instead immediately start 
the repeatedly promised negotiations on a new 
pharmacy contract and investment in improved 
pharmacy services – which will deliver benefit 
to Irish patients, the public and the health 
system overall.
Health Care Professionals returning  
to Front Line 
Secretary General to Minister for Employment 
Affairs and Social Protection, 25 March 2020
The Government has put out a call for health 
care professionals who are not currently 
working on the front line in Ireland to return 
to work in front line roles as part of the 
national effort to fight the Covid-19 pandemic 
in Ireland. That call has been answered by 
thousands of qualified professionals who 
wish to return to work to support the health 
system during this crisis. Pharmacists are no 
exception; many of them have contacted the 
Irish Pharmacy Union volunteering to return to 
front line community pharmacy.
One anomaly has arisen, however, that 
requires an immediate resolution. It affects all 
professionals, not just pharmacists. A health 
care worker who is currently on maternity leave 
and in receipt of State maternity benefit will, 
if she returns to work temporarily even for a 
short period before returning to maternity 
leave, immediately lose the entitlement to the 
maternity benefit for the remainder of her 
maternity leave. This permanent loss of benefit 
is inhibiting eligible qualified women from a 
temporary return to the front line in a time of 
crisis.
We urge you as a matter of urgency to amend 
the existing rules for the duration of the 
current emergency, so as to allow women who 
break their maternity leave to assist in a time of 
crisis to retain the remainder of their maternity 
benefit eligibility when they return to the 
maternity leave to which they are properly 
entitled.
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National Centre for 
Pharmoeconomics
MMP Best-value Biologicals Policy 
Director, National Centre for Pharmoeconomics, 
7 January 2020 
We are writing to you in relation to proposals by 
the HSE PCRS to introduce a reimbursement 
application system early this year to ensure 
uptake of the MMP Best-value Biological 
(BVB) medicines, on foot of recommendations 
by the Medicines Management Programme 
(MMP). Under such the proposed system, 
patients who are prescribed BVB medicines will 
automatically be approved for reimbursement 
and no application for reimbursement approval 
will be required. However, an application 
for reimbursement approval will be required 
for patients who are prescribed a non-BVB 
medicine, including the biological reference 
medicine. 
The IPU and its members is concerned that 
this policy may have unintended consequences. 
There is an inherent danger in recommending 
one specific biosimilar to the exclusion of all 
others, as it will likely result in it becoming 
financially unviable for the other biosimilars 
and even the biological reference medicine to 
remain on the Irish market if their market share 
is to be shrunk to near zero. Consequently, if 
any shortage of the BVB biosimilar were to 
occur, patients may be left with no alternative 
medicine. 
Using Humira as an example, there are 
currently three biosimilars on the Irish 
market in addition to the biological reference 
medicine: Amgevita, Hulio and Imraldi. The 
MMP recommends that prescribers prescribe 
Imraldi. If this recommendation is enforced 
across the entire relevant patient population, 
it is highly likely that this will result in Humira, 
Amgevita and Hulio disappearing from the Irish 
market, leaving us in the vulnerable position of 
having only one form of adalimumab to rely on, 
Imraldi. 
It would make more sense for pharmacists to 
be given the right to switch patients from a 
biological reference medicine to a biosimilar. 
Prescribers could be made aware of this 
switch through the High Tech Hub, which 
would reflect to prescribing clinicians and to 
pharmacists which biosimilar has been ordered 
and dispensed to the patient. 
The Health (Pricing and Supply of Medical 
Goods) Act 2013 sets out the rules for generic 
substitution of medicinal products identified 
as interchangeable by the HPRA. Pharmacists 
have demonstrated that they have the 
competence and capability to implement this 
legislation, resulting in a significant increase 
in the usage of generic medicines in Ireland, 
from 17% to over 40%, generating total savings 
for the State of over €1.145 billion since the 
introduction of reference pricing in 2013. 
An amendment to primary legislation would 
be required to facilitate substitution by a 
pharmacist from a biological reference product 
to a biosimilar. The IPU has long advocated for 
this to happen, as it would be the most effective 
and easily implemented option to achieve 
increased uptake of biosimilars in Ireland. Such 
an amendment would permit a pharmacist, on 
receiving the initial High Tech prescription for 
a patient, to dispense and supply a biosimilar or 
the biological reference medicine. The HPRA 
could provide relevant information, mapping 
biological reference medicines to biosimilars, 
thus providing community pharmacists with a 
guide on which of a range of biosimilars could 
be dispensed. 
Applied Strategic, a UK consultancy firm with 
expertise in biosimilar markets, previously 
identified a potential saving of €370 million 
over an initial three years with optimum 
biosimilar entry and preparation. 
Pharmacists are concerned that current 
policies including the proposed implementation 
of the current BVB policy will result in many 
suppliers choosing not to place their biosimilars 
on the Irish market in future and believe that 
the most effective and efficient way to increase 
biosimilar usage is to allow pharmacists to 
substitute. 
We would welcome the opportunity to meet 
with the MMP to discuss the above.
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Compassionate Access Programmes – 
Impact on Pharmacists
Secretary General to CEO of the Irish 
Pharmaceutical Healthcare Association - 11 
April 2019
As a result (most probably) of the ongoing 
and well-ventilated delays in granting 
reimbursement status for new medicines, an 
increasing number of compassionate access 
programmes have been put in place by IPHA 
member companies under which they provide 
medicines which are not yet eligible for 
reimbursement on a non-cost basis to specified 
patients. I am writing to you in relation to the 
impact of these arrangements on community 
pharmacists – an impact that has, for some 
time, been causing disquiet among our 
members.   
Typically, it is reported to us that patients who 
are prescribed such medicines are advised by 
their consultant to go to their chosen pharmacy 
where they can collect the medicine “free 
of charge”, although the pharma companies 
generally will not have consulted with 
pharmacists, the benefit of whose premises and 
professional services they seem to expect to 
secure free gratis. Pharmacists are healthcare 
professionals whose primary concern is the 
health and wellbeing of their patients. However, 
their time has a value and their professional 
services come at a cost. As such, pharmacists 
regard it as presumptuous of anyone to assume 
that they would be prepared to provide their 
services free of charge in order to facilitate 
arrangements which pharma companies 
wish to enter into in advance of securing 
reimbursement from the HSE. Given the heavy 
workload that exists in community pharmacies 
and the significant professional and regulatory 
obligations on pharmacists, this kind of free 
service is simply not sustainable. 
It is open to pharma companies to directly 
compensate pharmacists for providing such a 
dispensing service on their behalf; alternatively, 
in the interests of providing accurate 
information to prescribers and patients, 
they need to make it clear in their written 
information that, although the medicine is 
being provided at no cost to the HSE or the 
patient, a dispensing charge may apply at the 
pharmacy. Obviously it is a matter for each 
pharmacist to decide whether or not to charge 
for their services and, if so, to set the amount 
themselves but it is to nobody’s benefit for 
patients to be informed that something will be 
“free of charge” when that is not necessarily 
going to be the case.
If you believe it would be helpful, I would be 
happy to discuss this issue with you further.
PRODUCT RECALL Emerade 
150/300/500 micrograms solution  
for injection in pre-filled pens 
Secretary General to Bausch Health,  
8 October 2019 
The Irish Pharmacy Union is the representative 
and leadership body for community 
pharmacists in Ireland, with a membership 
comprising approximately 2,200 pharmacists 
and almost 1,800 pharmacies. Our members 
received and have implemented the recent 
patient-level product recall of all in-date 
batches of Emerade which was required due 
to a serious defect in the product. This recall 
has created significant administrative and cost 
implications for pharmacies. Pharmacists are 
healthcare professionals whose primary concern 
is the health and wellbeing of their patients. 
However, their time has a value and their 
professional services come at a cost. Although 
it is a matter for each pharmacist to decide 
whether or not to charge for their services and, 
if so, to set the amount themselves, it would be 
unrealistic of you to assume that pharmacists 
should provide their professional services free 
of charge to rectify an issue caused solely by a 
defect in your product. 
This recall required pharmacists to: 
• Immediately quarantine all units in their 
possession and complete a fax back form 
for credit; 
• Check dispensing records to identify all 
patients to whom Emerade products had 
been dispensed since 1 April 2018; 
• Contact patients or their carers to 
ascertain if they have any unused units 
of Emerade and arrange for them to 
return the units to the pharmacy for 
replacement with an alternative; 
• Contact any GP clinic, paramedic, other 
pharmacy or any other party to whom 
they may have supplied these products, 
to arrange for their return to the 
pharmacy for quarantine and uplift; 
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• As a priority, source the requisite number 
of pens of an alternative product(s) 
from the wholesaler to replace all pens 
returned by patients; 
• Dispense and supply two equivalent 
replacement pens of the same type to 
each patient;
• Instruct patients on the use of their new 
pen using the package insert, the relevant 
company’s website and/or simulator 
devices; 
• Quarantine packs returned by a patients 
and contact the wholesaler to arrange for 
uplift. 
As acknowledged in your recall notice, no 
replacement Emerade products are available to 
order at this time. This means that our members 
need to replace each Emerade 500mcg pen 
with 2x300mcg pens, which carry higher trade 
prices. Given that patients have a minimum 
of two pens to replace (if not more), there is a 
minimum €48.16 trade price differential per 
patient, before accounting for any additional 
dispensing fee or the cost of administration 
involved in complying with the recall notice. 
The advice given to patients by the Health 
Products Regulatory Authority was “If you are 
in the possession of any Emerade pen, please 
return it to your pharmacy where you will 
receive a replacement alternative product”. 
There was no suggestion that a charge would 
be applied to replace these pens and, as such, 
our members have not been able to recover the 
trade price differential or their usual dispensing 
fee when implementing the replacement of one 
Emerade 500mcg with two pens of 300mcg 
of another, more costly, brand. 
We contacted your colleague Sobhey Nassar 
on 3 October regarding this issue, as our 
members were understandably concerned 
about the cost of complying with this recall 
notice. He informed us that pharmacists would 
be reimbursed for the returned pen only. That 
position is unacceptable to us, as your recall 
letter clearly states to our members that they 
should “ensure that the requisite number of 
pens of an alternative product(s) is ordered 
from your wholesaler, to replace all pens 
returned by your patients.” 
As acknowledged in your letter, our members 
were required to provide additional advice 
and instructions of use for any replacement 
product and they also needed to reassure 
patients. We therefore insist that not only 
must you reimburse our members the price 
of the recalled product, but you should also 
reimburse them for the price differential of the 
replacement products plus their professional 
fee and a contribution to their administration 
costs. 
I look forward to hearing your proposals for 
dealing with this important matter.
PRODUCT RECALL Emerade 
150/300/500 micrograms solution for 
injection pre-filled pens
Secretary General to Bausch Health,  
11 November 2019 
The IPU wrote to you on the 8 October 
outlining our members’ concerns with 
implementing the patient-level product 
recall of all in-date batches of Emerade, 
which recall was required due to a serious 
defect in the products. We outlined in our 
correspondence that this recall had created 
significant administrative and cost implications 
for pharmacies. 
We have not received a response from you, 
which is disappointing given the inconvenience 
that the serious defect in your company’s 
products caused to both our members and their 
patients. Our position remains the same: that 
you must reimburse our members the price of 
the recalled product plus any price differential 
arising with regards to the replacement 
products, plus their professional fee and a 
reasonable contribution to their administration 
costs. 
In the absence of any proposal from your 
company as to how you intend to compensate 
pharmacists for their costs, we will recommend 
to our members that they raise invoices to 
your company in order to recoup the cost of 
providing professional advice, administration 
of the recall and, in the case of the 500mcg 
Emerade pre-filled pens, the cost differential 
for replacement products. 
I look forward to hearing your proposals for 
dealing with this important matter.
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lrish Pharmacy Union Members’ 
PSWT Tax Refunds
Accountant to Medium Enterprises Division, 
Office of the Revenue Commissioners,  
10 September 2019
The lrish Pharmacy Union (IPU) is the 
representative and professional body for 
community pharmacists in lreland, with a 
membership of almost 1,800 or over 95%  
of all pharmacies. 
Our members have been experiencing lengthy 
delays in the processing of their withholding 
tax refunds by way of offset or direct refunds. 
The delays in issuing the refunds are leading 
to significant problems for our members, 
including:
• Tax Clearance Certificates being 
rescinded (leads to a cessation of 
payments from HSE);
• Cashflow difficulties;
• Offsets not being allocated in advance  
of payment dates;
• Growth in members’ frustrations.
In an environment of declining State revenues 
and ever-tightening margins, the above is a 
cause of great concern. It is unacceptable that 
refunds are being held for such a length of time 
before being issued. We would welcome an 
explanation as to what is causing these delays 
and your proposal as to how these matters will 
be addressed.
Should you wish to discuss the above in more 
detail or require additional information, please 
do not hesitate to contact us. We look forward 
to your reply.
lrish Pharmacy Union Members’ 
PSWT Tax Refunds
Assistant Principal, Medium Enterprises 
Division, Office of the Revenue Commissioners 
to Accountant, 21 October 2019
I refer to your letter dated 10th September 
2019, in which you highlight the delay your 
members are experiencing with their PSWT  
tax refunds.
I wish to advise you that due to operational 
changes within the Revenue’s Service to 
Support Compliance units, processing times 
temporarily increased for PSWT interim refund 
claims.
In August, Revenue addressed this issue and 
implemented a plan to reduce the processing 
time of these items. Additional resources were 
directed to process outstanding claims and 
refunds were prioritised.
I expect your members will have noted reduced 
processing times more recently as a result of 
this action.
We regret any inconvenience this temporary 
issue has caused your members. If you have any 
queries, please contact me.
MEPS
Elections to the European  
Parliament 2019
Secretary General to European Election 
candidates, 3 May 2019
The new term of the European Parliament 
will offer an unprecedented opportunity for 
Members of the European Parliament to 
determine the course of EU action on health 
issues. 
A new regulatory framework, which will 
become binding in 2020 and 2022, is expected 
to increase the safety, development and 
performance of medical devices and in-vitro 
diagnosis medical devices. Furthermore, as 
of February 2019, the Falsified Medicines 
Directive requires that all prescription 
medicines packages entering the EU need 
to carry special safety features to prevent 
counterfeit medicines reaching Irish and 
European patients. A new Regulation on 
veterinary medicines, recently adopted by 
the European Parliament, will introduce more 
responsible ways to produce, supply and 
use medicated feed to tackle antimicrobial 
resistance. These three pieces of legislation 
are clear examples of what EU Member States 
can do together to provide added benefit and 
contribute to an EU in which a high level of 
health protection and access to safe and high-
quality healthcare are a reality for everyone.
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In addition to specific legislative initiatives, it 
is vital to maintain health matters high in the 
political agenda of the European institutions. 
For example, the European Commission has 




• e-health and digital health data;
• Medicines for children and rare diseases;
• Artificial Intelligence; and
• Health Inequalities.
In 2019, EU Member States as well as the 
EU institutions themselves will face an 
unprecedented challenge following the exit 
of the UK from the EU. At this stage, the 
impact of Brexit on the continuity of supply 
of medicines to patients and the recognition 
of professional qualifications for health 
professionals on both sides of the Channel 
is still uncertain. However, the European 
Medicines Agency has stated it is likely this 
will result in medicines shortages and it may 
also impact on clinical research, which is 
crucial in delivering innovative treatments no 
patients. The IPU is working closely with the 
Department of Health, the HSE, the Health 
Products Regulatory Authority (HPRA), the 
wholesalers, manufacturers and all stakeholders 
involved in the supply chain of medicines, to 
plan for any potential disruptions to medicine 
supplies as a result of Brexit. We have sought 
and received assurances that everything that 
can be done is being done to anticipate, plan 
for, and mitigate against any potential problems 
that may arise and to develop solutions to 
protect medicine supplies to Irish pharmacies 
and patients, with a particular focus on the 
supply of those that have been identified as 
critical medicines.
The Pharmacy profession strongly believes 
that, by working together, the Member States 
of the EU can add genuine value to national 
efforts to improve the effectiveness of health 
systems and delivering patient-centred care to 
their communities. 
Pharmacists provide an essential service to the 
public in every town, village and community 
across the EU and have the expertise and 
the capacity to provide additional services to 
patients and the public as part of a Primary 
Healthcare Strategy. The international trend is 
to develop the role of the pharmacist in primary 
care in response to changing demographics, 
health policies and life expectancy. In many 
European countries, the health authorities 
recognise that many services, which up to 
now were not provided at all, or were only 
provided by other healthcare professionals, can 
be provided in a more timely, accessible and 
cost-effective manner through community 
pharmacies. The authorities in these countries 
realise that community pharmacy is an 
untapped professional resource which, if used 
to its full potential, can relieve pressure in other 
parts of the health service, including Accident 
& Emergency facilities and institutional care. 
This can be achieved in a cost-effective manner 
for each country as well as saving patients time 
and money.
Members of the European Parliament have an 
important role in promoting and facilitating 
such coordination. We believe however that 
this should happen within the framework of 
certain principles:
1. All EU citizens, regardless of their 
position in life or their ability to pay, have 
the right to receive affordable, timely and 
high-quality healthcare. Guaranteeing 
the availability of medicinal treatment 
to patients within the EU is key in this 
regard.
2. To enhance the health status and quality 
of life of EU citizens it is crucial to involve 
healthcare professionals in raising public 
health awareness, participating in disease 
prevention and control and supporting 
self-care.
3. Promoting a responsible use of digital 
solutions in healthcare to complement 
the face-to-face advice delivered by 
health professionals to patients.
4. The main driver of EU policies concerning 
pharmaceuticals and health technologies 
should be promoting and protecting 
health and patient safety. The success 
of health systems must be measured 
by how healthy people are, not by their 
contribution to the EU single market or 
to economic growth.
5. Providing innovative and effective 
pharmaceutical services is essential to 
reduce the burden on other health care 
services and ultimately improve the 
sustainability and resilience of European 
health systems.
We would really appreciate your support on 
these issues.
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APPENDIX II
Continued
Please also find attached a copy of 
Pharmacists: Healthcare at the heart of the 
Community, a brief paper which sets out our 
proposals for the provision of community 
pharmacy services in Ireland to better meet the 
needs of patients and the public. 
We would also be very happy to meet with you 
after the election to discuss the issues further 
with you, if you so wish. 
We look forward to hearing from you.
PGEU 60th Anniversary Event 
Secretary General to Irish MEPs, 23 July 2019
As Secretary General of the Irish Pharmacy 
Union (IPU), the representative body for 
community pharmacists, I am writing to you 
on behalf of our 2,300 member pharmacists 
across the country to congratulate you on your 
election to the European Parliament and to 
wish you success in the position. 
The new term of the European Parliament 
will offer an unprecedented opportunity for 
MEPs to determine the course of EU action on 
health issues. In addition to specific legislative 
initiatives, it is vital to maintain health matters 
high in the political agenda of the European 
institutions. The European Commission has 
recently launched initiatives in: Vaccination; 
Anti-Microbial Resistance; e-health and Digital 
Health Data; Medicines for Children and Rare 
Diseases; Artificial Intelligence; and Health 
Inequalities. 
Through our membership of the 
Pharmaceutical Group of the European Union 
(PGEU), we seek to work together with 
our European pharmacy colleagues to add 
genuine value to national efforts to improve 
the effectiveness of health systems and deliver 
patient-centred care to their communities. 
Pharmacists provide an essential service to the 
public in every town, village and community 
across the EU and have the expertise and 
the capacity to provide additional services to 
patients and the public as part of a Primary 
Healthcare Strategy. 
To celebrate their 60th Anniversary, PGEU is 
hosting an event in the European Parliament 
on 10 September 2019 at 16.30. I enclose an 
agenda and hope you are able to attend; you 
can register here. 
We would also be very happy to meet with 
you, either in Ireland or in Brussels, to discuss 
the issues outlined above in more detail, if you 
so wish. 
I look forward to hearing from you.
Other
Tailored Regimens for Combined 
Hormonal Contraception
Director of Pharmacy Services to Women’s 
Health Co-ordinator, National Women’s Council 
of Ireland & Vice President for Welfare, The 
Union of Students in Ireland, 17 February 2020
The Irish Pharmacy Union is the membership 
organisation that represents over 1,800 
community pharmacies and over 2,200 
individual pharmacists. Our vision is to be the 
authoritative voice of community pharmacy and 
the driving force in the evolution of accessible, 
equitable and patient-focused primary 
healthcare. Members of the IPU are committed 
to delivering a quality, accessible, personal and 
professional service that puts the patient first 
and have, as their primary goal, the optimisation 
of the health and wellbeing of society.
As you are probably aware, the Faculty of 
Sexual and Reproductive Healthcare (FSRH) 
of the Royal College of Obstetricians and 
Gynaecologists published a Guideline on 
Combined Hormonal Contraception (CHC) 
in January 20191. This guideline supports 
the use of “tailored regimens” for CHC and 
highlights that there is no health benefit from 
the seven-day hormone-free interval and that a 
shorter interval or fewer intervals may increase 
contraceptive efficacy.
The FSRH guideline is summarised below:
• Tailored regimens for CHC allow users to 
have fewer and/or shorter hormone-free 
intervals, with fewer scheduled bleeds. 
All women who are medically eligible to 
use CHC can be given the choice of a 
tailored regimen;
• Fewer and shorter hormone-free 
intervals maximise the non-contraceptive 
benefits of using CHC and may increase 
patient satisfaction with CHC methods;
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• Tailored regimens offer theoretically 
greater contraceptive efficacy than 
traditional regimens and have similar 
safety profiles, although long term studies 
are lacking.2
Community pharmacists have reported that 
many clinicians and prescribers are now 
tailoring the CHC regimes that they offer to 
their patients based on this expert guidance. 
However, the HSE PCRS has decided that 
they will only provide reimbursement support 
for traditional regimes, i.e. PCRS will reimburse 
a maximum of thirteen CHC packs per 
calendar year. This decision affects women 
who access their contraception via either the 
General Medical Card Scheme (GMS) or the 
Drug Payment Scheme (DPS).
This reimbursement decision impacts such 
patients in one of two ways: it limits clinicians’ 
choice to tailor a CHC regime for women who 
access contraception via the State’s medicines 
schemes or, alternatively, it financially 
penalises patients as they are required to pay 
privately for any additional packs over the 
thirteen packs currently being reimbursed. 
It is worth noting that the use of tailored 
CHC regimens is currently outside the 
manufacturer’s product authorisation, which 
is the reason advanced by HSE PCRS for not 
reimbursing the cost of the medicine.
The IPU is concerned that this HSE PCRS 
reimbursement policy will act as a barrier to a 
woman’s right to health and lead to inequality 
between groups of women. We note that your 
organisation advocates for the Irish healthcare 
system to develop policies and deliver services 
which respond to the needs of women, uphold 
women’s right to health and reduce health 
inequity between groups of women. We 
believe the HSE PCRS reimbursement policy 
does not align to either of our organisation’s 
positions on equitable access to healthcare and 
therefore wanted to make you aware of the 
current situation.
I am available to discuss this issue or provide 




Thank you on behalf of Irish 
community pharmacists 
Secretary General to Chairperson,  
Feed the Heroes, 28 April 2020
I am writing on behalf of Irish community 
pharmacists to thank you and your team at 
Feed the Heroes for the generous hampers sent 
to pharmacies over the last number of weeks. 
This was a very welcome and kind gesture, which 
was gratefully received by pharmacists and 
pharmacy staff across the country.
We have received very positive feedback on 
your work, and it has provided a much needed 
morale boost at a time when, as you know, 
those working in our pharmacies are doing 
trojan work on the frontline during this  
health crisis.
We appreciate your solidarity and support. 
Thank you.
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APPENDIX III
A LIST OF PRESS RELEASES 
ISSUED TO THE MEDIA 
SINCE THE 2019 AGM
2019
April
n	 IPU Statement on FEMPI Reversal  
for GPs
n	Hay Fever warning issued by pharmacists 
as pollen count set to rise
n	 ‘Ridiculous’ Red Tape contributing to 
shortage of young pharmacists
May
n	Pharmacists to demand reversal in 
FEMPI cuts
n	Sláintecare requires more involvement 
from pharmacies
n	Tips to reduce exam stress
n	Pharmacists offer advice to students  
and parents
n	Public urged to proactively manage 
health all year round
June
n	Take the hassle out of your holidays – use 
the checklist at your local pharmacy
n	Attention all men! Start your new health 
journey at your local pharmacy today
n	New survey shows public want 




n	Pharmacists call for Better Access to 
Contraception
n	Relieve GP waiting lists by expanding 
Pharmacy services
n	Get the Facts on the HPV Vaccine! Talk 
to your Pharmacist
n	Sex, Dehydration and Rock n’ Roll
September
n	Schools are back and so are head lice, 
warn pharmacists
n	Do you have questions about your child’s 
vaccinations? – Talk to your Pharmacist
n	Lifesaving blood pressure screening could 
be delivered in pharmacies
n	Lives could be saved with pharmacy based 
chronic disease management programme
October
n	Pharmacists demanding reversal of 
recession era cutbacks in Budget 2020
n	Avail of Flu Vaccine Early in the Season 
Advise Pharmacists
n	Budget 2020: Reductions in prescription 
costs welcome
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November
n	 IPU/IPHA campaign urges public to visit 
their pharmacy to manage winter illnesses
n	Pharmacists can help manage Patients 
with Diabetes
n	Pharmacists warn Antibiotic Overuse is a 
Major Threat to Irish Healthcare
n	Attention all men! Start your new health 
journey at your local pharmacy today
n	Pharmacy Based New Medicine Service 
would improve COPD patient outcomes
December
n	Pharmacists’ Shock at Minister’s U-turn 
on Funding
n	 IPU welcomes Minister Harris’ 
announcement that pharmacy contract 
talks will start in 2020
n	Mixing Alcohol and Medicines can be 
Highly Dangerous warn Pharmacists




n	Flu season is here
February
n	 Irish Pharmacy Union urges all election 
candidates to Support Community 
Pharmacy
n	Smokers being deprived of much  
needed help to quit
March 
n	 Irish Pharmacy Union statement on 
Covid-19: Patients with Covid-19 
symptoms should NOT attend  
at the pharmacy
n	 Irish Pharmacy Union statement 
on Covid-19: Public reassured that 
pharmacies remain open and well supplied
April
n	Pharmacists say new Covid-19 
prescription regulations are good for  
Irish patients
n	Pharmacists and Age Action Recommend 
Deferral of Prescription Levy
n	Know the Difference between Hay 
Fever and COVID-19 Symptoms – 
Pharmacists issue Advice
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